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ABSTRACT
Obesity and diabetes are common in dogs, which in human studies have been linked to 
derangements in insulin sensitivity and macronutrient metabolism. However, unlike human 
based research, insulin resistance and its consequences have not been extensively studied in 
the dog. It was therefore the aim of this thesis to establish a suitable method to measure 
insulin sensitivity in dogs and to investigate the effect of marine fish oil (MFC) 
supplementation.
The glucose/insulin minimal model used to analyse data from the intravenous glucose 
tolerance test (IvGTT) was constructed from published literature and validated using data 
from the literature and other groups. To test reproducibility in vivo, three dogs were 
investigated six times using the IvGTT with model analysis. All dogs showed mean values 
for insulin sensitivity (Sj) of 1.05, 0.75 and 0.76 xlO“^ min'^pM'\ and glucose effectiveness 
(S g) of 3.32, 2.27 and 2.93 xlO  ^min'\ Mean intraindividual coefficients of variation of 16 % 
(S i) and 46 % (S q) were found.
Measures of insulin sensitivity as assessed by the oral and intravenous glucose tolerance tests 
(OGTT and IvGTT) and the insulin tolerance test (ITT) were each made once in five dogs. 
The OGTT was considered unsuitable due to rises in plasma glucose late in the test, which 
were possibly a result of the glucose dose used. Of the other tests the IvGTT appeared more 
sensitive as the ITT classified a possibly insulin insensitive dog as the most insulin sensitive 
of the group (IvGTT Sj = 0.53 xlO"^  min'^pM'  ^ (range 0.53-2.76), ITT kg.i^  = 8.15 %/min 
(range 6.40-8.15)).
To assess the effect of MFO supplementation, 6 dogs were compared with MFO enriched and 
unenriched diets. Intakes of 0.08g EPA and 0.06g DHA per lOOg food resulted in high levels 
of incorporation in red blood cell membranes. Testing with an IvGTT at the end of each diet 
found no observed effects on insulin sensitivity in the group as a whole. However one dog 
with a reduced insulin sensitivity (0.53 xlO"^  min'^pM'^) did show an improvement with MFO 
supplementation (0.94 xlO'^  min"\pM'^).
In conclusion, insulin sensitivity in the dog can be reliably assessed by a number of measures 
but the best of these appears to be the IvGTT with minimal model analysis. Dietary 
manipulation to increase intake of MFO does not appear to improve insulin sensitivity in 
normal dogs. Further studies might focus on dogs with known insulin resistance or those 
with risk factors for resistance such as age, breed and body composition.
Simulation and mathematical modeling will power the 
Twenty-first century the way steam powered the Nineteenth.
William H. Press 
Harvard University, author of Numerical Recipes
11
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Chapter 1 -  Introduction
First extracted from dogs by Banting in 1921, insulin has been extensively studied and 
shown to be an extremely important regulatory molecule. Primarily involved in the 
control of metabolism, insulin is also implicated in cellular growth and regulation.
Found in most mammalian systems, insulin is synthesised and stored in the B-cells of 
the pancreas (Kaneko 1989; Sanger, Brown, & Kitai 1955; Stryer 2000). The insulin 
molecule consists of two peptide chains which are linked by two disulphide bonds 
(Panayotou & Waterfield 1989). This same pattern is found in the majority of species 
as the molecule is highly conserved. Only very small differences occur between 
species and are centered on non-critical sites, only affecting the immunological 
characteristics. For instance dog and human insulin only differ by one amino acid 
residue on the B chain (Kaneko 1989).
As a single polypeptide, preproinsulin varies in length from 97 to 105 amino acid 
residues according to species. Synthesised into the lumen of the rough endoplasmic 
reticulum, a signal sequence is cleaved off to leave proinsulin. Also in the lumen, the 
disulphide bonds form. The proinsulin molecule is then transported, via the Golgi 
apparatus, to the secretory granules. Here the peptide joining the A and B chains is 
cleaved to leave insulin. The peptide sequence cleaved is called the C-peptide and is 
biologically inactive. Newly produced insulin crystalises with zinc for storage 
(Kaneko 1989; Stryer2000). Insulin release is then stimulated by glucose, amino acids, 
hormones (glucagon, GIP, GLP-1) and drugs (sulfonylureas, isoproterenol) 
(Kaneko 1989).
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Once released insulin circulates bound to p-globulin and acts via receptors found on 
the surface of cells. There is a family of these receptors which have a similar structure 
and response to insulin (Kahn 1995; Moller & Flier 1991; Panayotou & 
Waterfieldl989; Stryer2000). The extracellular portion of these receptors have a high 
affinity for insulin. It is thought that once insulin binds the receptor undergoes a 
conformational change. This change may then cause tyrosine residues on the 
cytosolic side of the receptor to become autophosphorylated (Kahn1995; Moller & 
Flierl991; Panayotou & Waterfield1989). These tyrosine residues may regulate the 
activity of the now active receptor, which acts as a tyrosine kinase. Other tyrosine 
residues, once phosphorylated, are thought to interact with SH domains of different 
proteins and enzymes (Kahnl995). Though unclear, it is thought that this is how 
insulin receptors are able to recognise and activate or deactivate cellular enzymes. 
This then is how it is thought that insulin is able to control metabolism, cellular 
growth, and other cellular pathways.
1.1 Actions of Insulin.
Insulin is an extremely important regulatory molecule in biological systems. Primarily 
associated with metabolism, it is the major molecule to promote the reduction of 
circulating glucose levels, and activates glucose utilisation and oxidation within cells. 
In addition insulin inhibits and reduces the rate at which glucose is synthesised within 
the cell and the rate at which fat and protein are broken down to provide energy.
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1.2 Insulin & Carbohydrate.
In response to a mixed meal, which results in an increase in the circulating glucose 
concentrations, insulin release is stimulated. Once in the circulatory system insulin 
acts, via the insulin receptors, to reduce the circulating glucose levels.
The movement o f glucose from the blood into the cell is via the glucose transporters, 
(GluT) which are non-energy requiring (Lienhard et al. 1992). Consisting of five 
known isomers, these transporters are very similar in structure and function and are 
found to be tissue specific. So far only GluT4, found in muscle and adipose tissue, 
has been shown to have an association with insulin (Lienhard, Slot, James, & 
Muecklerl992). At normal basal levels of insulin, muscle and adipose tissues have 
low uptake rates of glucose. However these rates increase 15-20 fold with elevated 
insulin levels. Acting via insulin receptors, insulin causes vesicles rich in GluT4 
transporters to fuse with the cell membrane. This explains the large increase in uptake 
rates as elevated insulin levels stimulate an increase in the number o f GluT4 present in 
the cell membrane. The GluT4 are then removed by endocytosis and recycled into 
new GluT4 rich vesicles (Lienhard, Slot, James, & Muecklerl992).
Once in the cell, glucose is quickly converted to glucose-6-phosphate by glucokinase, 
which, in peripheral tissues, has a high affinity for glucose. With this fast 
accumulation and phosphorylation of glucose in the cell subsequent steps in glucose 
metabolism are enhanced (Panayotou & Waterfieldl989).
As the central organ for glucose homeostasis the liver is a major absorber of
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postprandial glucose. Unlike muscle and adipose, liver cells have GluT2 which are 
unaffected by insulin. In addition the GluT2 require a high glucose concentration for 
half-saturation, which makes them very effective at balancing glucose concentrations 
inside and outside of cells (Lienhard, Slot, James, & Muecklerl992). Organs which 
have GluT2, (including the pancreas), are therefore very sensitive to changes in 
circulating glucose allowing them to respond accordingly. Insulin affects the liver 
cells in a different way from muscle and adipose tissue. Instead of acting on the 
glucose transporters, insulin alters the metabolic pathways within the cell causing the 
utilisation of glucose to be altered.
In the liver, insulin has as effect on various enzymes, but the one of greatest 
importance is glucokinase. Similar to the glucokinase found in peripheral tissues 
hepatic glucokinase has a lower affinity for glucose and as a result is rate limiting for 
the utilisation of glucose (Panayotou & Waterfleldl989; Stryer2000). This is essential 
if  the liver is to release glucose into the circulatory system to maintain glucose 
homeostasis. If the glucokinase were to have a high affinity for glucose then release 
would not be possible as phosphorylated glucose can not move across the cell 
membrane. Liver is the only tissue to be able to supply glucose to the circulatory 
system as it has the enzyme glucose-6-phosphatase, which converts glucose-6- 
phosphate to glucose. However, glucose-6-phosphatase is not exclusive to the liver 
and is also present in the kidney and the intestine. With raised glucose levels and 
consequently raised insulin levels, activity of glucokinase is increased by the action of 
insulin. Conversely the action of glucose-6-phosphatase is inhibited by insulin 
(Panayotou & Waterfieldl989). The overall effect is that glucose release from the
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liver is suppressed while glucose utilisation by the liver is increased. These effects on 
enzyme activity are produced by phosphorylation or de-phosphoiylation of enzymes 
by insulin receptors. By this action insulin is also able to stimulate the storage of 
glucose as glycogen and the utilization of glucose for energy and the production of 
cellular components when glucose is readily available.
1.3 Insulin and Lipid.
From recent advances in the understanding of lipid metabolism and transport within 
the circulatory system it has been possible to follow some of the actions of insulin.
What is known is that insulin has its most important role in controlling the activity of 
the enzymes hormone sensitive lipase (HSL) and lipoprotein lipase (LPL) (Frayn 
1993; Frayn et al. 1994; Frayn et al. 1995; Sethi, Gibney, & Williams 1993). Both of 
these enzymes are mainly found in adipose tissue.
HSL acts to hydrolyse triacylglycerols (TAG) to glycerol plus non-esterified fatty 
acids (NEFA), at basal insulin levels. While the majority o f NEFA produced enters 
the circulation some is converted back into TAG to be stored in the adipose tissue 
(Fraynl993; Frayn, Shadid, Hamlani, Humphreys, Clark, Fielding, Boland, & 
Coppackl994; Frayn, Coppack, Fielding, & Humphreys 1995; Sethi, Gibney, & 
Williamsl993).
The released NEFA is then taken up by the liver where some is oxidised to produce
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energy - what is left is converted to TAG which becomes incorporated into very-low- 
density-lipoprotein (VLDL) particles within the hepatocyte. These newly synthesised 
VLDL particles are released into the circulation and removed mainly by the adipose 
tissue (Fraynl993; Frayn, Shadid, Hamlani, Humphreys, Clark, Fielding, Boland, & 
Coppackl994; Frayn, Coppack, Fielding, & Humphreys 1995; Sethi, Gibney, & 
Williamsl993).
In adipose tissue the TAG present in VLDL, and chylomicron particles are hydrolysed 
to NEFA by LPL. The released NEFA are then absorbed by the adipose tissue to be 
stored as TAG. With low basal insulin levels the activity of LPL is low such that 
more NEFA is released from adipose tissue than absorbed (Fraynl993; Frayn, Shadid, 
Hamlani, Humphreys, Clark, Fielding, Boland, & Coppackl994; Frayn, Coppack, 
Fielding, & Humphreys 1995; Sethi, Gibney, & Williams 1993).
At raised insulin levels, for instance, following a meal, insulin effects a change in 
HSL and LPL activity and in the production of VLDL by the liver.
Under the action of insulin, the activity of HSL is drastically reduced depressing the 
hydrolysis of TAG and release of NEFA from adipose. Likewise, insulin has been 
shown to have a direct effect in reducing the synthesis and release of VLDL by the 
liver (Cummings et al. 1995; Lewis & Steiner 1996; Salhanick, Schwartz, & 
Amatruda 1991). This effect is further enhanced by the large reduction in the supply 
of NEFA to the liver (Fraynl993; Frayn, Shadid, Hamlani, Humphreys, Clark, 
Fielding, Boland, & Coppackl994; Frayn, Coppack, Fielding, & Humphreys 1995;
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Frayn &, Kingman 1995; Howard 1993; Sethi, Gibney, & Williams 1993).
A suppression of VLDL secretion by insulin is seen as a way of preventing 
competition with chylomicrons, produced from the gut, for lipolysis by LPL. 
Although this hypothesis has not been proven, it would explain why VLDL levels 
increase in the late postprandial phase as insulin secretion and release of NEFA from 
adipose tissue are re-established.
The activity of LPL, in adipose tissue, is increased by insulin so that the removal of 
TAG from chylomicron particles is increased. As with VLDL particles the 
chylomicron renmants are metabolised by the liver. The action of LPL on TAG rich 
lipoproteins is also linked to the transfer of cholesterol and excess surface materials to 
high density lipoproteins (HDL) (Frayn, Coppack, Fielding, & Humphreysl995). 
Chylomicron processing by LPL is also seen in muscle tissue, though the activity of 
this LPL is less efficient, not sensitive to insulin and appears unable to process VLDL 
particles (Frayn, Shadid, Hamlani, Humphreys, Clark, Fielding, Boland, & 
Coppackl994; Frayn, Coppack, Fielding, & Humphreysl995).
Insulin activation of LPL is relatively slow, taking approximately six hours to achieve 
in vivo. This is advantageous as it can take this long for TAG levels in the plasma to 
reach peak levels, depending on meal composition. TAG levels are also influenced by 
the previous meal with the release of ‘trapped’ TAG from the mucosal lining of the 
intestine (Sethi, Gibney, & Williams 1993). In addition this lag period prevents lipid 
oxidation in cells from blocking glucose oxidation, which has implications in insulin 
resistance (Randle et al. 1963).
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1.4 Insulin and Protein
For many years it was reported that patients with insulin-dependent diabetes mellitus 
(IDDM) were typically in a protein catabolic state. With the emergence of insulin 
therapy a reversal was reported in this catabolic state to the extent that muscle wastage 
and emaciation are seldom reported in IDDM patients (Abu-Lebdeh & Nair 1996). A 
knowledge of the cellular mechanisms for this have advanced in recent years with 
protein turnover studies and the use of stable isotope tracers.
From various studies, overall protein metabolism is described by the rates of protein 
synthesis, protein breakdown and amino acid oxidation. In the young rat it has been 
shown that insulin decreases protein breakdown and amino acid oxidation (Abu- 
Lebdeh & Nair1996; Millward 1995). Insulin has also been shown to have a direct 
effect on protein synthesis, specifically the eucaryotic initiation factors (elF) in the 
peptide chain initiation cycle (Millwardl995). Two sites of action are known. The 
first involves the eIF-2.GDP/eIF-2B complex where phosphorylation will inhibit the 
exchange of GDP for GTP. In some instances insulin has been shown to maintain 
eIF-2 in a dephosphorylated state thereby preventing it from complexing with eIF-2B. 
The second site of regulation is in mRNA binding to the 43 S ribosomal preinitiation 
complex which is mediated via eIF-4F. In this instance, insulin has been shown to 
stimulate the phosphorylation of eIF-4F thereby increasing its activity 
(Millwardl995).
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The situation in large animals and humans differs with regards to protein synthesis. In 
the majority of the studies conducted it has been shown that insulin reduces the rates 
of protein breakdown and amino acid oxidation, however, the observed effects on 
protein synthesis are more variable. Studies which have only administered insulin 
have shown a slight decrease in protein synthesis, an effect which has also been 
observed in patients with IDDM who have undergone insulin treatment 
(Millwardl995; Millward et al. 1996). Conversely, studies that have clamped the 
plasma amino acid levels, or infused amino acids, have shown a marked increase in 
protein synthesis (Millwardl995; Millward, Fereday, Gibson, & Pacyl996; Tessari et 
al. 1996). From these studies it appears that in large animals and humans, while 
insulin inhibits protein breakdown, it is the circulating amino acid levels that stimulate 
protein synthesis and not insulin (Millwardl995; Millward, Fereday, Gibson, & 
Pacyl996; Tessari, Barazzoni, Zanetti, Kiwanuka, & Tiengol996). Further exidence 
for this hypothesis comes from studies that have used differing levels of protein and in 
those that have clamped insulin levels while altering plasma amino acid levels 
(Millward1995; Millward, Fereday, Gibson, & Pacyl996).
Another factor affecting protein metabolism is the action of other hormones. Several 
studies have shown that growth hormone, and insulin-like-growth-factor 1 exert a 
strong anabolic effect on protein metabolism. A similar effect is seen with thyroid 
hormones and testosterone, though to a lesser extent. Conversely glucagon, 
glucocorticoids and adrenaline exhibit catabolic effects on protein balance (Umpleby 
& Russell-Jones 1996). The action of these hormones is complex as each has a 
slightly different effect and some, eg insulin, exert an effect on the release of others.
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eg glucagon.
In summary, insulin in young rats has been shown to inhibit protein breakdown and 
amino acid oxidation while stimulating protein synthesis. Conversely in humans and 
large animals insulin only inhibits protein breakdown and amino acid oxidation. It is 
only with raised plasma levels of amino acids that protein synthesis becomes 
stimulated.
1.5 Insulin and Insulinotropic Gut Hormones
For many years it was observed that the insulin response to an oral glucose load was 
greater than that from an intravenous glucose load of similar size. This observation 
was also related to the size and volume of the meal, with a large meal effecting a 
relatively large insulin response.
From various studies it was found that this effect was partly due to gastro-intestinal 
hormones, which are released in response to nutrient absorption. In addition, 
measurement of circulating insulin and C-peptide concentrations have indicated that 
the secretion of insulin is increased by some gastrointerstinal hormones.
Insulinotropic gut hormones are defined as stimulating insulin secretion at 
physiological concentrations in response to nutrient absorption, especially glucose. Of 
the known gut hormones only gastric inhibitory polypeptide (GIF) and glucagon-like 
peptide-1 (GLP-1) fulfill the above criteria.
11
Chapter 1 -  Introduction
1.5.1 Actions of GIP
Secreted from the jejunum, the 5 kDa form of GEP is the major bioreactive form. GIF 
also fits the criteria for an insulinotropic gut hormone as it has a potent insulin 
stimulating activity at physiological concentrations. In addition GIF secretion is 
stimulated by amino acids, lipids and glucose absorption.
While amino acid absorption stimulates GIF secretion, the ingestion of protein yields 
a very poor secretion of GIF. This discrepancy occurs as protein is not fully 
hydrolysed into its constituent amino acids before absorption. As a result, the amount 
of amino acids present is very small, which in turn results in a very poor secretion of 
GIF. Conversely, glucose and fat are major effectors of GIF secretion. Studies in 
different species have shown glucose to have a more potent effect than fat, however, 
this situation is reversed in humans. This situation may be due to humans having a 
diet which is relatively higher in fat. Whatever the explanation, the level of GIP 
secretion is positively correlated to the size of a glucose load. However, a mixed meal 
produces more variable results as the energy and volume size of the meal affects the 
rate of gastric emptying, and consequently the absorption rate (Morgan 1992).
As previously mentioned, GIF stimulates increased insulin secretion. This only 
occurs with mild to moderate hyperglycaemia. Therefore a fat only meal will not 
stimulate insulin secretion despite increased GIF levels. In addition GIP reduces 
hepatic glycogenolysis, thereby stopping the metabolism of amino acids and lipids
12
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(Morgan! 992).
In adipose tissue, GIP activates LPL and stimulates de novo synthesis of fatty acids 
from glucose. Combined with similar effects from insulin, the uptake and utilisation 
of glucose and TAG by adipose is made more effective. There is also the possibility 
that GIP may enhance the ability o f insulin to initiate fatty acid synthesis from glucose 
(Morgan! 992).
1.5.2 Action of GLP-1
Despite GIP having been extensively studied there are other gut hormones that may be 
just as important. One such hormone is glucagon-like peptide-! (GLP-!).
The precursor for GLP-! is proglucagon but, the products from progtucagon are tissue 
specific. In the pancreas proglucagon is metabolised to produce glucagon, glicentin- 
related pancreatic peptide, and proglucagon(72-!60). Conversely proglucagon is 
metabolised in the gut to produce glicentin, oxyntomodulin and two glucagon-like 
sequences, GLP-! and GLP-2. GLP-! is then further cleaved to yield GLP-1(7-3 8) 
amide, which is the major form found in the circulation following a meal 
(Morgan! 992).
From the work conducted to date, GLP-1 has been found to be a very potent 
stimulator of insulin secretion, being more effective than GIP on a molar comparison. 
However circulating levels of GLP-1 never reach the levels of circulating GIP. GLP-1
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secretion may also mainly derive from lower in the gut than GIP. Similar to GIP, 
GLP-1 appears to be secreted in response to glucose absorption and may stimulate de 
novo synthesis of fatty acids in adipose (Morgan! 992).
Overall the various gut hormones, particularly GIP and GLP-1, appear to amplify the 
insulin response of pancreatic B-cells to ingested nutrients, particularly glucose. In 
addition they may enhance the effect insulin has on the uptake and utilisation of 
absorbed nutrients by various tissues. However much work is still required to fully 
elucidate the physiological effects of the currently known hormones, and those that 
may yet be discovered.
1.6 Insulin Resistance.
As can be seen from the above, insulin is a very important regulator and controller of 
body metabolism and therefore any defects in insulin or its action have major effects 
on health. The most notable of these is IDDM, where the pancreas fails to secrete 
insulin almost completely. The majority of cases of IDDM develop early in life and, 
as the condition suggests requires regular injections of insulin.
However, in addition to IDDM, non-insulin dependent diabetes (NIDDM) is also a 
common western disease. In this situation the pancreas secretes insulin, but through 
multiple factors, the actions of insulin are severely impaired. Such a state is referred 
to as insulin resistance. In contrast to IDDM, cases of NIDDM tend to develop late in 
life and are associated with obesity and a sedentary lifestyle.
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Within the population as a whole insulin sensitivity varies between individuals. An 
individual’s degree of insulin sensitivity is not static however, and amongst other 
factors has been shown to decline with increased age (DeFronzo 1979) and percentage 
body fat (Boden et al. 1993). In addition, insulin sensitivity has been found to change 
throughout the day, as previously demonstrated in this laboratory (Apostolakou 1995). 
Measuring insulin sensitivity, by an insulin tolerance test (ITT), in the morning and 
comparing it to that in the afternoon it was found that ‘normal’ subjects became 
increasingly insulin insensitive as the day progressed. Though the exact mechanisms 
are unknown, it does highlight the fact that normal individuals experience reduced 
insulin sensitivity at times. However, care must be taken to not confuse this with 
pathological insulin resistance which tends to be more severe and associated with 
varying clinical symptoms.
Insulin resistance can be defined in pathophysiological terms as the production of a 
reduced physiological response to a given dose of insulin. For example the rate at 
which glucose is removed at a given insulin concentration from the circulation will 
decrease with increasing insulin resistance. The majority of those that are 
pathologically insulin resistant exhibit basal hyperinsulinaemia, where the body is 
seen as trying to overcome the effects of insulin resistance. This increase in 
circulating insulin comes about from increased secretion by the B-cells and a 
reduction in the removal of insulin by the liver and peripheral target cells (Moller & 
Flier 1991; Reaven 1988).
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Though both IDDM and NIDDM are clinically defined, pathological insulin resistance 
is harder to diagnose as most individuals who are resistant appear healthy and without 
any associated symptoms. There is also the added problem of deciding at which point 
a naturally low insulin sensitivity can be classed as pathological insulin resistance. 
Population based studies that examined insulin sensitivity suggest that as much as 25 
% of the diagnosed population may be pathologically insulin resistant (Reavenl988; 
Reaven 1993a; Reaven 1995). A figure this high has been suggested as sensitivity 
measurements in these resistant individuals have been found to not differ substantially 
from those with impaired glucose tolerance or NIDDM (Reavenl995).
Insulin resistance is an important health problem, not just because it appears to affect 
such a large part o f the population, but it has also been linked to other conditions. 
Through epidemiological studies it has emerged that insulin resistance has been linked 
to hypertension, cardiovascular disease, NIDDM, obesity, and hyperlipidaemia 
(Frayn1993; Moller & Flier 1991). It has also been found that if  someone has one of 
these conditions then it is almost always accompanied by insulin resistance. However 
the converse is not always true as someone who is insulin resistant does not 
necessarily have any or all of the conditions mentioned (Boden et al. 1991; 
Reavenl988).
For a very small portion of cases there are some known causes for the resistance and 
they include errors in insulin synthesis and defective insulin receptors (Kahnl995). 
However since most of these are genetic defects or specific conditions they affect only 
a small proportion of people. As mentioned above, insulin resistance is thought to
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effect approximately 25 % of the population for which, at the moment, the molecular 
causes and mechanisms are unknown.
1.6.1 Insulin Resistance in Dogs
Macronutrient metabolism and the actions of insulin have been well studied and the 
descriptions above are equally applicable to humans and dogs. In fact dogs have often 
been used as an experimental model for diabetes, insulin action and metabolism in 
humans. However, there is a distinct lack of knowledge as regards insulin resistance 
and its consequences within dogs. This is due in part to a lack of well controlled, 
blinded, randomised clinical trials within veterinary medicine, a point that has 
received recent criticism (Keene 2000). Currently the vast majority of research and 
knowledge in veterinary medicine is evidence derived from expert opinion and 
extrapolation from bench research.
Research has also been hampered from a lack of financial investment for research. In 
addition biochemical tests considered routine in human based medicine might not be 
available or cost effective to most veterinary practices. For example the measurement 
of plasma insulin in dogs has only been commercially available for the past 3 years 
and costs a practice ~£40 per sample, which is passed to the pet owner with an 
addition cost.
Despite the lack of direct evidence, there is circumstantial evidence to suggest that 
insulin resistance exists in dogs. From Human based studies it is now well established
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that obesity is a major risk factor for developing insulin resistance and in turn diabetes 
and coronary heart disease (CHD). In addition, if  left unchecked, it is known that 
insulin resistance can progress to impaired glucose tolerance, NIDDM and in extreme 
cases IDDM. Within the dog population obesity and weight maintenance problems 
are common and on the increase. Levels of obesity have been estimated to affect 11.6 
-  44 % of dogs and are linked to over feeding and a sedentary lifestyle (Burkholder & 
Toll 2000; Markwell et al. 1994). There also appears to be a genetic link to obesity 
with certain purebred dogs, such as Labrador retrievers, having an increased risk of 
developing obesity (Wills, Johnson, & Whyte 1992). It has also been shown that 
neutering a dog increases its risk of becoming obese, particularly neutered female 
dogs (Markwell & Butterwick 1994).
As with humans, obesity has been linked to various conditions in the dog and is 
considered the single most important contributing factor to the development of 
diabetes (Kanekol989). Due to a lack of post-mortem examinations in dogs the true 
prevalence of diabetes is unknown, but has been estimated to be between 0.0005 -  
1.52 % of the dog population (Kanekol989; Maskell & Graham 1994). Similar to 
obesity there appears to be a genetic factor in the aetiology of diabetes. Hereditary 
diabetes has been reported in golden retrievers and keeshounds (Feldman & Nelson 
1996; Kanekol989) and certain breeds have a higher incidence of diabetes in the 
population (Nelson 1995). Age and gender are also important factors with a peak 
incidence of diabetes at 7 -  9 years of age and female dogs being affected about twice 
as frequently as male dogs (Feldman & Nelsonl996). Neuter status is also a risk 
factor with entire female dogs having a greater incidence of diabetes, particularly
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secondary diabetes as a result of pregnancy and diestrus (Nelsonl995).
Similar to human medicine canine diabetes has been classified into three types 
according to fasting plasma insulin concentration and the insulin response to an 
intravenous glucose load (Kaneko et al. 1978; Mattheeuws et al. 1984). Type I 
diabetes is characterised by a low or undetectable fasting insulin concentration and a 
failure to produce insulin in response to a glucose load. This type of diabetes most 
resembles juvenile onset diabetes (type I) in humans and is characterised clinically by 
sudden onset of symptoms and a dependency on insulin therapy to maintain life. One 
important difference between the human and canine forms of type I diabetes is the age 
of onset. The majority of type I cases in dogs appears late in life compared to the 
early onset seen in humans.
Type n  diabetes in dogs has been subdivided into those dogs that are either obese or 
non-obese. The major difference between the two groups is that obese dogs tend to 
exhibit a raised fasting plasma insulin concentration compared to normal levels in 
non-obese dogs. Both groups also fail to produce insulin in response to a glucose 
load, similar to type I diabetes in the dog. Dogs with type II diabetes are dependent on 
insulin therapy to sustain life and are prone to develop ketosis. In contrast, most 
human patients with type II diabetes present with minimal or no symptoms, are not 
prone to ketosis, and produce a low to supranormal insulin response to intravenous 
glucose. However, since dogs are not presented to i  veterinarian until the diabetes is 
severe there is the suggestion that type II diabetes as seen in dogs represents the end 
stage sometimes observed in advanced type II diabetes of humans (Kaneko,
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Mattheeuws, Rottiers, & Vermeulenl978).
Finally, type HI diabetes in dogs, as in type n, has been subdivided into those dogs 
that are obese and non-obese. Initially detected on the basis of a persistent fasting 
hyperglycaemia there is also glucose intolerance as seen in humans. Obese dogs have 
a raised fasting plasma insulin concentration and an increased peak insulin response 
following intravenous glucose. By contrast non-obese dogs with type III diabetes 
have a normal fasting insulin concentration and a reduced peak insulin response to 
intravenous glucose. In both instances however, there may also be a delay in the 
appearance of the insulin peak or a failure of insulin levels to return to fasting levels 
by 60 minutes from the infusion of glucose. These responses are characteristic of 
chemical diabetes as seen in humans.
While the aetiology and natural history of diabetes in dogs is unclear there is the 
suggestion that the different types represent the clinical progression of diabetes. 
Kaneko, Mattheeuws, et al. (1978) have reported that when dogs initially develop 
diabetes they present the chemical form, type IH. If left undetected and untreated it is 
then proposed that the diabetes progress to one of the two other types depending on 
the nature of the insulin deficiency, whether absolute (type I) or relative (type II). A 
similar pattern of progression can be seen in the development of diabetes in humans 
where insulin resistance combined with a failure of the pancreatic response can lead to 
glucose intolerance and if left untreated, NIDDM.
By comparison with human medicine, it is likely that insulin resistance exists in dogs
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and has a similar aetiology and consequence for health. However, unlike human 
based medicine dogs are only taken to a veterinary surgery when the owner suspects 
there is a problem. As a result insulin resistance remains hidden and early diabetes 
often goes undetected until a dog is severely diabetic and showing clinical symptoms 
such as polyuria, weight loss, exercise intolerance, cataracts and ketotic breath 
(Maskell & Graham1994).
1.6.2 Insulin Resistance and Cardiovascular Disease.
While insulin resistance has been linked epidemiologically to conditions like coronary 
heart disease the underlying mechanisms are unknown. There has also been some 
debate as to whether CHD is directly linked to insulin action or is a result of one or 
more secondary consequences of insulin resistance.
Work conducted to date has lead to the formation of theories linking insulin resistance 
to the development of such conditions as CHD, hpyertension, obesity and NIDDM. 
The most notable of these is by Reaven who defined a clinical syndrome referred to as 
‘Syndrome X ’, which focuses on insulin-mediated glucose uptake. In recent years this 
has been modified by Frayn who has focused on insulin resistance within the adipose 
tissue as a link to these metabolic abnormalities.
1.6.2.1 Reaven’s proposal.
Reaven proposes that when insulin activation of glucose uptake is impaired (insulin 
resistance) the B-cells of the pancreas will secrete more insulin in order to obtain the
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required response at elevated levels. However should this hyperinsulinaemic response 
fail to achieve the required response, then hyperglycaemia will result (Boden, Jadali, 
White, Liang, Mozzoli, Chen, Coleman, & Smith 1991; Koranyi et al. 1991; 
Reavenl988; Reaven 1993b; Reavenl993a).
A similar case is put forward for plasma NEFA levels, where increased insulin will 
decrease circulating NEFA levels. Therefore should the hyperinsulinaemic response 
fail then increased circulating NEFA levels will prevail (Koranyi, Bourey, Slentz, 
Holloszy, & Permuttl991; Reavenl988; Reavenl993b). Reaven goes further to 
propose that with raised NEFA levels, hepatic glucose production from NEFA 
oxidation will increase. The mechanism proposed centers around acetyl-CoA, 
generated from oxidation of NEFA, activating pyruvate carboxylase and inhibiting 
pyruvate dehydrogenase thereby stimulating gluconeogenesis (Koranyi, Bourey, 
Slentz, Holloszy, & Permuttl991; Reavenl988; Reavenl993b). This production of 
glucose could then add to the problem of hyperglycaemia.
In terms of the link with hypertension, Reaven proposes that increased insulin levels 
may cause similar increases in catecholamine levels, which will activate the 
sympathetic nervous system and increase blood pressure (Koranyi, Bourey, Slentz, 
Holloszy, & Permuttl991; Reavenl988). Alternatively, high insulin levels may cause 
increases in sodium and water resorption in the kidneys (Koranyi, Bourey, Slentz, 
Holloszy, & Permuttl991; Reavenl988). To what extent these two systems continue 
to cause increased blood pressure is unknown.
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Finally with regards cardiovascular disease Reaven has put forward a collected list of 
related risk factors for cardiovascular disease known as syndrome X (Table 1-1) 
(Koranyi, Bourey, Slentz, Holloszy, & Permuttl991; Reavenl988). He states that 
they are all secondary to insulin resistance and an impairment o f insulin stimulated 
glucose uptake. The remaining factors, which may or may not develop, then increase 
the risk of cardiovascular disease. Also it is mentioned that not all the conditions 
mentioned appear in cases of cardiovascular disease. However he does state that 
resistance to insulin mediated stimulation of glucose uptake may be the critical factor 
as to whether or not someone suffers from cardiovascular disease.
Table 1-1 - Syndrome X.
Resistance to insulin-stimulated glucose uptake
Glucose intolerance
Hyperinsulinaemia
Increased very-low-density lipoprotein triglyceride
Decreased high-density lipoprotein cholesterol
Hypertension
1.6.2.2 Frayn’s proposal.
Frayn proposes an alternative mechanism for the link between insulin resistance and 
cardiovascular disease, via alterations in lipid metabolism.
With impaired insulin action on adipose tissue HSL there may be an increased release 
of NEFA’s, particularly as NEFA re-esterification, which is dependent on insulin, 
would be inhibited. This increase in plasma NEFA levels combined with hepatocyte
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insulin resistance would cause the liver to continue to produce VLDL-TG in the 
postprandial state (Fraynl993; Frayn & Kingmanl995). Also in the postprandial state 
increased NEFA levels would affect carbohydrate metabolism by competing for 
oxidation with glucose (Boden, Jadali, White, Liang, Mozzoli, Chen, Coleman, & 
Smith 1991; Randle, Garland, Hales, & Newsholmel963). This could then result in 
glucose intolerance and hyperglycaemia. This, in combination with inadequate 
hepatic removal of insulin because of NEFA levels, could then result in 
hyperinsulinaemia and the down regulation of insulin receptors with postcellular 
desensitisation (Moller & Flierl991).
Insulin resistance would also affect LPL activity. As a result of the non-activation of 
this enzyme, there would likely be an impairment in the removal of TAG rich 
lipoproteins from the circulation (Fraynl993; Frayn & Kingmanl995). With this 
increase in plasma concentrations of TAG rich lipoproteins, neutral lipid exchange 
with HLD cholesterol ester would increase. In addition neutral lipid exchange 
between TAG rich VLDL and LDL may occur. This would in turn lead to the 
formation of small dense LDL particles (Fraynl993; Frayn & Kingmanl995). In 
combination with the increased glucose concentrations, lipoprotein glycation might 
also occur (Fraynl993). This would increase the atherogenic potential of the particles, 
in particular the small dense LDL particles which have been associated with 
cardiovascular disease (Griffin 1995; Reaven et al. 1993; Sethi, Gibney, & 
Williamsl993).
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1.6.3 ns-PUFA and Insulin Resistance
From the work mentioned above, it can be seen that cardiovascular disease is a major 
consequence of insulin resistance. The risk from cardiovascular disease also appears 
to be modulated by diet and epidemiological studies have shown that the type of 
dietary fat can have an effect (Collier & Sinclair 1993; Klimes et al. 1993). 
Specifically, studies of populations with a high intake of fish have a reduced risk of 
cardiovascular disease. Further analysis of these diets have shown an increased intake 
of ng-PUFA, in particular eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) (Collier & Sinclair1993). This knowledge has spawned a large number of 
claims and trials about the effect of EPA and DHA.
Unfortunately the design of the studies vary greatly. As a result many of the results 
show differing degrees of effect. Notably the amount of ng-PUFA in the diet varies as 
well as the amount of time over which the supplementation takes place.
However, it has been shown in many studies that ng-PUFA supplement lowers 
circulating TAG levels, particularly in patients with hypertriglyceridaemia (Collier & 
Sinclair1993; Klimes, Howard, Storlein, & Sebokoval993; Popp-Snijders et al. 1987). 
It is thought that this may arise by ng-PUFAs effecting a reduction in hepatic 
triglyceride synthesis.
Other studies have shown ng-PUFAs to increase the rate of lipoprotein remnant 
clearance from the circulation. While the results are variable, it does appear in some 
studies that plasma LDL cholesterol increases. One proposal for this increase in LDL
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levels is that ns-PUFA causes an increased conversion of small VLDL into LDL 
thereby reducing the atherogenisity of the lipoprotein particles (Annuzzi et al. 1991; 
Collier & Sinclairl993). A similarly variable response is seen in HDL cholesterol 
levels. One study has shown that these effects may be due to the levels of EPA and 
DHA, where DHA-rich oils decrease LDL cholesterol levels and EPA-rich oils 
decrease HDL cholesterol levels (Collier & Sinclairl993).
The effects of ns-PUFA on glucose tolerance in normal and NIDDM subjects have 
shown greatly varying results. While some studies have shown ns-PUFA 
supplementation to reduce the fasting insulin:glucose ratio and increase the glucose 
clearance rate in an insulin tolerance test, other studies have only shown some of these 
effects or none (Aimuzzi, Rivellese, Capaldo, Di Marino, lovine, C, Marotta, & 
Riccardil991; Heine 1993). There are also some studies that show ns-PUFAs 
decrease glucose tolerance and glycaemic control, however the levels of 
supplementation for this were considered excessive (Collier & Sinclairl993). This 
evidence suggests a bimodal dose response to ns-PUFAs, where very low or high 
dietary levels may be ineffective or detrimental.
Though the mechanisms by which ns-PUFAs change insulin sensitivity are unknown, 
there is one theory that involves membrane fluidity (Devynck 1995; Popp-Snijders, 
Schouten, Heine, van der Meer, & van der Veenl987; Tong et al. 1995). It is known, 
and has been shown, that ns-PUFA supplementation results in incorporation of ns- 
PUFA into cell membranes. By increasing the amount of unsaturated phospholipids 
in a membrane it is thought that the membrane fluidity increases. Unfortunately there
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is no conclusive evidence for this as different studies have used different cells, eg. 
erythrocytes and leucocytes, membrane markers, and in some circumstances different 
techniques (Devynckl995; Popp-Snijders, Schouten, Heine, van der Meer, & van der 
Veenl987; Tong, Thomas, Berrish, Humphriss, Barriocanal, Stewart, Walker, 
Wilkinson, & Albertil995). The issue is further complicated as the fluidities have 
been measured at differing depths of the membrane. In addition, that membrane 
fluidity varies at different parts of the membrane. This means that any measurement 
made may not necessarily represent the membrane fluidity around an insulin receptor 
(Devynckl995).
These problems aside, it is proposed that as the membrane fluidity increases with ns- 
PUFA incorporation the activity of insulin receptors increases. In other words they 
are more able to bind insulin, undergo conformational changes, and form complexes 
with other membrane proteins. If this is the case then it would account for the 
increase in insulin sensitivity seen in some studies (Popp-Snijders, Schouten, Heine, 
van der Meer, & van der Veenl987).
From epidemiological studies and some experimental trials there does appear to be a 
positive effect of ns-PUFA supplementation. However the underlying mechanisms for 
any effects are unknown and there is the possibility that these effects are mediated by 
a reduction in saturated fat intake. Only with further intervention studies will these 
issues be resolved.
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1.7 Methods of Determining Insulin Sensitivity.
As stated above insulin resistance is potentially a major risk factor for public health, 
particularly with links to diabetes, CHD, hypertension and obesity. It is therefore 
advantageous to be able to identify and quantify insulin resistance for health and to aid 
research.
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Figure 1-1 A simple representation of the interactions between glucose and 
insulin following the administration of glucose and/or insulin (test dependant) as 
a means of assessing glucose tolerance or peripheral tissue insulin sensitivity.
The clinical tests currently used focus on glucose kinetics and the action of insulin to 
promote glucose clearance from the plasma (Figiire 1-1). Tests can be divided into 
those that challenge a system with glucose (oral and intravenous glucose tolerance 
tests), insulin (insulin tolerance test), or both (euglycaemic insulin clamp technique). 
The oral and intravenous glucose tolerance tests are the most general and provide 
results that are influenced by peripheral tissue insulin sensitivity and the ability of the
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pancreas to secrete insulin and maintain normal glucose tolerance. An insulin 
tolerance test ignores the influence of the pancreas by infusing exogenous insulin and 
therefore gives a measure of peripheral tissue insulin sensitivity. However, since the 
insulin tolerance test is conducted in a fasting state any measurement is also 
influenced by the suppression of hepatic glucose production by insulin. Finally, the 
euglycaemic insulin clamp technique is the test of choice and provides the most 
accurate measurement of peripheral tissue insulin sensitivity. By infusing exogenous 
insulin the influence of the pancreas is ignored as in the insulin tolerance test. 
However glucose is also infused, which negates the influence of a reduced hepatic 
glucose production due to the insulin infusion.
A more detailed description of each test and the inherent advantages and 
disadvantages are provided below.
1.7.1 Oral Glucose Tolerance Test
Being one of the simplest tolerance tests the oral glucose tolerance test (OGTT) is 
easy to administer and causes the least amount of stress to the subject being studied. 
However, the test lacks sensitivity and doesn’t allow adequate quantification of 
glucose tolerance.
The test is initially carried out by taking a blood sample in the morning following an 
adequate fast of 10-16 hours. Care must also be taken to ensure that an unrestricted 
diet has been followed for a minimum of three days and that smoking and strenuous
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activity is avoided during the test (Bennet 2000). The test is then started with the 
consumption of a standard 75g of glucose in a liquid state. Blood samples are then 
taken at regular intervals, with the sample at 2 hours being the one that gives most 
information (Bennet2000; Kanekol989). Criteria established by the World Health 
Organisation (WHO) for the diagnosis of impaired glucose tolerance and diabetes are 
shown in Table 1-2 (WHO 1985). A diagnosis may be made either on the fasting 
value alone or on a raised 2 hour value.
Table 1-2 - Diagnostic Criteria (WHO1985) for Diabetes Using Oral Glucose 
Tolerance to a Standard 75g Oral Glucose Load.
Normal Impaired Glucose 
Tolerance
Diabetes
Fasting Glucose <6.4 mmol/L <7.8 mmol/L <7.8 or >7.8 mmol/L
2 Hour Glucose <7.8 mmol/L 7.8-11.1 mmol/L >11.1 mmol/L
Studies have shown that this test is relatively insensitive at detecting and providing a 
quantitative value for insulin resistance. In addition the test assumes that gut motility 
and absorption of glucose are normal, which is clearly not always the case. Altered 
rates of gastric emptying can greatly affect the rate of glucose moving into the small 
intestine. Also the results are the consequence of the interactions of all the hormones 
that regulate glucose homeostasis as well as the actions of the liver. It is thus a broad 
integrated test of the whole glucose homeostatic system. For this reason, it is not used 
in the quantification of tolerance/resistance.
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1.7.2 Intravenous Glucose Tolerance Test.
Similar to the oral glucose tolerance test, the intravenous glucose tolerance test 
(IvGTT) is primarily a measure of the B-cell response to a glucose load (Kaneko, 
Mattheeuws, Rottiers, & Vermeulenl978; Kaneko 1989; Mattheeuws, Rottiers, 
Kaneko, & Vermeulenl984; Rottiers et al. 1981). Greater specificity is achieved, 
compared to the OGTT, as the gut is by-passed by infiision of the glucose load directly 
into the circulation. Elevated blood glucose levels are reached very quickly so it is 
possible to measure the disappearance rate of glucose fiom the system, as a measure 
of the B-cell/insulin response. In addition the time course of the test is shorter than 
the OGTT, about 1 hour (Kaneko, Mattheeuws, Rottiers, & Vermeulenl978; 
Kaneko 1989; Mattheeuws, Rottiers, Kaneko, & Vermeulenl984; Rottiers, 
Mattheeuws, Kaneko, & Vermeulenl981).
Another advantage over the OGTT is that because of the increased sensitivity it is now 
possible to not only diagnose diabetes, but also its type based upon the glucose and 
insulin curves obtained. Most of the increase in sensitivity comes from the fact that 
the system gives a maximal response within a very short time of starting the test 
(Kaneko, Mattheeuws, Rottiers, & Vermeulenl978; Mattheeuws, Rottiers, Kaneko, & 
Vermeulenl984; Rottiers, Mattheeuws, Kaneko, & Vermeulenl981).
Similar to the OGTT it is difficult to achieve an indication of peripheral insulin 
resistance as it would have to assume a completely healthy pancreas that gives a 
maximal insulin secretatory response. As a result this test is mainly affected by the B- 
cell sensitivity to glucose rather than tissue sensitivity to insulin (Kaneko,
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Mattheeuws, Rottiers, & Vermeulenl978; Mattheeuws, Rottiers, Kaneko, & 
Vermeulenl984; Rottiers, Mattheeuws, Kaneko, & Vermeulenl981).
1.7.3 Euglycaemic Insulin Clamp Technique.
The euglycaemic insulin clamp technique is seen as the best way in which to 
determine the level of peripheral tissue insulin resistance (Akinmokun et al. 1992; 
Hasegawa et al. 1992). This is also the test against which all other tests and models 
are compared. Unlike the OGTT and IvGTT, this technique measures insulin 
resistance directly avoiding the B-cells sensitivity to glucose and ability to secrete 
insulin.
Following an overnight fast, and the measurement of the basal glucose concentration, 
the subject is given a continuous insulin infusion for around 2 hours. The aim is to 
achieve a hyperinsulinaemic state, which is variable from species to species. This 
high level of insulin then simulates maximal insulin output from the pancreas and 
inhibits endogenous release of glucose from the liver.
Exogenous glucose is then infused at a variable rate. By checking the circulating 
levels of glucose and varying the infusion rate it is possible to achieve euglycaemia. 
Usually the level of euglycaemia is slightly below basal level as this will ensure 
insulin is not secreted from the pancreas. In this steady state the rate o f infusion can 
be assumed to represent the rate of removal of glucose from the blood system by non- 
hepatic tissue. It can be assumed that the uptake of glucose by the liver in a
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euglycaemic state is minimal. The level of tissue sensitivity to insulin is then 
represented the rate of glucose infused in mg/kg/min.
The disadvantage to this technique is that, in states of insulin deficiency or resistance, 
glucose production by the liver may not be completely suppressed by the 
hyperinsulinaemia. A way to avoid this confounding effect is to use stable isotope 
labeled glucose to measure liver production of glucose. However this would make the 
technique even more expensive and complex. Presently the technique requires highly 
trained personnel to use the sophisticated machines necessary in order to carry out an 
analysis.
Despite this, the technique is highly repeatable with a high degree of sensitivity and 
reliability yielding a lot o f information on insulin resistance.
1.7.4 Insulin Tolerance Test.
Similar to the euglycaemic clamp technique the insulin tolerance test (ITT) is easier to 
carry out and requires less sophisticated equipment (Akinmokun, Selby, Ramaiya, & 
Alberti1992; Bonora et al. 1989; Gelding et al. 1994; Hirst et al. 1993).
Following an overnight fast, the subject is given an intravenous bolus of insulin (0.1 
U/kg body weight). This produces sufficient hyperinsulinaemia such that endogenous 
glucose production is inhibited and glucose uptake is stimulated by non-hepatic tissue 
(Akinmokun, Selby, Ramaiya, & Alberti1992; Bonora, Moghetti, Zancanaro, Cigolini,
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Querena, M, Cacciatori, Corgnati, & Muggeol989). Following the injection of 
insulin, arterialised blood is taken every minute for 15-20 minutes from an arterialised 
hand vein. A value for the removal rate of glucose by tissue can then be calculated by 
taking the slope of the best fit straight line of logarithm of blood glucose plotted 
against time, between 3 and 15 minutes (Akinmokun, Selby, Ramaiya, & Alberti 1992; 
Hirst, Phillips, Vines, Clark, & Hales 1993).
The glucose disappearance rate. K m , for arterialised blood then correlates very well 
with the euglycaemic clamp technique (Akinmokun, Selby, Ramaiya, & Albertil992; 
Gelding, Robinson, Lowe, Niththyananthan, & Johnston1994). However the same 
correlation does not exist if  venous blood is used, this being a possible consequence of 
the action of the capillary beds stripping out the plasma glucose.
The advantages of the ITT, are that it is relatively cheap, quick to carry out and that 
the results obtained are comparable to the euglycaemic insulin clamp technique. 
These considerations make the ITT ideal for low budgets and multiple tests 
(Akinmokun, Selby, Ramaiya, & Alberti1992; Bonora, Moghetti, Zancanaro, Cigolini, 
Querena, M, Cacciatori, Corgnati, & Muggeol989; Gelding, Robinson, Lowe, 
Niththyananthan, & Johnstonl994; Hirst, Phillips, Vines, Clark, & Halesl993). A 
problem with the test is that if  a subject is very sensitive to insulin they will become 
hypoglycaemic, so intravenous glucose for injection must be readily available and a 
glucose drink must be provided at the end of the test e.g. hycal.
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1.7.5 Minimal Model.
By using mathematical modeling it has been possible to use another method for 
quantitating insulin resistance. The minimal model, which was devised by Bergman 
et al in 1979, uses data obtained from an IvGTT to estimate insulin mediated glucose 
disposal(Si) and the ability of glucose to restore its own concentration regardless of 
changes in insulin (Sq) (Bergman, Beard, & Chen 1986; Godsland 1994; Toffolo et al. 
1980). The model uses the insulin data from an IvGTT and transforms this using the 
model equations to fit the observed glucose data. A best fit is achieved by altering 
some of the models parameters, which are used to calculate Si and Sq.
The IvGTT as mentioned above consists of the intravenous injection of a bolus of 
glucose and then frequent blood samplings to measure the plasma glucose and insulin 
levels. Taking 180 minutes, 30 time points are required for the full minimal model 
analysis (Bergman, Beard, & Chenl986; Godslandl994; Toffolo, Bergman, Finegood, 
Bowden, & Cobellil980). The sensitivity for this method can be further increased by 
the injection of an intravenous bolus of tolbutamide 20  minutes after the glucose 
bolus. This produces a substantial increase in the peak plasma insulin levels aiding 
the disposal of glucose and also the accuracy of the subsequent model analysis. It has 
also been shown that there is good correlation between the minimal model analysis of 
the tolbutamide IvGTT and the euglycaemic hyperinsulinaemic clamp in normal and 
obese non-diabetic subjects (Coates et al. 1995; Saad et al. 1994).
However because the minimal model requires a substantial increase in plasma insulin 
to occur (Godsland1994), minimal model analysis is restricted to non-diabetics. Also
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despite the fact that the test is relatively easy to carry out, the data analysis is complex 
and the Si value is only an estimate. In addition the analysis does not distinguish 
between hepatic and peripheral glucose uptake.
The minimal model method is cheap, relatively easy to carry out and has a good 
degree of repeatability (Ferrari et al. 1991; Krempf et al. 1994). Also the use of the 12 
time point method makes things easier, but this results in a decrease of the accuracy of 
the test (Coates et al. 1993; Steil et al. 1993; Steil et al. 1994). These criteria make 
this test ideal for large population studies. However it is not the best test for more 
detailed studies.
1.8 Use of stable isotopes in investigations of glucose metabolism
Stable isotopes have been used in biological experiments since the 1930’s (Wolfe 
1992). However with the emergence of scintillation counting and a wide range of 
tracers, radioactive isotopes became the preferred choice from the 1950’s onwards 
(Pacy et al. 1989; Wolfe1992). Use of stable isotopes has been limited by the 
excessive cost of the actual isotopes and the mass spectrometers required for analysis. 
This trend has changed in recent years with the development and increased availability 
of the quadruple mass spectrometer and cheaper stable isotope tracers. With an ever 
increasing number of labeled compounds it is becoming possible to investigate more 
systems and pathways.
The transition to the use of stable isotopes has been fueled by the recognition that
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radioactive tracers can be potentially very hazardous over a number of years (Pacy, 
Cheng, Thompson, & Hallidayl989; Wolfel992). Other advantages of stable isotopes 
include the smaller quantities of plasma required, multiple doses with multiple stable 
isotopes, and smaller biopsy samples (Pacy, Cheng, Thompson, & Hallidayl989). 
Another considerable advantage is that there are more stable isotope elements than 
radioactive elements to chose from. Notably there are stable isotopes of nitrogen and 
oxygen, but no equivalent radioactive isotopes (Pacy, Cheng, Thompson, & 
Hallidayl989). Lastly samples for stable isotope analysis seldom require excessive 
sample purification and it is possible to measure tracer enrichment and concentration 
within the same sample also molecular specificity is often inherent in the analysis.
Apart from the high costs stable isotopes do have some draw backs which need to be 
taken into consideration. The issues of most concern are natural isotope abundance 
and isotope position within the tracer.
With regards natural abundance, which for ^^C is about 1.1%, this needs to be 
quantified for kinetic measurements. If this is not carried out then any measurement 
made will give a false enrichment level. Also if looking for a small change in isotope 
enrichment this could be hidden within the natural variation of the isotope enrichment 
(Pacy, Cheng, Thompson, & Hallidayl989; Wolfel992). To counter this, a greater 
amount of isotope tracer is needed, but there is a possibility that this may exert a 
substrate effect. This however has not proved to be a problem with enrichment levels 
between 2 and 5% (Pacy, Cheng, Thompson, & Hallidayl989).
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Isotope position within the tracer is important with regards to mass spectrometric 
analysis and metabolic fate (Thompson et al. 1989). For GCMS analysis the stable 
isotope must be in the part of the molecule that produces the most stable and abundant 
ions when the tracer is ionised. However this must be considered in conjunction with 
the metabolic fate of the tracer molecule as this can greatly affect flux measurements. 
For example, alanine flux measurements using (3 ,3 ,3 -^H3) alanine are about twice that 
measured using (^^N) alanine. The difference comes about from the transamination of 
alanine. appears to recycle through glutamine, with which alanine interacts, while 
the ^H labels are lost irreversibly while alanine is complexed to pyridoxal phosphate 
(Thompson, Pacy, Ford, & Hallidayl989).
Taking these points into consideration the use of stable isotope tracers can be a very 
powerful tool clinically. Together with mathematical models it is possible to further 
enhance the power of this technique as enrichment levels can be used to model flux 
kinetics (Pacy, Cheng, Thompson, & Hallidayl989; Thompson, Pacy, Ford, & 
Hallidayl989; Wolfel992).
1.9 Application of measurement of insulin resistance to dogs
As described above there are various tests for assessing insulin sensitivity and each 
has its own advantages and disadvantages. The euglycaemic insulin clamp technique 
is considered the reference test, or ‘gold standard’, however it is complex and time 
consuming. While it may be possible to study a small group of 10 individuals, it is 
impossible to conduct a population based study of 1000+ individuals using the
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euglycaemic insulin clamp. The other tests are not without disadvantages. At best 
they only provide an estimate of peripheral insulin sensitivity, which includes other 
factors such as hepatic glucose production. There may also be undesired side effects 
such as the possibility of hypoglycaemia in the ITT. As a result of the differences 
between tests there is much debate in the literature as to which test is easiest and most 
discriminating (Davis et al. 1992; Davis et al. 1993; Hermans et al. 1999).
Assessing insulin sensitivity in dogs offers addition problems as a dog may not be 
agreeable to having a blood sample taken, being cannulated, having an intravenous 
infusion, or having a paw placed in a hot box in order to obtain arterialised blood. In 
addition there is a lack of studies assessing or using the various tests, as insulin 
sensitivity has not been measured in the dog population. As a consequence the 
incidence of insulin resistance in dogs is unknown and there is no accepted normal 
range for insulin sensitivity.
With obesity and diabetes being significant problems in the dog, and on the increase, 
further investigations into the aetiology and likely causes are warranted. In particular, 
the assessment of the currently available insulin sensitivity tests and the establishing 
of accepted ranges for normal and deranged levels of insulin sensitivity. Drawing 
from research in humans further investigations in the dog should also assess the 
influence of diet, a sedentary lifestyle and the possible benefits obtained from dietary 
intervention with fish oil.
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1.10 General Aims
This study was initially concerned with evaluating the currently available insulin 
sensitivity tests in the dog to find the most suitable. In particular the glucose/insulin 
minimal model was established for the analysis of data generated from the intravenous 
glucose tolerance test.
The minimal model was then characterised by a reproducibility study for use in an 
intervention study. Out of this work on the minimal model the stable-isotope labelled 
intravenous glucose tolerance test with ‘hot’ minimal model analysis was to be 
assessed in the dog and in six human volunteers.
The aim of the above was to establish a method to assess the effect of dietary 
supplementation with fish oil on insulin sensitivity in the dog. It was also planned to 
compare the results from the supplementation with those in a concurrent investigation 
in middle aged men (data not presented) on insulin sensitivity and macronutrient 
metabolism.
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CHAPTER 2 - MATERIALS AND METHODS
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2.1 INTRODUCTION
Described in this chapter are the methods used in the various experimental studies. 
Included are details of the enzyme reactions for commercially bought automated 
analyser kits and fatty acid analysis using gas chromatography. There is also the 
validation of a method used to quantify insulin in dog plasma using reagents used for 
the determination of insulin in human plasma. Finally there is a comparison of 
methods for the measurement of glucose, labelled with stable isotopes, in plasma. 
Specific study designs and method modifications are outlined in the relevant chapters.
2.2 EQUIPMENT
Equipment Supplier
Cobas Mira plus Auto-analyser 
Gamma Counter (Wizard 1470 with 
MultiCalc Level 4.M Software)
Gas Chromatogram (Varian 3400)
MD800 gas chromatograph-mass 
spectrometer with MassLab (vr. 1.3) 
software 
Polystyrene LP4 tubes 
Fluoride/Oxalate Blood tubes (1 ml) 
Lithium Heparin Blood tubes (5 & 10 ml) 
Sodium EDTA Blood tubes (1 ml) 
Nescofilm
Whatman No 1 filter paper (11 cm)
Roche Products Ltd, Welwyn Garden City 
Labsystems, Life Sciences International, 
Basingstoke 
Varian Associates Ltd., Walton-on-Thames, 
Surrey 
Fisons Instruments
L.I.P. Ltd, Shipley 
L.I.P. Ltd, Shipley 
L.I.P. Ltd, Shipley 
L.I.P. Ltd, Shipley 
Merck Ltd, Poole 
Merck Ltd, Poole
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2.3 REAGENTS
All standard chemical reagents were purchased from Merck Ltd, Poole or Sigma
Chemical Company Ltd, Poole and were of Analar Grade unless otherwise stated.
Method specific chemicals were:
Reagent Supplier
General reagents
Acetic acid Merck Ltd, Poole
Agarose (Type ni-A  High EDO) Sigma Chemical Company Ltd, Poole
Albumin, Bovine Serum (BSA) Fraction V Sigma Chemical Company Ltd, Poole
powder
Butylated hydroxytoluene Sigma Chemical Company Ltd, Poole
Charcoal, activated (Norit A) Merck Ltd, Poole
Chloramine T Sigma Chemical Company Ltd, Poole
Glacial acetic acid Merck Ltd, Poole
D-Glucose Merck Ltd, Poole
Polyethylene glycol 6000 Merck Ltd, Poole
Potassium chloride Merck Ltd, Poole
Potassium iodide Sigma Chemical Company Ltd, Poole
Sephadex, G-15 for gel filtration Sigma Chemical Company Ltd, Poole
Sodium chloride Merck Ltd, Poole
Sodium dihydrogen phosphate dihydrate Merck Ltd, Poole
di-S odium hydrogen orthophosphate Merck Ltd, Poole
Sodium metabisulphite Sigma Chemical Company Ltd, Poole
Sodium methylate Sigma Chemical Company Ltd, Poole
Automated analyser reagent kits
Unimate 5 CHOL Test Kit Roche Diagnostic Systems, Welwyn
Garden City
Unimate 5 GLUC HK Test Kit Roche Diagnostic Systems, Welwyn
Garden City
Unimate 5 TRIG Test Kit Roche Diagnostic Systems, Welwyn
Garden City
WAKO NEFA C Test Kit Alpha Laboratories Ltd, Eastleigh
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Reagent Supplier
Stable and radioactive isotone labelled comnounds
[6,6-2H]-D-Glucose Cambridge Isotope Laboratories, Woburn, 
Massachusetts, USA
1251-sodium iodide (3.7 GBq/ml) ICN Biomedicals Ltd, Thame
Derivatisation reagents
Butane boronic acid Sigma Chemical Company Ltd, Poole
Acetic anhydride Sigma Chemical Company Ltd, Poole
Hydroxylamine.HCl Sigma Chemical Company Ltd, Poole
bis-Trimethylsilyltriflouroacetamide + 1 
trimethylchlorosilane (BSTFA + 1 % 
TMCS)
% Phase Separations Ltd.
Solvents
Acetone Merck Ltd, Poole
Ethanol Merck Ltd, Poole
Pyridine Sigma Chemical Company Ltd, Poole
di-Ethyl ether Merck Ltd, Poole
Hexane Merck Ltd, Poole
Methanol Merck Ltd, Poole
Propan-2-ol Merck Ltd, Poole
Chloroform Merck Ltd, Poole
2.4 STANDARDS
Standard/Quality Control Supplier
Assayed MultiSera Normal RANDOX Laboratories Ltd, Crumlin
Calibrator 1 Roche Diagnostic Systems, Welwyn 
Garden City
Control Serum N Roche Diagnostic Systems, Welwyn 
Garden City
Insulin standard Dr S. Hampton, School of Biological 
Sciences, University o f Surrey
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2.5 SERA/ANTISERA
Sera/Antisera Supplier
Donkey anti-Guinea Pig antiserum Guildhay Antisera Ltd, Guildford
Insulin antiserum (GP2, C5/1, C5/4, Mab Dr S. Hampton, School of Biological
64) Sciences, University o f Surrey
Normal Guinea Pig serum Sigma Chemical Company Ltd, Poole
2.6 CHROMATOGRAPHY COLUMNS
Chrom atography Column Supplier
Chrompack CP-SIL88 Varian Chrompack Ltd, Walton-on- 
Thames, Surrey
Crosslinked methyl siloxane high Hewlett Packard
performance capillary column (HPl)
Disposable column (11 cm x 0.7 cm, with Evergreen Scientific, Los Angeles, USA
35mm filter)
NH2 Isolute SPE International Sorbent Technology Ltd, Mid 
Glamorgan
2.7 GASES
Gas Supplier
Helium BOC Gases, Guildford, Surrey
Hydrogen BOC Gases, Guildford, Surrey
Oxygen BOC Gases, Guildford, Surrey
Oxygen Free Nitrogen BOC Gases, Guildford, Surrey
2.8 BUFFERS
0.04 MPhosphate Buffer (pH 7.4)
23 g <i/-Sodium hydrogen orthophosphate 
5.97 g Sodium dihydrogen phosphate dihydrate 
Made to 5 litres in distilled water and stored at 4°C
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2.9 Assay of Plasma Metabolites Using an Automated Analyser
Below are details of the enzyme reactions employed in the relevant assay kits for the 
quantitative measurement of glucose, glycerol, NEFA, TAG and cholesterol in 
plasma. The analyses were carried out using a Cobas Mira plus Auto-analyser.
2.9.1 Determination of Plasma Glucose Concentrations
Plasma glucose concentrations were determined using the Unimate 5 GLUC HK K it, 
Calibrator 1 was used to calibrate the standard curve, and Control Serum N was used 
as a quality control. The kit is a colorimetric enzyme method employing the reactions 
described below.
Initially plasma glucose is phosphorylated to D-glucose-6-phosphate by hexokinase 
and then dehydrogenated to D-gluconate-6-phosphate by glucose-6-phosphate 
dehydrogenase. The second enzyme reaction yields NADH, which is measured 
photometrically at 340 nm and used to calculate the glucose concentration.
D - glucose + ATP — Hexokinase  ^ - 6  - phosphate + ADP
D - glucose - 6 - phosphate + NAD —2éLdh—  ^p) _ gluconate - 6 - phosphate + NADH + H^
(* - Glucose-6 -phosphate dehydrogenase)
Inter- and intra-assay coefficients of variation for this method are 1.85 % and 0.99 % 
respectively at 3.90 mM glucose.
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2.9.2 Determination of Plasma NEFA Concentrations
Plasma NEFA concentrations were determined using the Wako NEFA C kit and 
assayed multi-sera normal was used as a quality control. The kit is a colorimetric 
enzyme method employing the reactions described below.
Unlike more traditional methods, there is no requirement for the extraction of NEFA 
by being converted to copper salts and extracted with solvent. Instead NEFA is used 
in the acylation of coenzyme A (CoA) by acyl-coenzyme A synthetase to produce the 
thiol ester of CoA known as acyl-CoA. The second enzyme in the process, acyl- 
coenzyme A oxidase, oxidises the acyl-CoA to produce 2,3-trans-enoyl-CoA and 
hydrogen peroxide. Finally, peroxidase uses the hydrogen peroxide for the oxidative 
condensation of 3-methyl-N-ethyl-N-(p-hydroxy-ethyl)-aniline (MEHA) with 4- 
aminoantipyrine, the product of which has a maximal absorbance at 550 nm and is 
used to calculate the NEFA concentration.
RCOOH + ATP + Coenzyme A Acyi-coA synthetase  ^ _ CoA + AMP + Pyrophosphate
Acyl - CoA + Oj A ey i-coA  oxidase  ^^,3 - trsns - Enoyl - CoA + H 2O2 
2H 2O2 + MEHA* + 4 - aminoantipyrine — Pg^ °^ ‘dase  ^purple coloured product + 4H 2O
(* - 3-methyl-N-ethyl-N-(p-hydroxy-ethyl)-aniline)
To prevent an increase in NEFA levels from TAG hydrolysis the plasma samples were 
analysed immediately after being defrosted. Ascorbate oxidase was also present in the 
kit reagents to remove any ascorbic acid which, because of its strong anti-oxidative 
properties, may interfere with the production of hydrogen peroxide.
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Inter- and intra-assay coefficients of variation for this method are 3.87 % and 0.89 % 
respectively at 1.05 mM NEFA.
2.9.3 Determination of Plasma TAG Concentrations
Plasma TAG concentrations were determined using the Unimate 5 TRIG Kit, 
Calibrator 1 was used to calibrate the standard curve, and Control Serum N was used 
as a quality control. The kit is a colorimetric enzyme method employing the reactions 
described below.
Under the action of lipase, TAG is cleaved to produce the constituent fatty acids and 
glycerol. The resulting glycerol is phosphorylated to glycerol-3-phosphate by glycerol 
kinase and then oxidised to dihydroxyacetone-phosphate by glycerol phosphate 
oxidase. The third enzyme reaction also produces hydrogen peroxide, which reacts 
with peroxidase causing the oxidative condensation of 4-chlorophenol with 4- 
aminoantipyrine. The product of this final reaction absorbs at 500 nm and is used to 
calculate the TAG concentration.
TAG — > glycerol+ fatty acids 
Glycerol + ATP < Giycerol.kmase  ^giy^erol - 3 - phosphate + ADP 
Glycerol - 3 - phosphate + phosphate oxidase  ^dihydroxyacetone phosphate + H 2O2
2 H 2O2 + 4 - chlorophenol + 4  - aminoantipyrine — P^mxidase  ^ coloured product + 4 H 2O2
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Inter- and intra-assay coefficients of variation for this method are 3.60 % and 0.96 % 
respectively at 0.95 mM TAG.
2.9.4 Determination of Plasma Cholesterol Concentrations
Plasma cholesterol concentrations were determined using the Unimate 5 CHOL Kit, 
Calibrator 1 was used to calibrate the standard curve, and Control Serum N was used 
as a quality control. The kit is a colorimetric enzyme method employing the reactions 
described below.
Cholesterol is cleaved from the cholesterol esters by cholesterol esterase and then 
oxidised to A^^-cholesten-3-one by cholesterol oxidase. The second enzyme reaction 
also produces hydrogen peroxide, which reacts with peroxidase causing the oxidative 
condensation of phenol with 4-aminoantipyrine. The product of this final reaction 
absorbs at 500 nm and is used to calculate the cholesterol concentration.
Cholesterol esteraseCholesterol ester + H 2O  oesero es erase  ^cholesterol + fatty acids
Cholesterol + ch .M ox.te   ^^4 _ cholesten - 3 - one + H 
+ phenol + 4 - aminoantipyrine — > Red coloured product +
Inter- and intra-assay coefficients of variation for this method are 2.29 % and 1.06 % 
respectively at 4.18 mM cholesterol.
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2.10 Determination of Red Blood Cell Membrane Fatty Acid Profile
A variety of methods have been developed over many years for the extraction and 
analysis of fatty acids and are widely reported in the currently available literature. The 
majority of these methods follow the same process with some differences in the 
reagents and conditions used.
Essentially the process begins with the extraction of lipid from the sample of interest, 
typically by the use of an organic solvent like chloroform. An alcohol, such as 
methanol, is also used for lipid extraction from cell membranes to disrupt lipid-protein 
complexes, for the dissolution of the lipids and as a means of inactivating the 
degradative enzymes. Aqueous contaminants; sugars, salts and amino acids; are then 
removed by an aqueous wash. Contained within the lipid extract are cholesterol ester, 
cholesterol, fatty acids, phospholipids, and mono-, di-, and tri-acylglycerides. The 
separation of each of these components is then achieved chemically and by thin layer 
chromatography (TLC), or with solid phase extraction (SPE) columns. The relevant 
spot can then be scrapped from a TLC plate, or the relevant elution from a SPE 
column collected and processed further.
Prior to gas chromatography the fatty acids need to be released from the glycerol 
molecule to which they are attached. This process of freeing the fatty acids is called 
saponification (see Figure 2-1), and involves the hydrolysis of the ester bonds by 
which the fatty acids are attached to the glycerol molecule.
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(i) Saponification
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(ii) Méthylation
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+  @ @
Water
Figure 2-1 Saponification and Méthylation of Fatty Acids
For analysis by gas chromatography it is a prerequisite that the molecules of interest 
are volatile and thermally stable. This is not true for fatty acids, particularly 
polyunsaturated fatty acids. However, this problem is overcome by forming the 
methyl ester derivatives of the fatty acids (see Figure 2-1) with methanol. While 
saponification and méthylation have been described as two individual processes, it is 
possible to produce the fatty acid methyl esters (FAME’s) in a single step by 
transestérification with, for instance, sodium methylate. Once produced the FAME’S 
are ready for analysis by gas chromatography.
Described below is the method used for the determination of the fatty acid 
composition of red blood cell membranes. This method was previously established
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within the Nutrition Department, University of Surrey and is based on the methods 
described by (Schmarr, Gross, & Shibamoto 1996), (Kaluzny et al. 1985) and 
(Maunder 1991).
In order to prevent oxidation and degradation of the fatty acids, glass was used 
throughout and all solvents contained 0.1% w/v butylated hydroxytoluene (BHT).
10ml of venous blood was collected into a blood tube containing lithium heparin as an 
anti-coagulant. The sample was then centrifuged at 1700 g  for 10 minutes at 4 °C and 
the plasma layer removed. The packed red cells were then washed by making the 
volume up to 10 ml with fresh 0.9 % w/v NaCl solution and mixing to re-suspend the 
cells. During the washing process the red cells and NaCl solution were kept at 4 °C. 
After centrifuging at 1700 g  for 10 minutes at 4 °C the NaCl layer was removed and 
the cells washed another two times as before. The washed red cells were tipped into a 
clean glass tube to which was added 250 |il of BHT solution (0.1 % w/v BHT in 
propan-2-ol). After capping the tubes they were sealed with Nescofilm, mixed and 
stored at -20 “C until required.
Once thawed, 1 ml o f red blood cells was taken and placed in a glass conical flask. 
To this was added 1 ml of distilled water and the cells left for 15 minutes to lyse. 
Dissociation of lipid-protein complexes was then achieved by adding, slowly with 
mixing, 6 ml of propan-2-ol and leaving for 1 hour with occasional mixing. Lipids 
were then extracted by adding 4 ml of chloroform and leaving overnight at -20 °C. 
The cells were filtered using Whatman N ol, 11 cm filter paper. The extract was then
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transferred into 12 ml of chloroform:methanol (2:1) and placed in a glass separating 
funnel. Inorganic material was removed by adding 5 ml of 0.05 M KCl, mixing and 
allowing the two phase layers to separate. The lower, organic, phase was collected 
and the chloroform/methanol was evaporated under a stream of nitrogen. The lipid 
extract was then resuspended in 0.5 ml of chloroform.
Lipid separation was achieved by solid phase extraction with NH2 ISOLUTE SPE 
columns. At no point in the separation process was the column allowed to dry as this 
could effect the stability and recovery of the lipid fractions. Using a new column for 
each sample, the column was washed twice with 4 ml of hexane. At this point the 
lipid extract was loaded onto the column. The first elution used 4 ml of 
chloroform:propan-2-ol (2:1) which removed the neutral lipids. The second elution, 
collected into a clean 4 ml glass LP4 tube, used 4 ml of 2 % v/v acetic acid in c/z-ethyl 
ether to obtain the fatty acids. Finally the phospholipids were eluted into a clean glass 
LP4 tube using 4 ml of methanol. Both of the collected fractions were then mixed 
together in a glass universal and evaporated to dryness under a stream of nitrogen.
The fatty acid methyl esters were formed by transestérification with sodium methylate. 
To the dried lipid fraction was added 0.5 ml of 10 % w/v sodium methylate in 
methanol, which was vortex mixed for 1 minute before being placed in a water bath at 
55 °C for 10 minutes. Excess alkali was then neutralised by adding 2 ml o f distilled 
water followed by 50 |il of glacial acetic acid. The FAME’S were extracted by 
shaking the sample twice with 2 ml of hexane and retaining the lower organic layer. 
After evaporating under a stream of nitrogen the FAME’s were reconstituted in 100 |il
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of hexane.
The f a m e ’s were analysed on a Varian 3400 gas chromatogram fitted with a 
Chrompack CP-SIL88 column and hydrogen flame ionisation detector. Helium was 
used as the carrier gas at a flow rate of 30 ml/minute. The injector and detector were 
both set to 250 °C with an initial column temperature of 160 °C. 1 ]Lil of the sample 
was injected and the oven temperature raised at 4 °C/minute to 240 °C and held for 
lOminutes. Detected fatty acids peaks were identified by comparison with known 
standards and the results expressed as a percentage of the total detected area. An 
example of a chromatograph trace obtained is represented in Figure 2-2.
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2.11 Plasma Insulin Radioimmunoassay
2.11.1 Measurement of Insulin Concentrations in Human Plasma
The radioimmunoassay (RIA) for plasma insulin used here was that described by 
(Hampton 1983). This is a competitive binding assay using insulin radiolabeled with 
^^^lodine, an antiserum raised against porcine insulin in guinea pigs, a donkey anti­
guinea pig antiserum and polyethylene glycol to facilitate precipitation of the immune 
complex.
The procedure is outlined in Table 2-2. All samples were analysed in duplicate at 4 
°C on a cold tray.
On the first day the assay was set-up using polystyrene LP4 tubes and consisted of a 
standard curve, plasma samples and quality controls. In addition there were tubes to 
measure non-specific binding (NSB) for the standard curve, plasma samples and 
quality controls. The reagents were added in the order shown in Table 2-2, beginning 
with assay diluent (0.04 M phosphate buffer pH 7.4 + 0.5 % w/v bovine serum 
albumin (BSA)). Next the plasma sample or insulin standard was added to the 
corresponding tubes. The insulin standard was reconstituted in assay diluent and 
serially diluted to give a range of standard concentrations from 23 pM to 1500 pM. 
Charcoal stripped serum (CSS) (section 2.11.2) was added to each tube in the standard 
curve as a carrier for the insulin standard. Finally the insulin antiserum was 
reconstituted in assay diluent to give a 1:10,000 dilution before being added to all 
tubes except the NSB’s. All tubes were vortex mixed and left overnight at 4 °C.
56
Chapter 2 -  Materials and Methods
On the second day of the assay ^^^I-insulin label (section 2.11.3) was diluted with 
assay diluent to give 10,000 cpm/100 p.1 and added to every tube. Two extra tubes, 
total counts, were included and contained only ^^^I-insulin and were used in the 
standard curve. All tubes were vortex mixed and left overnight at 4 °C.
On the final day of the assay each tube, excluding the total count tubes, had added in 
order donkey anti-guinea pig serum, normal guinea-pig serum and polyethylene glycol 
6000 (4 % w/v in 0.04 M phosphate buffer pH 7.4). After vortex mixing the tubes 
were left to incubate at 4 °C for 2 hours. At the end of the 2 hours the tubes were 
centrifuged at 1500 g  for 30 minutes at 4 °C. Finally the supernatant was aspirated 
and the pellets and total count tubes counted on a Wallac Wizard gamma counter. A 
standard curve was constructed and sample concentrations read automatically from 
this using the built-in software.
Sensitivity for the assay was 11.7 pM. Inter- and intra-assay coefficients of variation 
for this method are shown in Table 2-1.
Table 2-1 Insulin Inter- and Intra-assay Coefficients of Variation
Low Q.C. (46 pM) High Q.C. (625 pM)
Inter-assay Variation 10.2%
Intra-assay Variation 6 T % T094
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Table 2-2 Insulin Radioimmunoassay Protocol
Reagents 
added (ill)
Total
Counts
Non-specific
Binding
Zero
Standard
23-1500 pM 
Standards
Plasma
Sample
Quality
Control
Day 1
Assay
Diluent - 350 pi 250 pi 200 pi 250 pi 250 pi
Plasma
Sample - - - - 50 pi
-
Standard - - - 50 pi - -
CSS - 50 pi 50 pi 50 pi - -
QC - - - - - 50 pi
Insulin
Antiserum - - 100 pi 100 pi 100 pi 100 pi
All tubes were vortex mixed and incu Dated at 4 °C for 24 hours
Day 2
125i_
insulin
100 pi 100 pi 100 pi lOOpl 100 pi 100 pi
All tubes were vortex mixed and incu Dated at 4 °C for 24 hours
Day 3
Normal 
Guinea- 
pig Serum
- 100 pi 100 pi 100 pi 100 pi 100 pi
Donkey 
anti- 
Guinea- 
pig Serum
- 100 pi 100 pi 100 pi 100 pi 100 pi
4%
PEGôooo
- 700 pi 700 pi 700 pi 700 pi 700 pi
All tubes were vortex mixed and incu 
Tubes were then centrifuged at 1500 
The supernatant was then aspirated and the pel
Dated at 4 °C for 2 hours, 
g for 30 minutes at 4 °C. 
lets counted on a gamma counter.
2.11.2 Charcoal Stripped Serum
In order to use serum as a carrier for the insulin standard in the insulin 
radioimmunoassay protocol it was essential that all insulin had been removed prior to 
use. This was achieved by treating the serum with agarose coated charcoal which 
binds to low molecular weight proteins present in the serum, thus allowing them to be 
removed.
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Before using the activated charcoal, it was de-fined to remove the very small particles 
of charcoal. This was achieved by suspending the charcoal in 2-3 volumes of 
deionised water and allowing to settle. Fines present in the charcoal remained on the 
surface of the water and were removed with filter paper. The process was repeated 
until little or no fines were found, after which the charcoal was filtered and dried 
completely at 50 °C.
Agarose coated agar was prepared by heating 25 g of agarose in 500 ml distilled water 
to 70 °C in a water bath in a fume cabinet. Once dissolved, 100 g of de-fined charcoal 
was added and mixed well. After cooling to 50 °C the mixture was poured into 1 L of 
acetone and stirred. The mixture was filtered through Whatman No. 1 filter paper and 
dried at 37 °C overnight.
Once dried, 25 g of the agarose-coated charcoal was added to every 200 ml of pooled 
serum. The slurry was stirred overnight at 4 °C then centrifuged at 1300 g  for 10 
minutes. The supernatant was filtered the serum was clear of charcoal. To check if 
the serum was clear of fines, 1 ml of serum was centrifuged at 20,000 g  for 10 minutes 
in a microfuge. If a black pellet of charcoal was then present the serum was refiltered.
Finally the clear serum was aliquoted into 5 ml volumes and stored at -20  °C until 
needed.
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2.11.3 lodination of Insulin
Because of the hazardous nature of this procedure extra precautions are legally 
required. The iodination reaction was carried out in a fume cabinet in a designated 
laboratory with personal protective equipment including multiple gloves and lab coats 
and a lead castle to surround the reaction. An additional person was present 
throughout to constantly monitor the surroundings and the person carrying out the 
iodination.
Prior to the iodination the following was prepared:-
• A disposable autoanalyser cup containing 5 pg of insulin dissolved in 25 pi of 
0.04 M phosphate buffer pH 7.4.
• 40 mg of chloramine T in 10 ml of 0.04 M phosphate buffer pH 7.4.
• 2.5 mg sodium metabisulphite in 10 ml of 0.04 M phosphate buffer pH 7.4.
• 20 mg potassium iodide in 10 ml 0.04 M phosphate buffer pH 7.4.
• A disposable column (11 cm x 0.7 cm with 35 micron filter) of pre-swelled 
sephadex G15 in 0.04 M phosphate buffer pH 7.4, containing 0.5 % w/v BSA, 
giving 7 cm of packing. A tail of PVC tubing was attached to the end of the 
column to allow easier dispensing into the fraction collector.
Once prepared everything was transferred to the designated radiochemical laboratory.
The column was clamped above a fraction collector and the autoanalyser cup was 
clamped behind the lead castle. To the cup was added ^^^I-sodium iodide (5 jil
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containing 1 8 .5  MBq) followed by 5 p,l of the chloramine T solution to start the 
reaction. Throughout the reaction the contents of the cup were mixed with the pipette 
used to add the chloramine T solution. After 1 5 -2 0  seconds 2 0 0  |li1 of the sodium 
metabisulphite solution was added to stop the reaction. Finally 5 0  j L i l  of the potassium 
iodide solution was added to ‘mop up’ the free iodine.
Using a disposable pipette the contents of the autoanalyser cup was loaded onto the 
column and carried through with protein buffer (0.04 M Phosphate buffer, pH 7.4 with 
0.5 % w/v BSA). The fraction collector was set to collect 10 drops per fraction for 
approximately 30 fractions. Each fraction was collected into a polystyrene LP4 tube. 
At no point during the fraction collection was the column allowed to dry.
Once collected, 10 jul of each fraction was transferred into LP4 tubes, capped and 
counted for 10 seconds in a gamma counter. An elution profile is shown in Figure 
2-3. Two peaks are shown, the first is ^^^I-insulin and the second is unincorporated 
^^^iodine. The two highest ^^^I-insulin fractions were kept and aliquoted (10 p,l) into 
LP4 tubes that contained protein buffer (100 p,l). These were then capped and stored 
at -20 °C until required.
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Figure 2-3 Elution Profile of lodinated Insulin
To check the quality of the label, a standard insulin curve and quality control samples
were set-up using each of the retained fractions. The label would only be used for
analysis if  the standard curve showed good displacement in the standards and had a
maximum binding of 30% or more.
2.11.4 M easurement of Insulin Concentrations in Dog Plasma
Human and dog insulin molecules are the same length and have the same amino acid 
sequence, except the 30*^  residue on the B-chain where human insulin has a threonine 
residue and dog insulin has an alanine residue. Also the insulin antiserum used in the 
insulin assay is polyclonal and so is not site specific. However it can not be inferred 
that the insulin antiserum will have the same immunospecifity for dog insulin as it 
does for human. Similarly there is a possibility that the antiserum may react with 
other proteins present in dog plasma. To investigate these points and in turn validate
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the human assay for measuring dog plasma insulin concentrations, the assay was 
checked for parallelism and recovery using dog plasma. Measurement was as for 
human plasma except for the substitution of charcoal stripped dog serum.
2.11.4.1 Assay Sensitivity
The lower limit of detection for the assay was determined by running a standard curve 
together with 12 zero standards (CSS only). The mean of the zero standards response 
plus two standard deviations corresponds to the limit of detection and is read from the 
standard curve. A value of 10.9 pM was obtained as the lower limit of detection when 
dog plasma was substituted into the assay.
2.11.4.2 Assay Precision and Reproducibility
Intra-assay variation over the standard curve range was determined by running twelve 
of each standard and calculating the coefficients of variation (CV). The CV’s ranged 
from 4.7 % to 6.5 % (Figure 2-4).
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Figure 2-4 Standard Insulin Curve (mean + S.D., N=12)
Inter-assay variation over the standard eurve range was determined from 16 assays ran 
using the same ^^^I-insulin label. The calculated CV’s ranged from 3.3 % to 17.1 % 
(Figure 2-5 Standard Insulin Curve (mean + S .D ., N=16)).
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Figure 2-5 Standard Insulin Curve (mean + S .D ., N=16)
Inter- and Intra-assay variation was also determined from quality control plasma
64
Chapter 2 -  Materials and Methods
samples which were included in every assay and assayed multiple times within the 
same assay. The calculated CV’s are presented in Table 2-3.
Table 2-3 Insulin Inter- and Intra-assay Coefficients of Variation
Low Q.C. (80 pM) High Q.C. (185 pM)
Inter-assay Variation 9 T % 9.6%
Intra-assay Variation 6 j % 6.7%
2.11.4.3 Assay Recovery
Assay recovery was assessed by spiking aliquots of a fasting dog plasma sample with 
known amounts of insulin. In total there were seven samples which had 50 p,l of assay 
diluent replaced with 50 pi of 23, 47, 94, 188, 375 or 750 pM of insulin standards. 
These were assayed in sextuplet, and the results expressed as a percentage of the 
expected insulin concentration. The values obtained ranged from 93-130 % and are 
summarised in Table 2-4.
Table 2-4 Results from Determining Assay Recovery
Expected insulin 
concentration
Assayed insulin 
concentration
S.D. % Recovery
58 pM 58 pM 5.4 100 %
81 pM 75.5 pM 2.2 932%4
105 pM 136.3 pM 84.6 129.8 %
152 pM 145.8 pM 17.9 95^94
246 pM 237.0 pM 24.3 9&3%4
433 pM 413.6 pM 53^ 9 5 J Ï4
808 pM 780.2 pM 75.7 9&6%4
2.11.4.4 Parallelism
Parallelism was assessed by taking a post-prandial dog plasma sample and measuring 
insulin levels at different dilutions. The plasma was diluted with dog CSS to give
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plasma insulin levels that were 100%, 80%, 60% and 40% of the original 
concentration. These were assayed and the results expressed as a percentage of the 
expected insulin concentration. The values obtained ranged from 92-98 % and are 
summarised in Table 2-5.
Table 2-5 Results From  Determining Assay Parallelism
Expected insulin 
concentration
Assayed insulin 
concentration
% of Expected insulin 
concentration
190.0 pM 190.0 pM 100 %
146.4 pM 152.0 pM 96.3%
111.2 pM 114.0 pM 97.6%
70.0 pM 76.0 pM 92.1%
2.12 Gas Chrom atography -  Mass Spectrometer Stable Isotope Analysis
Plasma levels of metabolic tracers labelled with non-radioactive stable isotopes, ^^ C 
and ^H, are measured using a gas chromatogram-mass spectrometer (GCMS). Prior to 
analysis the plasma samples are treated to remove proteins and the metabolites of 
interest are derivatised. The derivatisation process involves adding extra chemical 
groups to the metabolite for three reasons. First, and most important, the 
derivatisation process makes the molecule of interest more volatile and therefore 
easier to vaporise and separate by gas chromatography. Secondly, the derivatised 
molecule will ionised more readily, as it is more volatile. Finally the ion fragments 
produced when the derivatised molecule is ionised will be larger and therefore easier 
to detect above background noise. The derivatisation processes for glucose are 
described below.
There are a variety of glucose derivatives reported in the literature, as reviewed by
6 6
Chapter 2 -  Materials and Methods
(Knapp 1979).
Initial experiments used the butaneboronate acetate derivative of glucose, which is 
described below (Gelding et al. 1993; Widen 1993). This produced a valid derivative. 
However it was found that the measures of sample enrichment were too variable i.e. 
%CV’s >5 %. As a result o f this variability this method was abandoned in favour of 
the oxime, trimethylsilyl derivative. The protocol used to produce the oxime, 
trimethylsilyl derivative of glucose was supplied by Dr P Watt, Department of 
Anatomy and Physiology, University of Dundee (personal communication), and has 
been described by (Knapp1979) and (Shippee et al. 1992).
2.12.1 Butaneboronate Acetate Derivative of Glucose
The reactions for the following method are summarised in Figure 2-6.
Each assay was set-up in duplicate and consisted of plasma samples and an 
enrichment curve. The enrichment curve was constructed by mixing different ratios 
of D-glucose to (6,6-^H)-D-glucose and was essential to account for the influence of 
isotopomers arising from the isotopes of boron.
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Figure 2-6 Butaneboronate Acetate Derivatisation Reaction for Glucose
Plasma samples (50 |ll) were aliquoted into 1.5 ml Eppendorf tubes, to which was 
added 1 ml of ice-cold ethanol. The samples were then vortex mixed and centrifuged 
in a microfuge at 10,500 g  for 10 minutes. The supernatant was transferred to a clean 
Eppendorf tube and evaporated to dryness at 50 °C under nitrogen.
Once dried 5 0  |li1 of butane boronic acid solution (1 0  mg/ml butane boronic acid in 
pyridine) was added and the samples heated at 9 5  °C for 3 0  minutes. After cooling, 
5 0  p,l of acetic anhydride was added and the samples left at room temperature for 1 
hour. All samples were then evaporated to dryness at 5 0  °C under nitrogen and re­
suspended in 5 0 0  |il of pyridine. Finally the samples were transferred to brown 
autosampler vials and sealed immediately.
Isotope enrichment analysis was carried out using the MD800 GCMS fitted with a 
crosslinked methyl siloxane capillary column (HPl). The autosampler was set to 
inject 1 p.1 of a sample into a splitless configuration with helium as the carrier gas.
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The injection port and transfer line were maintained at 270 °C. The GC oven was 
initially set at 130 °C and held at this temperature for 1 minute post-injeetion. The 
temperature was then increased at 25 °C/minute to 240°C, followed by an increase of 
10 °C/minute to 260 °C. Finally the temperature was increased at 50 °C/minute to 300 
°C, where it was held for 2 minutes. The mass spectrometer was set to run with 
electron impact ionisation (El) in selective ion recording (SIR) mode. Data was 
acquired at mass range with a dwell time of 50 milliseconds for each mass and 
analysed using the MassLab (vr. 1.3) software. The masses acquired were 297.1 and
299.1 m/z.
The correct peak was identified by comparing a sample blank, low and high 
concentrations of glucose and 0, 50 and 100 % enriched samples. Further 
conformation of the correct peak was achieved by comparing the spectra obtained, 
with one produced by (Wiecko & Sherman 1976).
The intra-assay CV’s were determined from multiple injections of each standard in an 
enrichment curve (0 -  0.9 APE), and ranged from 5.8 % to 60 %. (Figure 2-7) From 
these results the butaneboronate acetate derivative of glucose was considered to be too 
variable and therefore abandoned. The observed variability was most likely due to the 
influence of the and isotopes of boron, which have relative natural abundances 
of 19.7 % and 80.3 % respectively.
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Figure 2-7 Multiple Injections of each S tandard in an Enrichm ent Curve (N=8)
2.12.2 Oxime, Trimethylsilyl Derivative of Glucose
The reactions for the following method are summarised in Figure 2-8.
H#
D-Glucose
k 0 —
+ #
(H H
+  y
HydroxyIainine.HCl
H,
0  © ^  
0 - 6 - 0 - 0 - 0 - Æ /
0 0 &
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D-Glucose Oxime Derivative 
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Figure 2-8 Oxime, Trimethylsilyl Derivatisation Reaction for Glucose
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Each assay was set-up in duplicate and consisted of plasma samples and an 
enrichment curve (0-2.2 APE). The enrichment curve was constructed by mixing
different ratios of D-glucose to (6,6-^H)-D-glucose.
Plasma samples (10 jxl) were aliquoted into 1.5 ml Eppendorf tubes, to which was 
added 200 |il of ice-cold ethanol. The samples were then vortex mixed and left to 
cool at 4 °C for 15 minutes. After centrifuging the samples in a microfuge at 10,500 g  
for 10 minutes, the supernatant was transferred to a clean Eppendorf tube and 
evaporated to dryness at 50 °C under nitrogen.
The glucose ring structure was converted into an open hexose chain by reaction with 
100 |Lil of fresh oxime reagent (25 mg/ml of hydroxylamine in pyridine) at 70 °C for 
60 minutes. Once cooled the hexose chain was derivatised by reaction with 100 |il of 
BSTFA + 1 % trimethylchlorosilane (TMCS) at 70 °C for 30 minutes. After cooling 
the derivatised samples were transferred to brown autosampler vials and sealed 
immediately.
Isotope enrichment analysis was carried out using the MD800 GCMS fitted with a 
crosslinked methyl siloxane capillary column (HPl). The autosampler was set to 
inject 1 pi of a sample into a splitless configuration with helium as the carrier gas. 
The injection port and transfer line were maintained at 250 °C. The GC oven was 
initially set at 140 °C and held at this temperature for 1 minute post-injection. The 
temperature was then increased at 10 °C/minute to 290°C, followed by an increase of 
50 °C/minute to 300 °C, where the temperature was held for 2 minutes. The mass
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spectrometer was set to run with electron impact ionisation (El) in selective ion 
recording (SIR) mode. Data was acquired at mass range with a dwell time of 50 
milliseconds for each mass and analysed using the MassLab (vr. 1.3) software. The 
masses acquired were 319.2, 320.2 and 321.2 m/z.
The correct peak was identified by comparing a sample blank, low and high 
concentrations of glucose and 0, 50 and 100 % enriched samples. Further 
conformation of the correct peak was achieved by comparing the spectra obtained, 
with one provided by Dr P. Watt (personal communication).
The intra-assay CV’s were assessed from multiple injections of each standard in an 
enrichment curve (0 -  2.2 APE), and ranged from 0.22 % to 3.4 %. (Figure 2-9)
2.5 1
5 "
i  '
O 0.5 -
0.5 1.5 2.5
-0.5
Theoretical APE
Figure 2-9 Multiple Injections of each Standard in an Enrichment Curve (N=8)
72
Chapter 2 -  Materials and Methods
The inter-assay coefficient of variation was determined from an enriched quality 
control plasma sample that was included in each assay. For this method the inter­
assay CV was 2.87 % at a mean enrichment of 5.6 APE.
2.13 Mathematical Modelling; Glucose/Insulin Minimal Model
Mathematical modelling is a powerful technique that can be used to analyse and 
summarise scientific data. A ‘model’ is a function or set of functions, with adjustable 
parameters, that provide a description of the data. The functions used can either come 
from a convenient class of functions, such as polynomials, or represent an underlying 
theory that the data are supposed to satisfy. By altering the adjustable parameters it is 
possible to minimise the difference between model and observed data and find the 
best-fit parameters.
In the case of the glucose/insulin minimal model (Bergman et al. 1979) the functions 
used describe the relationship between the glucose and insulin responses following an 
intravenous glucose tolerance test. Two of the adjustable parameters in this model 
provide indices for insulin sensitivity and glucose tolerance.
Further details o f mathematical modelling and a description of the glucose/insulin 
minimal model are provided in chapter 3.
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3.1 Introduction
Mathematical modelling, in particular biological mathematical modelling, is a vast 
and rapidly changing subject. It is not the purpose of this chapter to give an all 
encompassing review. Instead it is aimed at providing a brief introduction to areas of 
mathematical modelling relevant to this thesis and some of the underlying practical 
processes. The main part of the chapter will then focus on the glucose/insulin minimal 
model (Bergman, Ider, Bowden, & Cobellil979) and its use in determining insulin 
sensitivity.
While there are some mathematical formulae and terminology used within this chapter 
it has been kept to a minimum. The main emphasis has been placed on introducing the 
processes involved and most importantly the glucose/insulin minimal model. 
Thankfully with the availability of computers and software packages a biological 
modeller can focus on the biology instead of the mathematics.
Within the context of this thesis a mathematical model is defined as “..a function or 
set of functions, with adjustable parameters, that provide a description of the data. 
The functions used can either come from a convenient class of functions, such as 
polynomials, or represent an underlying theory that the data are supposed to satisfy.” 
(Press et al. 1999b).
3.2 Glucose/Insulîn Minimal Model
A mathematical model to study in vivo glucose kinetics and insulin sensitivity was
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devised by Bergman et al. (1979) as an alternative to the euglycaemic clamp 
technique. The model uses data obtained from an IvGTT to estimate two conceptual 
parameters. (1) the ability of glucose, at basal insulin, to stimulate clearance and 
inhibit endogenous production of glucose (So), and (2) the ability of insulin to 
enhance the ability of glucose to stimulate clearance and inhibit endogenous 
production of glucose (Si). Plasma insulin concentrations are used to drive the model 
equations and produce a model-derived plasma glucose profile. A best-fit between the 
actual and model derived plasma glucose concentrations may be achieved by altering 
some of the model parameters, which are used to calculate S% and Sq.
 ^ GLUCOSE
Peripheral 
Tissue
PLASMA k i /reMOTFA ks INSULIN 
INSULIN llNSULIN/  ^ DISPOSAL
- 2 2
Figure 3-1 The Glucose/Insulin Minimal Model Scheme as proposed by
Bergman et al. (1979)
The proposed minimal model scheme is represented in Figure 3-1, where each k
represents a rate constant characterising either material fluxes (solid lines) or control
actions (dashed lines). Plasma glucose is shown as a single compartment that is filled
by endogenous glucose production by the liver or during the IvGTT from an initial
intravenous injection of glucose. Glucose appearance from the gut is ignored as the
subject is fasted and not fed during the IvGTT. Glucose disposal is then related to the
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action of insulin levels raised above baseline that stimulate glucose disposal into the 
liver and peripheral tissues. Insulin also inhibits endogenous glucose production by 
the liver. Physiologically, plasma insulin is transported through the endothelium into 
the extracellular fluid where it is able to bind to the cellular insulin receptors and 
exhibit an effect (Bergman et al. 1990). This element of physiology is represented in 
the minimal model by the compartment F, or the remote insulin compartment. It is 
the remote insulin that affects glucose disposal rather than plasma insulin. To make 
the model uniquely identifiable and solvable it is re-parameterised to give equations
3.1 and 3.2, where plasma concentrations of glucose and insulin at time t are 
represented by G(t) and I(t) respectively (Vicini et al., 1998). Similarly, the 
magnitude of the action of insulin in the remote compartment at time t is represented 
byX(t).
At the start of the IvGTT, t = 0, the model assumes instant and uniform mixing of the 
intravenous glucose bolus, giving a theoretical glucose concentration of Go. In 
addition, with baseline plasma insulin levels at the start o f the test, the remote insulin 
compartment is assumed to be empty i.e. X(0) = 0.
The equation for change in plasma glucose (equation 3.1) represents hepatic glucose 
production (Sq.Gss), glucose uptake by the liver and other tissues [-Sc.G(t)] and the 
insulin enhanced uptake of glucose [-X(t).G(t)].
AG(t) = Sg.Gss -  So.G(t) -  X(t).G(t) G(0) = Go (3.1)
Where
Sg = ki +  ks
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Gss = glucose steady-state concentration at the end of the test
The equation for the change in insulin action in the remote compartment represents
the increase from insulin secreted above baseline (p2.Si.[I(t)-Iss]) and insulin clearance
[-P2.X(t)].
AX(t) = p2.Si.[I(t) -  Iss] - P2.X(t) X(0) = 0 (3.2)
Where
X(t) = (k4+k6)r(t)
P2 =  k3
S i  =  —  ( k 4  +  k g )  
ks
Iss = Insulin steady-state concentration at the end of the test
Within equations 3.1 and 3.2 the adjustable model parameters are:
Glucose effectiveness Sg: measures the ability of glucose per se, at basal insulin, to 
stimulate glucose disappearance and to inhibit endogenous production (measured 
in min'^).
Insulin sensitivity Sj: measures the ability of insulin to enhance the glucose per se 
stimulation of its disappearance and the glucose per se inhibition of endogenous 
production (measured in min  ^per unit of insulin concentration, pM).
Insulin action parameter p% (measured in min'^).
Go: glucose concentration extrapolated at time 0 (measured according to the units of 
glucose concentration, mM).
While there is no standard IvGTT protocol a typical test consists of injecting glucose
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(300-500mg/kg body weight) over a 30-60 second period and frequently measuring 
the resulting plasma glucose and insulin concentrations. When originally conserved 
the sampling regime consisted of 32 blood samples taken at regular intervals until 60 
minutes from the start o f the test (Bergman, Ider, Bowden, & Cobellil979). In recent 
years this has been changed to consist of 28 blood samples taken at regular intervals 
until 3-4 hours from the start of the test (Vicini et ah, 1998). Whichever sampling 
protocol is chosen sample handling is crucial. The collected blood samples must be 
centrifuged and the plasma frozen within 30 minutes of the sample being drawn. Also 
due care should be taken during sample analysis to obtain accurate and reliable results. 
Both of these points are important, as the glucose/insulin minimal model is sensitive 
to ‘blips’ in the glucose and insulin profiles, which could result in an increase in the 
parameter errors or a failure to fit the model to the given dataset.
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3.3 Solving Non-Linear Models and Parameter Estimations
The glucose/insulin minimal model equations are non-linear ordinary differential 
equations (NODE’s) and as such have no or multiple solutions. In order to find a 
best-fit solution we have to take a step-wise iterative approach. A typical scheme for 
finding a best-fit solution is outlined in Figure 3-2.
NO
YES
Integrate
function
Set initial 
parameter values
Weighted Sum 
of Squares -  
Compare data
Is decrease in 
WSS zero or 
below accepted 
limit?
Finish and report best-fit values, error 
estimates and goodness-of-fit statistics
Take step closer to 
best-fit and adjust 
parameters -  
Levenberg-Marquardt 
method
Figure 3-2 Typical outline of an algorithm for finding the best-fit solution to a
mathematical model
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3.3.1 Integration of Differential Equations
After setting the initial values for the adjustable parameters the equations are 
integrated over the range of interest, e.g. 0-60 minutes. There are currently a variety 
of computational methods for solving NODE’s that can be classed as Runge-Kutta, 
Richardson extrapolation, or Predictor-corrector methods (Gershenfeld 1999a). Each 
has its own strengths and weaknesses, particularly the Runge-Kutta methods that are 
considered to be the slowest and least computationally efficient. However the Runge- 
Kutta methods are the most stable and almost always find a solution, even for 
complex functions. The other integration methods are best suited to very smooth, 
well-behaved functions (Press et al. 1999a). The most widely used method and that 
chosen by Bergman et al. (1979) to implement the glucose/insulin minimal model is 
the 4* order Runge-Kutta method.
3.3.2 Least Squares Error Method
Having integrated the function and obtained model-derived values it is important to 
measure how different the model derived data is from the experimental data. This can 
be achieved mathematically by squaring the difference between the observed and 
derived data and adding all of these together (sum of squares, SS) (Press, Teukolsky, 
Vetterling, & Flannery1999b). Data that is close in value will have a small difference, 
which when squared add little to the overall total. On the other hand data that have a 
large difference will add much to the total when squared. This method of comparing 
data is called the least squares error method (Figure 3-3). One draw back with the 
least squares error method is that all data are assumed to have the same gaussian
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measurement error. With many experimental protocols this is not always the case as 
the measurement error is a percentage of the data. Therefore data that are large in 
value can have a bigger scatter than data that are small in value and as a result overly 
influence the sum of squares. To get around this the difference between the model 
derived experimental data is divided by the measurement error, squared and all of 
these added together (weighted sum of squares, WSS). This is called the weighted 
least squares error method, and is the error method of choice (Gershenfeld 1999a).
Sum-of-Squares = a  ^+ b^ + c'
Figure 3-3 Least Squares Error method -  calculation of sum-of-squares
3.3.3 Model Parameter Estimations
3.3.3.1 Least Square Error Landscapes
With the ability to compare the model derived and experimental data, the goal of 
fitting the model is to minimise the value of the weighted least squares error. Finding 
the optimum values for the adjustable parameters is an iterative process where we
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search the weighted sum of squares landscape for the lowest point. This is best 
illustrated by finding the best-fit straight line through a set of data. If we take the 
basic formulae for a straight line, y  = m.x, we have one adjustable parameter, namely 
the gradient (m). By altering the value of the gradient it is possible to move the line of 
fit and thereby find the optimal value for the gradient of the line of best-fit through a 
set of data. The error landscape for this can be seen by plotting the sum of squares 
against the gradient for a range of gradient values (Figure 3-4).
2
E
O'
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0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
G radient (m)
Figure 3-4 The sum-of-squares error landscape for a straight line, y  = m.x, fitted 
to a series of jc and y  data over a range of gradient values from 0 to 1. The line of 
best-fit for the data used is found when the gradient is equal to 0.5
By looking at the error plot in Figure 3-4 it is easy to see that the lowest sum of 
squares occurs when the gradient was set to 0.5 for the data used to calculate this plot. 
The function for a straight line can also include a parameter for the y-axis intercept 
(c), such that y  = m.x + c. To visualise an error landscape for this function we plot the 
gradient and intercept on the x- and y-axis and the sum of squares on the z-axis 
(Figure 3-5). Interpreting such a 3-dimensional plot is not easy and it is not clear 
which values for the gradient and intercept produce the smallest sum of squares (in
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Figure 3-5 the minimum sum of squares is found when the gradient and intercept are 
equal to 0.5). The landscape becomes even harder to interperate when the number of 
adjustable parameters increases as there will be an increase in the number of 
dimensions in which to search. Even as little as 4 adjustable parameters would 
require a search of a 5-dimensional plot. It should also be noted that the equation for 
a straight line is a relatively simple function. More complex functions will generate 
error landscapes that have multiple minima, some of which will be close in value.
1
0.6
0.20.2 0.4
0.9 1.0
Figure 3-5 The sum-of-squares error landscape for a straight line, j  = m.x + c, 
fitted to a series of x  and j  data over a range of gradient and y-axis intercept 
values from 0 to 1. The line of best-fit for the data used is found when the 
gradient and j^-axis intercept are equal to 0.5
3.3.3.2 Levenberg-Marquardt Optimisation Method
The standard approach to search the error lanscape is the Levenberg-Marquardt 
method (Gershenfeld1999a; Press, Teukolsky, Vetterling, & Flannery1999b).
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Mathematically we can calculate the gradient of a given point on the error landscape 
by evaluating the first derivative of the weighted sum of squares error function. As a 
point of minimum has a gradient of zero we can find this by moving along the error 
landscape in the direction that decreases the gradient quickest. This is called the 
steepest decent method (Press, Teukolsky, Vetterling, & Flannery1999b). However, 
while the steepest decent method is effective far from a minimum it becomes less so 
close to a point of minimum as the gradient disappears. Alternatively we could use 
the inverse-Hessian method where the second derivative of the weighted sum of 
squares error function gives information about concavity of the function, i.e. the rate 
of change in the gradient of the function (Press, Teukolsky, Vetterling, & 
Flannery1999b). However, while this approach is effective near a point of minimum 
it becomes less so far from a minima as the change in the gradient becomes less. This 
dilema was solved by (Marquardt 1963) who developed a routine that smoothly 
changed between the steepest decent and inverse-Hessian methods during the search 
for a minima. The Levenberg-Marquardt method is currently the standard method for 
adjusting model parameters to find values that produce the best possible fit.
The cycle of adjusting parameter values and assessing the model fit stops when the 
decrease in the weighted sum of squares is zero, or more realistically below a pre­
determined limit. Finally the last step of the fitting process is to report the best-fit 
parameter values together with error estimates of the parameters and a statistical 
measure of the goodness-of-fit. In addition the parameter values should be 
meaningful, relating to the process being modelled, and the model fit should closely 
resemble the data.
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3.3.4 Local Minima and Initial Parameter Values
As was mentioned above, complex models can have error landscapes with multiple 
minima. This can pose problems for the Levenberg-Marquardt method as it will only 
find the minima that is closest to the initial starting point (Press, Teukolsky, 
Vetterling, & Flanneryl999b). With an error landscape that has only one minima 
there are no problems as there is only one possible solution. However, with the 
example in Figure 3-6 there are two possible solutions, one a local minima and the 
other the overall global minima. If initial parameter values are chosen such that the 
search starts a points A or B then the local minima will be found. In order to find the 
global minima the initial values would have to be set to start between points C and D.
(0
3cr
2
9
E
3
(0
Local Minima
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Value of Variable
Figure 3-6 Local minima in the error landscape and the choice of initial
parameter values
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Experimenting with a model and by analysing multiple data sets it is possible to 
define a set of initial parameter values that will allow a best-fit to be found for the 
majority of data analysed. Alternatively some computer programs have an option to 
perform a grid search that assesses the sum of squares over a range of parameter 
values. The set of parameter values that produce the lowest sum of squares are then 
used as the starting point for the Levenberg-Marquardt method. Though not discussed 
here, there are other methods of avoiding local minima that influence the search 
routine itself. These alternatives include giving the search routine an element of 
momentum so that it is able to climb out of local minima and better find the global 
minima (Gershenfeld 1999b). Other approaches take their lead from natural process 
such as simulated annealing, which treats the global minima as a problem in 
thermodynamics and finding the lowest energy level, and genetic algorithms, which 
use the principles of genetics and evolution (Gershenfeld1999b).
3.3.5 Modelling Software -  Use of the ModelMaker Program
ModelMaker (Cherwell Scientific Ltd, 1999) is a generic modelling program that 
allows virtually any process to be modelled or simulated, and was the program used 
by Dr R. Bradley, the modeller at Waltham Centre for Pet Nutrition (WCPN). 
Although not previously cited for solving the glucose/insulin minimal model, the 
model could be readily entered into the program.
In order to check that the model was working correctly the program was compared to
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demonstration versions of SAAM II (Saam Institute Inc., 1997) and Mlab (Civilized 
Software Inc., 1996), which have been used to solve the glucose/insulin minimal 
model and are supplied with example data sets. MinMod was the original program 
developed by Bergman et al to solve the glucose/insulin minimal model, and though 
not available there were published data sets and results to test and compare (Pacini & 
Bergman 1986; Vega-Catalan 1990). Finally, sample data sets and expected results 
were provided by Dr. I. Godsland at the National Heart & Lung Institute (personal 
communication). The ModelMaker program provided results that were consistent 
with the SAAM II program with the various data sets tested. The MLab program 
produced results that differed from SAAM II and ModelMaker and those expected 
from the sample data sets (Table 3-1).
Table 3-1 Model derived parameters, Sg and Si, obtained from the 
glucose/insulin minimal model implemented in the ModelMaker, SAAM II and 
Mlab computer programs. A comparison with results provided by Dr I.
Godsland (personal communiction).
SG(xlO-"min^) Si (xlO'^min ^[mU/mlf')
Dataset* Godsland* ModelMaker SAAM II Mlab Godsland* ModelMaker SAAM II Mlab
A 1.14 1.29 1.27 2.08 1.28 1.20 1.21 0.86
B 2.25 2.21 2.22 2.51 1.72 1.76 1.75 1.64
C 3.47 3.48 3.52 3.36 2.43 2.42 2.39 2.47
D 1.05 1.11 1.11 2.03 2.16 2.11 2.11 4.66
E 3.83 3.83 3.86 4.36 1.66 1.66 1.65 1.62
Datasets and model parameters provided by Dr I Godsland (personal communication) 
After contacting the producers of MLab their reply was that the differences were due 
to a difference in the data weighting schemes used during the fitting process. Overall 
it was concluded that the ModelMaker implementation of the glucose/insulin minimal 
model was correct and comparable to data produced by other institutions and
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computer programs.
3.3.6 Glucose/Insulin Minimal Model Data Weighting
As mentioned above with respect to the weighted least squares error method, it is 
typical to weight each data according to its measurement error. In the case of plasma 
glucose the measurement error should be less than 2%, and for the glucose/insulin 
minimal model the insulin data are without error. The only data that have the 
weightings changed are glucose data from the first 8 minutes of the IvGTT (Bergman, 
Ider, Bowden, & Cobellil979). During this time the glucose kinetics are thought to be 
dominated by the mixing of the glucose bolus within the extracellular fluid. The 
model assumes a single well mixed glucose pool, but this may not be true so, to 
ensure that a model fit is not influenced by the mixing phase data, it is zero weighted, 
or excluded from the data set. In addition to this, some researchers advocate the over­
weighting of the first data point after the mixing phase by a factor of 10-1000 fold 
(Godslandl994). This is unwise as that point may be an outlier and will not 
necessarily lie exactly along the line of best-fit. Overweighting of data has been 
recommended only when a model fit for normally weighted data generates negative 
parameter estimates or if  the user wishes to use the model for simulation purposes 
(Bergman, Beard, & Chenl986).
Within the context of this thesis glucose data from the first 8 minutes of the IvGTT 
was zero weighted, and the remaining data weighted according to a measurement error 
of 1% (section 2.9.1). None of the data was over-weighted.
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3.4 Glucose/Insulin Minimal Model Reproducibility
After establishing the glucose/insulin minimal model and having conducted some 
preliminary IvGTT tests (Chapter 4), the next step was to determine the 
reproducibility o f the IvGTT with minimal model analysis. Intra-individual variability 
was assessed in three dogs which were each studied on six separate occasions.
3.4.1 Study Design
This study was approved by the vetemary surgeons and carried out by the animal 
handlers employed at the WCPN. Animals were selected from those not involved in 
other trials and the study was conducted in accordance with WCPN policy. Sample 
and data analysis was carried out in the Centre for Nutrition, University of Surrey.
The animals used consisted of one male (EM3), aged 5 months, and two female (EM4 
and W Hl), aged 5 months and 6 years, large breed dogs weighing 77, 66 and 57 kg 
respectively. All were kept on a diet of Pedigree Advance Formula Junior Plus (36% 
CHO, 18% Fat, 28% Protein) for the duration of the study with consistent levels of 
exercise. In addition to this dog, W Hl was kept on an adult weight regime.
Each dog was tested with an IvGTT on 6 separate occasions at 4 weekly intervals. 
The tests began at 9.00 am following an overnight fast with water being removed at
8.00 am, and proceeded as follows.
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3.4.2 Intravenous Glucose Tolerance Test
Prior to commencement of the test two venous cannula were inserted into the 
Cephalic veins of the front left and right legs. Before starting the test, 2 mis of blood 
were taken at -10  and 0 minutes for basal glucose and insulin measurements. The 
blood was aliquoted equally (1 ml each) into fluoride/oxalate and Lithium heparin 
blood tubes.
Glucose for intravenous injection was administered at 300 mg/kg body weight as a 
50% w/v solution over 30 seconds followed by a saline flush to ensure complete 
delivery of the glucose bolus. The non-blood taking cannula was used for the 
inftision, and was removed afterwards. Timing started as soon as the glucose inftision 
began with venous blood samples being taken at 2, 4, 6 , 8 , 10, 12, 14, 16, 18, 20, 24, 
28, 32, 36, 40, 44, 48, 52, 56, 60, 90 and 120 minutes. At each time point 2 mis of 
blood was collected and aliquoted in the same manner as the basal blood.
The blood was placed in ice and centriftiged at 1500g for 10 minutes at 4 °C, within 
20 minutes of collection. After centriftigation the plasma was removed from the 
samples and frozen at -20 °C for ftiture analysis.
3.4.3 Data Analysis
The data collected from all the tests were analysed using the glucose/insulin minimal 
model implemented in the ModelMaker program. All of the insulin data were 
included, without error weighting. The 0, 2, 4 and 6 minutes glucose data were not
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entered into the model, equivalent to zero weighting. The remaining glucose data 
were weighted with a 1 % measurement error, which had been determined previously 
(Chapter 2.9.1). Finally the steady-state glucose (Gss) and insulin (Iss) values were 
taken as the end of test plasma glucose and insulin concentrations.
The initial values for the model parameters were as follows:
Go = 15 mM
p2 = 0.03 min'^
Sg = 0.03 min'^
Si = 0.0003 min\pM-^
In addition to minimal model analysis, glucose tolerance and insulin sensitivity were
assessed using the following measurements.
The glucose fractional turnover rate (kivGir) was calculated as minus the gradient of 
the best-fit straight line from 15 to 45 minutes of natural log glucose against time, 
multiplied by 100. This index has units of percentage change glucose per minutes 
(%/min). In addition the incremental glucose response was calculated from 0 to 120 
minutes as the total area under the curve, using the trapezoidal rule, minus the 
baseline value multiplied by the length of the test (lAUCo-no). Together with the 
fasting glucose level these measurements were used to describe glucose tolerance.
Insulin sensitivity was described by the fasting insulin level, the insulin peak response 
(AI) and the insulinogenic index (Al/glucose peak response (AG)). Both AI and AG 
were taken as the maximum increment of insulin or glucose above fasting levels. In 
addition the incremental insulin response was calculated from 0 to 120 minutes using
92
Chapter 3 -  Mathematical Modelling -  Glucose/Insulin Minimal Models 
the trapezoidal rule, IAUCo-i20-
3.4.4 Results
All tests were completed successfiilly, with the exception of the first test for WHl 
during which the blood taking cannula became blocked (Figure 3-9A). Initial 
inspection of the data revealed some anomalies which excluded data from a further 
two tests. The third test for W Hl (Figure 3-9C) had a peak of glucose at 48 minutes, 
which probably resulted from the accidental infusion of a small amount of glucose by 
the animal handlers carrying out the test. Consequently this data was unusable as the 
glucose/insulin model requires data that show a smooth decline in glucose 
concentration. The other data with problems was the second test for dog EM3 (Figure 
3-7B). In this test the plasma insulin concentrations were 2-5 times higher than any 
other test results for this animal. This was unexpected and unexplainable as all the 
insulin samples for EM3 were analysed within the same assay for which the standards 
and quality controls were within normal ranges. In addition, re-analysis of the insulin 
samples produced the same results, and minimal model analysis failed to find a best- 
fit.
The individual plasma glucose and insulin results for dogs EM3, EM4 and W Hl are 
shown in Figure 3-7, Figure 3-8 and Figure 3-9 respectively. The mean plasma 
glucose and insulin results for all three dogs are shown in Figure 3-10.
In all cases the mean plasma glucose concentrations start at a fasting level between 
4.27 -  5.04 mM, peaking at a concentration between 13.5 -  16.7 mM by 2 minutes
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(Table 3-2). The mean plasma glucose levels then decrease back to baseline, 4.2 -  5.1 
mM by 36-60 minutes where they remain until the end of the test.
The series of glucose profiles for each dog are consistent with an average coefficient 
of variation at each time point of 9 + 5 %. Dog EM3 on average is the most glucose 
tolerant as the intravenous glucose bolus is cleared quickly with the mean plasma 
glucose concentration returning to baseline by 36 minutes. This is reflected further by 
the IAUCo-120, which for this dog is the lowest at 135 + 21 mM .120  minutes (Table 
3-2). Dog W Hl has a similar mean glucose profile to EM3. However, it takes until 
60 minutes before the plasma glucose concentrations have returned to baseline, and 
the mean glucose IAUCo-120 is 207 + 51 mM .120  minutes (Table 3-2). Finally, dog 
EM4 is the least glucose tolerant as the mean glucose profile is higher and it takes 90- 
120 minutes to return to baseline. This worsening of glucose tolerance is also 
mirrored by the IAUCo-120 which is nearly double that of dog EM3 at 253 + 45 
mM.120 minutes (Table 3-2).
However, the above findings are not mirrored by the fasting glucose or the glucose 
fractional turnover rate (kivOTx)- hi both instances dog EM3 is the least glucose 
tolerant with the highest mean fasting glucose, 5.04 + 0.19 mM, and slowest kivGiXj
1.75 + 0.23 %/min (Table 3-2). Conversely, dog W Hl is the most glucose tolerant 
with the lowest mean fasting glucose, 4.27 + 0.35 mM, and quickest kivGrr, 2.30 + 
0.31 %/min (Table 3-2).
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Figure 3-7 Plasma glucose and insulin results following intravenous glucose 
infusion to determine the repeatability of the IvGTT in dog EM3 (N=6)
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Figure 3-8 Plasma glucose and insulin results following intravenous glucose 
infusion to determine the repeatability of the IvGTT in dog EM4 (N=6)
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Figure 3-9 Plasma glucose and insulin results following intravenous glucose 
infusion to determine the repeatability of the IvGTT in dog W H l (N=6)
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Figure 3-10 Mean plasma glucose and insulin profiles for three dogs following 
repeated IvGTT tests (Mean, N=6)
Compared to the glucose data the plasma insulin results are more variable with an 
average coefficient of variation at each time point of 29.5 ± 13.0%. The mean plasma 
insulin concentrations for dogs EM3 and EM4 show a fasting insulin concentration of 
48 + 17 and 55 + 15 pM (Table 3-2) that increased quickly to 375 and 253 pM by 2 
minutes. The plasma insulin concentrations then remain at approximately these levels 
until 14 and 18 minutes before returning to baseline by 32 and 56 minutes 
respectively. Dog W Hl has a mean fasting insulin of 55 + 17 pM (Table 3-2) that 
rises to 377 pM by 2 minutes. The mean plasma insulin levels then dip to 352 pM by 
6 minutes before increasing to a peak of 508 pM by 14 minutes. After this 14 minute 
peak the mean plasma insulin levels decrease returning to baseline by 44 minutes.
Despite having the lowest mean insulin peak response (AI) of 283 + 64 pM (Table 
3-2), dog EM4 is not the most insulin sensitive due to a prolonged phase of insulin 
secretion. Comparing the insulin responses (lAUCo-no), dog EM3 is the most insulin 
sensitive with a mean response of 6640 + 1249 pM.120 minutes, followed by dog
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EM4 with a response of 8312 + 2765 pM.120 minutes (Table 3-2). Dog W Hl is the 
least insulin sensitive with an insulin response that is 2 times that of dog EM3 of 
11018 pM. 120 minutes.
Table 3-2 Non-model derived measurements for glucose tolerance and insulin 
sensitivity from repeated IvGTT tests in three dogs (Mean + SD, N=6)
Measurement EM3 EM4 W Hl
Fasting Glucose (mM) 5.04 ±0.19 4.90 ± 0.41 4.27 ±0.35
Fasting Insulin (pM) 48 ± 17 55 ±15 55 ± 17
AI(pM) 322 ± 44 283 ± 64 479 ±110
AEAG (xlO-9) 35.9 + 14.2 25.1+7.8 53.0+10.8
Kjvgtt (%/min) 1.75 ±0.23 1.91 ±0.37 2.30 ±0.31
Glucose lAUC (mM.120 min) 135 + 21 253 + 45 207 + 51
Insulin lAUC (pM.120 min) 6640 ± 1249 8312 ±2765 11018 ±2326
Results from the glucose/insulin minimal model analysis of each data set are 
presented in Table 3-3 with an example of a model fit in Figure 3-11. Dog EM3 is the 
most insulin sensitive with an average Si measurement o f 1.05 + 0.15 xlO*'*mm\pM'^ 
Dogs EM4 and W Hl are less insulin sensitive with average Sj measurements of 0.75 + 
0.19 xlO"^ min'\pM'^ and 0.76 + 0.05 xlO"^ m in '\pM "\ respectively. The average 
coefficient of variation for the Sj measurement from the 3 dogs is 15.8 %.
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Figure 3-11 Example of the Glucose/Insulin minimal model fitted to a set of data
99
Chapter 3 -  Mathematical Modelling -  Glucose/Insulin Minimal Models
The average Sg results for each dog reflect that seen from the lAUC calculated from 
the average glucose profiles. Dog EM3 is the most glucose tolerant with an average 
Sg of 3.32 + 1.48 xlO'^ m in '\ Similarly dog EM4 is the least glucose tolerant with an 
Sg of 2.27 + 0.78 xlO'^ min"\ Finally dog W Hl is similar, but less glucose tolerant to 
dog EM3 with an average Sg of 2.93 + 1.75 xlO'^ m in '\ From this analysis the 
average coefficient of variation of Sg as measured in these three dogs is 46.3 %.
Table 3-3 Model derived parameters, Sq and Si, obtained from glucose/insulin 
minimal model analysis of multiple IvGTT tests in three dogs.
Test
S i (x lO -^  mm\pM-^) 
EM3 EM4 W Hl
SG(xlO‘^ m in ')  
EM3 EM4 W Hl
A 0.92 0.36 - 3.31 1.68 -
B - 0.82 0.77 - 1.60 1.72
C 1.27 0.86 - 2.04 2.35 -
D 1.14 0.77 0.81 4.12 1.94 4.88
E 0.97 0.89 0.69 5.34 3.74 1.20
F 0.93 0.78 0.75 1.78 2.29 3.91
Mean 1.05 0.75 0.76 3.32 2.27 2.93
SD 0.15 0.19 0.05 1.48 0.78 1.75
%CV 14.7 26.1 6.6 44.5 34.6 59.9
Statistical analysis of the data found no significant correlations between the measures 
of glucose tolerance and insulin sensitivity within each dog. Between dogs, W Hl had 
fasting glucose values that were significantly lower than dog EM3 ( f =0.001), and dog 
EM4 (P=0.017). The fractional glucose turnover rates (kivGir) were only significantly 
different between dogs EM3 and W Hl (P=0.01). Similarly, the insulin peak response 
(AI) and insulinogenic index (AEAG) were only significantly different between dogs 
EM4 and W Hl (P=0.004 and P=0.0004 respectively). With regards the model 
derived parameters, the Si values for dog EM3 were significantly different from dog 
EM4 (P=0.021) and dog W Hl (P=0.009). There were no significant differences for 
Sg calculated for each dog.
1 0 0
Chapter 3 -  Mathematical Modelling -  Glucose/Insulin Minimal Models
3.4.5 Discussion
Within this study and the dogs used, the model derived insulin sensitivity parameter. 
S i, was found to be reproducible with a mean coefficient of variation of 15.8 %. This 
was comparable to values reported in human studies of 20.2 % (Steil, Murray, 
Bergman, & Buchananl994), 18.2 % (Krempf, Got, Ziegler, Blanchard, Ranganathan, 
Drouin, & Charbonnel1994), and 14.4 % (Ferrari, Alleman, Shaw, Riesen, & 
Weidmannl991). By comparison the glucose effectiveness parameter, S q , was found 
to be less reproducible with a coefficient of variation of 46.3 %. The coefficient of 
variation for glucose effectiveness has been reported to be 25.1 % (Steil, Murray, 
Bergman, & Buchananl994).
Quite why the glucose effectiveness parameter should be so variable in this study is 
unclear. Part of the variability may be due to the fact that the value for Sq comprises 
of two components (Kahn et al. 1994; Page et al. 1991). By definition S q represents 
the ability of glucose to stimulate its own disappearance into insulin-independent and 
insulin-dependent tissue at basal insulin. Therefore Sg will comprise of basal insulin- 
dependent and non-insulin-dependent components. As a result the variability of Sg 
will be influenced by the variability of glucose uptake into tissue and fluctuations in 
basal insulin. There is also the suggestion that Sg is influenced by hormones, such as 
the andrenocortical hormones, as Sg has been found to be reduced in subjects with 
Cushing’s disease (Page, Boolell, Kalfas, Sawyer, Pestell, Ward, & Alfordl991). 
Since the model does not take into account the affect o f glucocorticoids this is another
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factor that may contribute to the observed variability.
3.5 Modifications to the Glucose/Insulin Minimal Model
The standard glucose/insulin minimal model, which has been described above, is 
widely reported in the literature, and has been used in a variety o f studies. However, it 
is not suitable for subjects that have an impaired insulin response such as those with 
IDDM and NIDDM as they will be unable to effectivley clear the intravenous bolus of 
glucose. This problem was addressed by the inclusion of an exogenous square wave 
insulin infusion of 0.01 U.kg'^min'^ from 20-25 minutes (Finegood, Hramiak, & 
Dupre 1990). This modification to the IvGTT protocol does not require a 
corresponding change to the glucose/insulin minimal model and the same system of 
equations described above are used. The inclusion of an insulin infusion has also 
been suggested for subjects with a normal insulin response as a means of improving 
the accuracy and precision of the minimal model analysis (Quon et al. 1994). As the 
glucose/insulin minimal model is driven by, and therefore dependant upon, the insulin 
response a large or elevated insulin response will be easier to fit and be more 
reproducible. There is a chance with the classic protocol that it may not be possible to 
find a best-fit solution if  a very insulin sensitive subject is studied who has a very low 
insulin response.
3.5.1 The ‘Hot’ Glucose/Insulin Minimal Model
One other modification to the IvGTT protocol in recent years has been the inclusion of 
a glucose tracer, typically stable labelled glucose (6 ,6-^H2-D-glucose) (Avogaro et al.
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1989). The Sj and Sg measurements from the classic glucose/insulin minimal model 
represent the clearance of glucose into the liver and peripheral tissues and the 
production of glucose by the liver. The glucose tracer allows segregation of glucose 
disappearance from endogenous production as the liver is not able to produce labelled 
glucose. Indices of glucose effectiveness (Sq) and insulin sensitivity (Si) for 
peripheral tissue can then be measured by minimal model analysis of the insulin and 
labelled glucose data resulting in reduced errors associated with the parameter 
estimates. This modified model is sometimes refered to as the ‘Hot’ minimal model.
Labelled
GLUCOSE,
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DISPOSAL
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Figure 3-12 The ‘Hot’ Glucose/Insulin Minimal Model Scheme
The ‘hot’ minimal model is very similar to the classic model and is presented in 
Figure 3-12. Within the ‘hot’ minimal model plasma insulin is still used to drive the 
model as the increment above baseline levels, acting through the remote insulin 
compartment, to enhance glucose clearance into the liver and peripheral tissue. The 
glucose profile that the model fits to is the labelled glucose concentration profile. For 
glucose labelled with stable isotope the concentration of labelled glucose is calculated
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from mass spectrometry measurements. As the liver is no longer included as a 
glucose producer it has been removed from the model, but it still exists as a glucose 
consumer. To make the ‘hot’ minimal model uniquely identifaible and solvable it is 
re-parameterised to give equations 3.3 (Vicini, et al. 1998).
G(t) = - [ S g  + X(t)]G(t) G(0) = Go
= -P2{:C(0  -  Si[i(t) -Iss]} :K(t)==() (3 3)
Where
x(t)=k4.r(t)
So = ki 
P2 = ks
^  (3.4)
ks
and Iss is the insulin steady-state concentration at the end of the test.
Within equations 3.3 the model adjustable parameters have the same definition as for 
the classic glucose/insulin minimal model.
As stated above, the concentration of labelled plasma glucose and the associated 
measurement error are calculated from the mass spectrometry measurements (Avogaro 
et al. 1996). Within the following calculations the isotope ratio of labelled species to 
the naturally most abundant species is defined as:
R = [6 ,6 -^H2] - Glucose
[6 ,6-^H2]-Glucose
From the mass spectrometry measurements and the specific derivative used R is
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defined experimentally as:
Peak area for mass 321 "k!R =
Peak area for mass 319*%
In addition R' is the isotope ratio of the incompletely labelled species to the naturally 
most abundant species:
[6 ,6 -^  ] - Glucose
[6 ,6 -^H2]-Glucose
or experimentally:
_ Peak area for mass 320 *%
Peak area for mass 319*%
Finally the subscripts used are defined as:
Rn, R'n - the values o fR  and R'in the baseline samples.
Ri, R'l - the values of R and R' in the infusate.
R(t) - the values of R in the samples taken at time t.
G(t) - plasma glucose concentration at time t.
G*(t) - labelled plasma glucose concentration at time t.
To determine the labelled glucose concentration at time t, the ratio Z between tracer
and tracee mass in each sample are calculated firom the isotope ratio measurements as:
^  Tracer glucose ^  [R(t) - R ^ ](l + R^ + R |)
Tracee glucose [Rj - R(t)](l + Rj^ + R ^ )
The labelled plasma glucose concentration can then be calculated from:
To determine the measurement error associated with each labelled glucose 
concentration the relationship between the isotope ratio, R, and its standard deviation
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(SD[R(t)]) are first evaluated experimentally and in our hands was found to be:
SD[R(t)] = 0.0275 R(t) -  0.0023 
Error propagation is then used to find the standard deviation associated with the 
tracer-to-tracee ratio Z:
Finally error propagation can be used again to find the fraction standard deviation 
(FSD) of the labelled glucose concentration:
FSD[G-(t)] =
where a  is the constant coefficient of variation of the error associated with the total 
glucose concentration, which in these experiments a  = 1%.
3.6 Comparisons of the ‘Hot’ and Standard Glucose/Insulin Minimal Models
With the ability to improve parameter estimates by using a stable isotope tracer and 
the ‘hot’ glucose/insulin minimal model it was possible to compare the classic and 
‘hot’ minimal models. The data for each model was generated &om one IvGTT which 
was conducted in 6 dogs and, within a separate study, in 6 human volunteers.
3.6.1 The ‘Hot’ and Standard Glucose/Insulin Minimal Models in the Dog
3.6.1.1 Study Design
This study was approved by the veterinary surgeons and carried out by the animal 
handlers employed at the WCPN. Animals were selected from those not involved in
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other trials and the study was conducted in accordance with WCPN policy. Sample 
and data analysis were carried out in the Centre of Nutrition, University of Surrey.
The animals used consisted of 4 male and 2 female dogs of mean age, 4.4 + 2.7 years, 
and mean weight, 30.4 + 3.8 kg. The details of each animal tested are presented in 
table Table 3-4. All were kept on a diet of Pedigree Advance Adult Maintenance 
(40.5 % CHO, 16 % fat, 26 % protein) for a minimum of 7 days prior to the test. All 
dogs were kept on an adult weight maintenance regime with consistent levels of
exercise.
Table 3-4 Characteristics of the animals used in the study
Dog Sex Age (yrs) Weight (kg) Breed
D1 Male 2.7 363 Labrador
D2 Female 7.8 263 Labrador
D3 Female 8.0 31.2 Labrador
D4 Male 2.6 323 Labrador
D5 Male 2.7 293 Labrador
D6 Male 2.7 26.4 Labrador
Each dog was tested with a single IvGTT following an overnight fast with water being 
removed at 8.00 am. The IvGTT was started at 9.00 am in each case, and proceeded 
as follows.
3.6.1.2 Labelled Intravenous Glucose Tolerance Test
Prior to commencement of the test two venous cannulae were inserted into the 
cephalic veins of the front left and right legs. Before starting the test 2 ml of blood 
were taken at -10 and 0 minutes for basal glucose and insulin measurements. The 
blood was aliquoted equally (1 ml each) into fluoride/oxalate and lithium heparin
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blood tubes.
Glucose for intravenous injection, containing 12 % w/w 6 ,6 -^H2-D-glucose, was 
administered at 300 mg/kg body weight as a 40 % w/v solution over 30 seconds 
followed by a saline flush to ensure complete delivery of the glucose bolus. The 
cannulae used for the infusion was removed immediately afterwards. Timing started 
as soon as the glucose infusion began with venous blood samples being taken at 2, 4, 
6 , 8 , 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 45, 50, 60, 70, 80, 90, 100, 110, 
120, 140, 160 and 180 minutes. At each time point 2 ml of blood was collected and 
aliquoted in the same manner as the basal blood.
The blood was placed in ice and centrifuged at 1500 g  for 10 minutes at 4 °C, within 
20 minutes of collection. After centrifugation the plasma was removed from the 
samples and frozen at -20 °C for future analysis.
Plasma glucose and insulin concentrations were measured at the Centre of Nutrition, 
University of Surrey. Glucose enrichments were measured using the oxime, 
trimethylsilyl glucose derivative by Dr P. Watt at the Department of Anatomy and 
Physiology, University of Dundee.
3.6.1.3 Data Analysis
The data collected from all the tests were analysed using the classic and ‘hot’ 
glucose/insulin minimal models implemented in the ModelMaker program. For both 
models all of the insulin data were included, without error weighting. The 0, 2, 4 and
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6 minutes plasma glucose and labelled glucose data were not entered into the relevant 
model, equivalent to zero weighting. The glucose data used in the classic 
glucose/insulin minimal model were weighted with a 1 % measurement error.
The concentration of labelled plasma glucose and the associated measurement error 
were calculated from the mass spectrometry measurements as described in section
3.5.1.
Finally the steady-state glucose (Gss) and insulin (Iss) values were taken as the end of 
test steady state plasma glucose and insulin concentrations.
3.6.1.4 Results
The individual plasma glucose and insulin results for all of the dogs are shown in 
Figure 3-13. The individual labelled plasma glucose concentrations and associated 
measurement errors calculated from the mass spectrometry data are presented in 
Figure 3-14.
The results obtained for each dog show similar patterns in the profiles of the total 
plasma glucose, labelled plasma glucose and plasma insulin concentrations. For the 
total plasma glucose profiles the animals have a mean fasting plasma glucose of 4.56 
+ 0.32 mM (mean + SD) that increases rapidly to peak between 13.04 and 17.23 mM 
by 2 minutes from the start of test. Total plasma glucose concentrations then decrease 
at differing rates returning back to baseline levels between 30 and 90 minutes where 
they remain until the end of the test.
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Figure 3-13 Total plasma glucose and insulin results following intravenous 
infusion of [ 6 , -Glucose in six dogs
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Figure 3-14 Labelled plasma glucose concentration in six dogs following 
intravenous infusion of [6,6-^H2]-Glucose plotted with the calculated standard
deviation for each sample
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The labelled plasma glucose profiles show very similar patterns to the total plasma 
glucose profiles. Starting with no labelled glucose being present in the fasting state 
concentrations quickly rise following the bolus infiision peaking between 8.44 and
11.98 mM at 2 minutes from the start of the test. The labelled plasma glucose 
concentrations then decrease at rates that mirror those seen for the total glucose 
concentrations. However unlike the total plasma glucose profiles the labelled plasma 
glucose does not level at a steady state concentration. Instead as the total plasma 
glucose concentrations return to baseline levels the rate at which the labelled plasma 
glucose decreases reduces in all animals to a steady exponential fall.
Finally, while the magnitude of the insulin response differs between each of the dogs 
the overall pattern o f each plasma insulin profile is the same. The plasma insulin 
concentrations start at a mean fasting concentration of 26 + 10 pM (mean + SD) that 
increases rapidly to an initial peak of between 175 and 786 pM insulin by 2 minutes. 
Insulin levels then drop slightly by 4-8 minutes before peaking a second time between 
190 and 624 pM at 12-16 minutes. After this second peak insulin levels then decrease 
returning to baseline levels by 30-45 minutes where they remain until the end of the 
test.
Parameter estimates for Si and Sg for each dog as determined from the ‘hot’ and 
standard glucose/insulin minimal model analysis are presented in Table 3-5.
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Table 3-5 Model derived parameters, Si and Sg, obtained from ‘hot’ and 
standard glucose/insulin minimal model analysis of each IvGTT test in six dogs
Test D1 D2 D3 D4 D5 D6
Standard Model
Si (xlO-^ min\pM-^) 0.93 0.98 0.53 2.34 0.80 1.39
SD 0.04 0.05 0.08 0.14 0.03 0.13
CV (%) 4.83 5.17 15.88 5.94 4.11 9.39
Sg (xlO '2 min'*) 3.17 2.51 1.56 3.00 6.24 4.39
SD 0.46 0.09 0.32 0.62 0.79 0.68
CV(%) 14.57 3.71 20.67 20 .66 12.62 15.40
Hot Model
S i (xlO"* m in '.pM '') 1.45 1.21 0.79 3.10 1.20 1.97
SD 0.07 0.13 0.14 0.17 0.06 0.20
CV(%) 4.89 10.97 17.55 5.45 5.03 10.07
S g  (xlO’^  min^) 0.61 1.04 0.43 0.74 0.94 1.19
SD 0.05 0.07 0.12 0.07 0.07 0.08
CV(%) 8.80 7.11 27.06 10.05 7.41 6.40
Statistical analysis of this data was carried out using the two-tailed students t-test to 
compare differences between groups and Pearson’s product-moment correlation 
coefficient to determine associations between parameter estimates.
From this it was found that the parameters Si and S q  were significantly different when 
calculated firom the standard and ‘hot’ glucose/insulin minimal models (P = 0.003 for 
S i and P = 0.007 for S q) .  It was found that Si was higher in value when estimated by 
the ‘hot’ model. Conversely Sg was smaller in value when estimated by the ‘hot’ 
model. However, there were no significant differences between the associated errors 
for the parameters Si (P = 0.179) and Sg (P = 0.270) for the standard and ‘hot’ 
models.
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When examining the relationships of the parameter estimates from the two models it 
was found that there was no significant correlation between Sg derived from the 
standard and ‘hot’ models (r  ^ = 0.317, P  = 0.245). However, there was a highly 
significant correlation between Si derived from the two models (i^ = 0.984, P = 
0 .0001).
3.6.1.5 Discussion
Overall the study was completed successfully without problems. Minimal model 
analysis was also successfiil in all cases and despite the additional calculations the 
‘hot’ minimal model behaved better than the standard model and was quicker and 
easier to fit to the data.
The differences in the parameter estimates from the two models was also consistent 
with reports in the literature where Si was higher and Sg lower when derived from the 
‘hot’ model (Avogaro, Bristow, Bier, Cobelli, & Toffolol989; Avogaro, Vicini, 
Valerio, Caumo, & Cobellil996). These differences are due to the fact that the 
parameters Si and Sg derived from the standard model also contain the inhibitory 
effect of insulin and glucose respectively on hepatic glucose production (Cobelli et al. 
1986). By contrast the ‘hot’ model parameters represent only the influence of glucose 
and insulin on glucose utilisation as the liver is not able to produce stable-isotope 
labelled glucose.
As well as being able to separate glucose utilisation from production the ‘hot’ 
minimal model is reported to improve parameter precision by reducing the associated
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coefficients of variation (CV). From the literature the average CV for Si derived from 
the standard model has been quoted, for human subjects, at + 22 % and + 105 % 
(Avogaro, Bristow, Bier, Cobelli, & Toffolol989; Avogaro, Vicini, Valerio, Caumo, 
& Cobelli 1996). By contract the average CV for Si from the ‘hot’ model within the 
same subjects, was quoted to be less at + 5 % and + 12 % (Avogaro, Bristow, Bier, 
Cobelli, & Toffolol989; Avogaro, Vicini, Valerio, Caumo, & Cobelli 1996). In a 
similar manner the average CV for Sq has been reported at + 74 % and + 16 % for the 
standard model ,and at + 5 % and + 12 % for the ‘hot’ model (Avogaro, Bristow, Bier, 
Cobelli, & Toffolol989; Avogaro, Vicini, Valerio, Caumo, & Cobelli1996). Contrary 
to this there was no improvement in the parameter CV’s from the use of the ‘hot’ 
minimal model in this study. However this lack of improvement is due to the low 
CV’s associated with the parameter estimates for Si (7.55 ± 4.48 %, Mean + SD) and 
Sg (14.61 + 6.25 %, Mean + SD) from the standard model. These levels of precision 
are comparable to those quoted in the literature for the ‘hot’ model and for the values 
of Si (8.99 ± 4.97 %, Mean + SD) and Sg (11.14 + 7.91 %, Mean + SD) derived from 
the ‘hot’ minimal model analysis in this study. This indicates that in our hands and 
for the dogs studied the standard minimal model is as precise as the ‘hot’ minimal 
model for determining insulin sensitivity.
Finally, comparing the values of Si found in this study with those reported in the 
literature we can see that these animals are insulin sensitive (1.16 + 0.64 x 10'"^  min' 
\pM'^). Reported normal values for human subjects range from 0.51 ± 0.29 xlO'"  ^
min \pM"^ (Avogaro, Bristow, Bier, Cobelli, & Toffolol989) to 1.42 + 0.13 xlO"^ 
min\pM"^ (Ferrari, Alleman, Shaw, Riesen, & Weidmannl991) for the standard
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model. By comparison values for human subjects with NIDDM or those who are 
obese and glucose intolerant range from 0.13 + 0.1 xlO"^ min"\pM'^ (Avogaro, Vicini, 
Valerio, Caumo, & Cobelli1996) to 0.28 + 0.06 xlO"^ min'\pM"^ (Davis, Monti, 
Piatti, Moller, Ng, Coppack, May, Brown, Orskov, & Albertil993).
In conclusion both the standard and ‘hot’ glucose/insulin minimal models were 
implemented successfully within this study. However in our hands and for the dogs 
studied the ‘hot’ model did not deliver improvements in the precision of the model 
parameters S i and S q  when compared to the estimates obtained from the standard 
model. However this lack of improvement may be due to the high levels of precision 
associated with the parameter estimates obtained from the standard minimal model.
Based upon this finding there does not appear to be any advantage to using the ‘hot’ 
model for determining insulin sensitivity in the dog. The ‘hot’ model also has the 
disadvantages of the added costs for the stable-isotope labelled glucose and the more 
complex sample and data analysis. However, this study was only conducted once with 
six healthy dogs and as a result may require further work to assess the reproducibility 
of the ‘hot’ model compared to the standard model. In addition diabetic or glucose 
intolerant animals need to be studied with the two models as it has been reported in 
human studies that the ‘hot’ minimal model is able to provide measures of insulin 
sensitivity in subjects with NIDDM where the standard model has failed (Avogaro, 
Vicini, Valerio, Caumo, & Cobelli 1996).
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3.6.2 The ‘Hot’ and Standard Glucose/Insulin Minimal Models in Humans
3.6.2.1 Study Design
This study was approved by both the ethics committee of the University of Surrey and 
the South West Surrey Local Research Ethics committee. Each of the tests were 
conducted in the Clinical Investigation Unit in The Royal Surrey County Hospital, 
Guildford. Sample and data analysis were carried out in the Centre of Nutrition, 
University of Surrey.
Volunteer subjects for the study were recruited from the staff and postgraduate 
students at the University of Surrey. Subjects were only considered for the study if 
they were over 18 years old, healthy, non-diabetic, non-obese (BMI>30), and free of 
medication that would effect carbohydrate metabolism, other than minor analgesics 
and oral contraceptives. In total 6 subjects were studied with a single IvGTT 
following a 12 hour fast with no food or drink, except water, being consumed after 
8pm. Volunteers were also asked to restrict their levels of exercise and to not 
consume alcohol 24 hours prior to the test.
O f the subjects recruited three were female and three male. The characteristics for 
each of the subjects is presented in Table 3-6 together with the overall group mean. 
The volunteers selected were of similar age, 24 + 2 years, and had fasting biochemical 
and anthropomorphic measurements that were within normal ranges.
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Table 3-6 Fasting biochemical and anthropomorphic characterisations for each 
of the volunteers recruited together with the group mean and standard deviation 
for each of the measured parameters (N=6)
IV l IV 2 IV3 IV 4 IV 5 IV 6 Mean + SD
Fasting Glucose (mM) 4.86 6.29 4.97 5.10 4.76 4.80 5.13 + 0.58
Fasting NEFA (mM) 0.219 0.496 0.520 0.356 0.317 0.500 0.401 + 0.122
Fasting TAG (mM) 0.99 1.35 1.09 1.60 1.32 1.15 1.25 + 0.22
Fasting Cholesterol (mM) 4.49 5.27 3.35 4.34 3.67 3.45 4.09 + 0.74
Fasting Insulin (pM) 22.9 20.6 38.4 33.5 27.6 49.4 32.1 + 10.8
Sex F M F M M F - -
Height (m) 1.59 1.76 1.61 1.77 1.75 1.73 1.70 + 0.08
Waist (cm) 75 75 71 92 75 87 79 + 8
Hip (cm) 102 98 107 109 94 112 104 + 7
Weight (kg) 59.5 67.5 63 81.5 62.5 75 68 + 8
BMI(kg/m^) 23.54 21.79 24.30 26.01 20.41 25.06 23.52 + 2.09
WaistiHip ratio 0.74 0.77 0.66 0.84 0.80 0.78 0.76 + 0.06
Age 25 25 26 25 22 21 24 + 2
3.6.2.2 Labelled Intravenous Glucose Tolerance Test
Prior to commencement of the test two venous cannulae were inserted into the 
Cephalic veins of the left and right arms. Before starting the test 2 ml of blood were 
taken at -10  and 0 minutes for basal glucose and insulin measurements. The blood 
was aliquoted equally (1 ml each) into fluoride/oxalate and lithium heparin blood 
tubes.
Glucose for intravenous injection, containing 12 % w/w 6 ,6 -^H2-D-glucose, was 
administered at 300 mg/kg body weight as a 40 % w/v solution over 60 seconds 
followed by a saline flush to ensure complete delivery of the glucose bolus. The 
cannulae used for the infusion was removed immediately afterwards. Timing started 
as soon as the glucose infusion began with venous blood samples being taken at 2, 4,
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6 , 8 , 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, 44, 45, 50, 60, 70, 80, 90, 100, 110,
120, 140, 160, 180, 210 and 240 minutes. At each time point 2 ml of blood was
collected and aliquoted in the same manner as the basal blood.
The blood was placed in ice and centrifuged at 1500 g  for 10 minutes at 4 °C, within 
20 minutes of collection. After centrifugation the plasma was removed from the 
samples and frozen at -20  °C for future analysis.
Plasma glucose and insulin concentrations were measured at the Centre of Nutrition, 
University of Surrey. Glucose enrichments were measured using the oxime, 
trimethylsilyl glucose derivative by Dr P. Watt at the Department of Anatomy and 
Physiology, University of Dundee.
3.6.2.3 Data Analysis
The data collected from all the tests were analysed using the classic and ‘hot’
glucose/insulin minimal models implemented in the ModelMaker program. For both 
models all of the insulin data were included, without error weighting. The 0, 2, 4 and 
6 minutes plasma glucose and labelled glucose data were not entered into the relevant 
model, equivalent to zero weighting. The glucose data used in the classic 
glucose/insulin minimal model were weighted with a 1 % measurement error.
The concentration of labelled plasma glucose and the associated measurement error 
were calculated from the mass spectrometry measurements as described in section
3.5.1.
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Finally the steady-state glucose (Gss) and insulin (Iss) values were taken as the end of 
test steady state plasma glucose and insulin concentrations.
3.6.2.4 Results
The individual plasma glucose and insulin results for all of the volunteers are shown 
in Figure 3-15. The individual labelled plasma glucose concentrations and associated 
measurement errors calculated from the mass spectrometry data are presented in 
Figure 3-16.
The results obtained for each subject show similar patterns in the profiles of the total 
plasma glucose, labelled plasma glucose and plasma insulin concentrations. For the 
total plasma glucose profiles the subjects have a mean fasting plasma glucose of 5.08 
+ 0.58 mM (mean + SD) that increases rapidly to a peak between 12.48 and 17.69 mM 
by 2-10 minutes from the start of the test. Total plasma glucose concentrations then 
decrease at differing rates returning back to baseline levels by 50-110 minutes where 
they remain until the end of the test.
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Figure 3-15 Total plasma glucose and insulin results following intravenous 
infusion of [6 ,6-^H2]-Glucose in six human volunteers
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Figure 3-16 Labelled plasma glucose concentration in six dogs following 
intravenous infusion of [6,6-^H2]-Glucose plotted with the calculated standard
deviation for each sample
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The labelled plasma glucose profiles show very similar patterns to the total plasma 
glucose profiles. Starting with no labelled glucose being present in the fasting state 
concentrations quickly rise following the bolus infusion peaking between 7.10 and 
11.80 mM at 2-10 minutes from the start of the test. The labelled plasma glucose 
concentrations then decrease at rates that mirror those seen for the total glucose 
concentrations. However unlike the total plasma glucose profiles the labelled plasma 
glucose does not level at a steady state concentration. Instead as the total plasma 
glucose concentrations return to baseline levels the rate at which the labelled plasma 
glucose decreases reduces in all subjects to a steady exponential fall.
Finally, while the magnitude of the insulin response differs between .each of the 
subjects the overall pattern of each plasma insulin profile is the same. The plasma 
insulin concentrations start at a mean fasting concentration of 32 + 11 pM (mean + 
SD) that increases rapidly to peak between 126 and 901 pM insulin by 2-8 minutes. 
Insulin levels then decrease at differing rates returning to baseline levels between 30 
and 90 minutes from the start of the test where they remain until the end of the test.
Parameter estimates for Si and Sq for each dog as determined from the ‘hot’ and 
standard glucose/insulin minimal model analysis are presented in Table 3-7.
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Table 3-7 Model derived parameters, Si and Sg, obtained from ‘hot’ and 
standard glucose/insulin minimal model analysis of each IvGTT test in six
human volunteers
Test IVl IV2 JV3 rv4 IV5 IV6
Standard Model
Si (xlO"* mm\pM-^) 1.04 1.98 0.94 0.74 0.84 0.50
SD 0.17 0.57 0.19 0.04 0.45 0.07
CV (%) 16.58 28.91 19.72 4.80 54.11 14.36
So (xlO'^ min )^ 3.67 1.22 1.89 1.52 1.96 1.65
SD 1.64 0.54 0.67 0.38 1.42 0.52
CV(%) 44.72 44.20 35.76 24.69 72.23 31.14
Hot Model
Si ( x W  min \pM -‘) 1.47 1.88 1.71 0.96 1.08 0.30
SD 0.10 1.20 0.20 0.11 0.12 0.06
CV(%) 6.72 63.60 11.45 11.86 10.96 19.03
Sq (x10‘^  min'^) 0.89 1.17 0.67 0.63 0.93 1.64
SD 0.09 0.08 0.11 0.11 0.09 0.42
CV(%) 10.01 7.22 15.95 17.49 9.34 25.49
Statistical analysis o f this data was carried out using the two-tailed students t-test to 
compare differences between groups and Pearson’s product-moment correlation 
coefficient to determine associations between parameter estimates.
From this it was found that the parameters Sj and Sg were not significantly different 
when calculated from the standard and ‘hot’ glucose/insulin minimal models {P = 
0.177 for Si and P  = 0.061 for S q) .  Similarly there was no significant difference 
between the associated errors for Si when calculated from the standard or ‘hot’ models 
(P = 0.822). However, the associated errors for S q  were significantly different for the 
two model with smaller parameter errors being produced by the ‘hot’ compared to the 
standard models (14.25 ± 6.80 vs 42.12 ±  16.63 % respectively, P  = 0.025).
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Examining the relationships of the parameter estimates from the two models found no 
significant correlations for Si (r  ^= 0.634, P  = 0.058) or Sq (r  ^ = 0.040, P  = 0.704) 
derived from the standard and ‘hot’ models.
3.6.2.S Discussion
The study was completed successfully together with the sample and data analysis for 
all of the subjects.
Unlike the labelled experiments in the dog the parameter estimates from the two 
models are not significantly different. However, the values for S q  showed a general 
trend towards lower values when derived from the ‘hot’ model. As mentioned 
previously this is due to the separation of the inhibitory effect of glucose on hepatic 
glucose production from glucose induced glucose utilisation at basal insulin (Cobelli, 
Pacini, Toffolo, & Saccal986).
With regards the associated measurement errors there was no difference between Si 
derived from the standard (23.08 ± 17.09 %) or the ‘hot’ (20.6 + 21.44 %) models. 
Values for the standard model were comparable with those reported in the literature (+ 
22 %, (Avogaro, Bristow, Bier, Cobelli, & Toffolol989)). However the CV’s from 
the ‘hot’ model were higher than those reported in the literature of + 5 % and + 12 % 
(Avogaro, Bristow, Bier, Cobelli, & ToffoIol989),(Avogaro, Vicini, Valerio, Caumo, 
& Cobellil996). However examining the individual data reveals that the CV for 
subject IV2 may be an outlier as the value of 63 % is far greater than any of the other 
values for the other subjects. Ignoring the values for IV2 and recalculating produces a
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mean of 12 + 4.44 % (mean + SD) which is closer to the values reported in the 
literature, however the CV’s from two models are still not significantly different. 
Conversely the errors associated with the values of Sq are significantly different 
between the models with improved precision in parameter estimates by the ‘hot’ 
model (P = 0.025). It should be noted however that in our hands the standard minimal 
model produces error estimates that are lower than those reported in the literature for 
the standard model.
Comparing the values of Si found in this study with those reported in the literature we 
can see that these subjects are insulin sensitive (1.01 + 0.51 xlO"^ min'\pM'^). 
Reported normal values for human subjects range from 0.51 + 0.29 xlO’"^ min \pM"^ 
(Avogaro, Bristow, Bier, Cobelli, & Toffolol989) to 1.42 + 0.13 xlO"^ min'\pM'^ 
(Ferrari, Alleman, Shaw, Riesen, & Weidmarml991) for the standard model. By 
comparison values for human subjects with NIDDM or those who are obese and 
glucose intolerant range from 0.13 +0.1 xlO"^ min'\pM'^ (Avogaro, Vicini, Valerio, 
Caumo, & Cobellil996) to 0.28 + 0.06 xlO"^ min'\pM"^ (Davis, Monti, Piatti, Moller, 
Ng, Coppack, May, Brown, Orskov, & Albertil993).
To conclude both the standard and ‘hot’ minimal models were implemented 
successfully in this study. From the results obtained for these subjects it is unclear if 
there is an advantage to using the ‘hot’ minimal model as there was no overall 
increase in parameter precision for Si, though there was a significant increase in 
precision for estimates of Sg with the ‘hot’ model. There is a possibility that the 
precision for estimates of Si from the ‘hot’ model may be skewed by one data point,
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however with only one measurement in six people it is not possible to confirm this. In 
addition all of the subjects were young, fit and healthy and as a result not exhibit any 
derangements in glucose tolerance or insulin sensitivity that would effect the 
modelling analysis. Further work is required to compare the two models with more 
individuals, to assess the intra-individual variation and more importantly to assess the 
models in those individuals with reduced glucose tolerance, insulin sensitivity and 
NIDDM.
3.7 Summary
In conclusion, mathematical modelling of experimental data is a powerful tool that 
allows multiple factors and data to be analysed. The glucose/insulin minimal model 
allows a measure of insulin sensitivity to be determined from the plasma glucose and 
insulin responses to a bolus infusion of glucose. In our hands the IvGTT with model 
analysis is reproducible and comparable with other groups.
Modifications to the IvGTT protocol with insulin infusion or the use of stable-isotope 
tracers allow for the improvement in parameter precision. However a comparison of 
the ‘hot’ and standard minimal models was inconclusive in dogs and humans due to 
the healthy nature of the subjects and their small number. Further work would be 
required to assess the two models in more individuals that would have to include 
those with glucose intolerance and NIDDM. However based on this preliminary 
experiment in the dog it appears that the standard minimal model is comparable to the 
‘hot’ model, and in our hands has a similar level of precision. The standard model 
also has the advantages of requiring a less complex sample and data analysis and is
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considerably cheaper.
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CHAPTER 4 - Assessment of Three Methods 
to Determine Insulin Sensitivity in the Dog
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4.1 Introduction
4.1.1 Aims
To evaluate an oral glucose tolerance test (OGTT), intravenous glucose tolerance test 
(IvGTT), and insulin tolerance test (ITT) as suitable tests to investigate glucose 
tolerance and insulin sensitivity in adult dogs. It was also the aim of this study to 
select one of these tests for use in future studies.
4.2 Study Design
This study was approved by the veterinary surgeons and carried out by the animal 
handlers employed at the Waltham Centre for Pet Care and Nutrition (WCFN). 
Animals were selected from those not involved in other trials and the study conducted 
in accordance with WCFN policy. Sample and data analysis was carried out in the 
Centre of Nutrition, University of Surrey.
4.2.1 Animals
Six dogs were originally selected, however, one was excluded at the beginning of the 
study as it came into season. The sex and weight details of each dog used in the study 
are presented in Table 4-1.
Table 4-1 Characteristics of the dogs used in the study
Dog Sex Age (years) Weight (kg) Breed
L1427 Female 3.8 25.7 Labrador
L124 Female 4.7 30.1 Labrador
L215 Male 6 40.0 Labrador
L142 Male 6.4 30.6 Labrador
L150 Female 4 2&3 Labrador
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Four of the dogs were kept on a diet of Pedigree Chum Adult Supreme Advance 
Formula (40.5% CHO, 16% Fat, 26% Protein). The fifth dog (LI427) was kept on a 
diet of Pedigree Chum Activity Plus Advance Formula (29.5% CHO, 20% Fat, 32 
%Protein) as it was lactating. All dogs were kept on an adult weight maintenance 
regime with consistent levels of exercise during the study.
4.2.2 Methods
Insulin sensitivity was measured in each animal using an oral glucose tolerance test 
(OGTT), intravenous glucose tolerance test (IvGTT) and an insulin tolerance test 
(ITT). Each test was conducted on a separate day in a randomised order with a two- 
week rest period between each test.
The tests started at 9.00 am, with the animals fasted overnight and their water 
removed at 8.00  am, and proceeded as follows.
4.2.2.1 Oral Glucose Tolerance Test
Prior to commencement of the test a venous cannula was inserted into the Cephalic 
vein of either the front left or right legs. Before starting the test, 4 mis of blood was 
taken at -10 and 0 minutes for basal glucose, NEFA and insulin measurements. The 
blood was aliquoted into fluoride/oxalate (1 ml), EDTA (1 ml) and Lithium heparin (2 
mis) blood tubes respectively.
Oral glucose was administered at 4 g/kg body weight as a 50% w/v solution. Timing 
started once half of the glucose had been given with venous blood samples being
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collected at 5, 15, 30, 45, 60, 90, 120 and 180 minutes. At each time point, 4 mis of 
blood was collected and aliquoted in the same manner as the basal blood.
The blood was placed on ice and centrifuged at 1500 for 10 minutes at 4 °C, within 
20 minutes of collection. After centrifugation the plasma was removed from the 
samples and frozen at -20 °C for future analysis.
4.2.2.2 Intravenous Glucose Tolerance Test
Prior to commencement of the test two venous cannula were inserted into the 
Cephalic veins of the front left and right legs. Before starting the test 4 mis of blood 
were taken at -10 and 0 minutes for basal glucose, NEFA and insulin measurements. 
The blood was aliquoted into fluoride/oxalate (1 ml), EDTA (1 ml) and Lithium 
heparin (2  mis) blood tubes respectively.
Glucose for intravenous injection was administered at 500 mg/kg body weight as a 
50% w/v solution over 30 seconds. The non-blood taking cannula was used for the 
infusion, and was removed afterwards. Timing started as soon as the glucose infusion 
began with venous blood samples being collected at 3, 5, 10, 15, 30, 45, 60, 90 and 
120 minutes. At each time point 4 mis of blood was collected and aliquoted in the 
same manner as the basal blood.
The blood was placed on ice and centrifuged at 1500 g  for 10 minutes at 4 °C, within 
20 minutes of collection. After centrifugation the plasma was removed from the 
samples and frozen at -20 °C for future analysis.
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4.2.2.3 Insulin Tolerance Test
Prior to commencement of the test a venous cannula was inserted into the Cephalic 
vein of either the front left or right legs. Before starting the test 1 ml of blood was 
collected into fluoride/oxalate blood tubes at - 1 0  and 0 minutes for basal glucose 
measurements.
A bolus dose of quick acting insulin (‘Velosulin’, by Nordisk Wellcome) was given 
intravenously at 0.1 U/kg body weight to start the test. Timing started immediately 
following the insulin dose. Venous blood samples (1 ml) were collected every minute 
for 20  minutes and aliquoted in the same manner as the basal samples.
The blood was placed on ice and centrifuged at 1500 g  for 10 minutes at 4 °C, within 
20 minutes of collection. After centrifugation the plasma was removed from the 
samples and frozen at -20 °C for future analysis.
Glucose for intravenous injection was kept ready in case any of the dogs became 
hypoglycaemic during the test.
4.2.3 Statistics/Calculations
Data are expressed as the mean + standard deviation (mean + S.D.) in both tables and 
graphs, unless otherwise stated. Statistical significance was taken at P  < 0.05.
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From an OGTT the measure for glucose tolerance was taken as the fasting plasma 
glucose concentration and that 2 hours from when the test was started. The diagnostic 
criteria, as stated by the World Health Organisation for venous plasma glucose 
(WHO 1985), are presented in Table 4-2. Fasting plasma NEFA and insulin 
concentrations were also noted together with the integrated responses (total area under 
the curve [TAUC]) and incremental responses ([lAUC] calculated from the TAUC 
minus the baseline value multiplied by the length of the test) for plasma glucose and 
insulin concentrations. The TAUC was calculated using the trapezoidal rule.
Table 4-2 Diagnostic Criteria (WH01985) for Diabetes Using Oral Glucose 
Tolerance to a Standard 75 g Oral Glucose Dose.
Normal Impaired Glucose 
Tolerance
Diabetes
Fasting Glucose <6.4  mmol/L < 7.8 mmol/L >7.8 mmol/L
2 Hour Glucose <7.8 mmol/L 7.8 -1 1 .1  mmol/L >11.1 mmol/L
The measure of insulin sensitivity from an ITT is calculated as minus the gradient of 
the best-fit straight line from 3 to 15 minutes of natural log glucose against time, 
multiplied by 100. This index of insulin sensitivity (knr) has units of percentage 
change glucose per minute (%/min).
From the IvGTT glucose results the glucose fractional turnover rate (k) was calculated 
in the same way as the k m  using data from 15 to 45 minutes and has units of 
percentage change glucose per minute (%/min). The glucose half time (T^) was 
calculated as natural log 2 divided by k and has units of time (mins). Together with 
the fasting glucose levels these measurements described glucose tolerance.
Insulin sensitivity from the IvGTT results was described by the lasting insulin levels,
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insulin peak response (AI) and insulinogenic index (AI/Glucose peak response (AG)). 
Both AI and AG were taken as the maximum increment above fasting levels, for AG 
this was always at 3 minutes post-infusion.
Finally, the integrated and incremental insulin and glucose responses were calculated 
from 0 to 60 minutes using the trapezoidal rule on the IvGTT data, TAUCo-eo and 
IAUCo-60 respectively.
This study was conducted prior to the establishment of the glucose-insulin minimal 
model to analyse IvGTT data and as such had a reduced sampling protocol. However, 
it was still possible to model the available data and calculate the indices of insulin 
sensitivity (Si) and glucose tolerance (So).
Due to the low number of dogs in this study, less than six, it was unwise to rely upon 
any significances found from the statistical tests used to analyse the data. However, 
statistical tests were applied to investigate any underlying trends that may, or may not 
be present in the data.
The test results were tested for approximation to normality using Shapiro-Wilks’ W 
test. If the data approximated to a normal distribution then the appropriate parametric 
tests were used (see below). Conversely, if  the data did not approximate to a normal 
distribution then non-parametric tests were used.
Prior to comparisons between different test results, data were tested for homogeneity
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of variances using Bartlett’s test. This test examines whether data, originating from 
different populations, have equal variations and standard deviations. If the results had 
equal variances then the appropriate parametric tests were performed, otherwise the 
relevant non-parametric tests were used.
Differences between test results (fasting and 2 hour plasma glucose concentrations of 
the OGTT) were analysed using the two-tailed paired Student’s /-test (parametric) or 
the Wilcoxon matched pairs test (non-parametric).
Associations between test results were examined using either the Pearson product- 
moment correlation coefficient (r) (parametric) or the Spearman rank correlation 
coefficient (non-parametric). Only statistically significant correlations are reported.
4.3 Results
The results from each test are presented and described as follows.
4.3.1 Oral Glucose Tolerance Test
The mean plasma glucose, NEFA and insulin results from the five dogs studied are 
shown in Figure 4-1 , Figure 4-3 and Figure 4-5, with the individual results shown in 
Figure 4-2 , Figure 4-4 and Figure 4-6.
The mean plasma glucose results (Figure 4-1) show a fasting level of 4.79 + 0.28 mM 
(mean ± SD, N=5), which increases to a peak glucose of 6.40 ± 0.45 mM by 30 
minutes. Plasma glucose levels then remain at approximately 6 mM for the duration
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of the test, ending at 3 hours with a mean concentration of 5.47 ± 0.72 mM. Contrary 
to this the individual glucose results (Figure 4-2) show extreme variance with no 
apparent pattern.
The individual plasma insulin results (Figure 4-6) are similar to the glucose results in 
that there is extreme variability with no apparent pattern. The mean results (Figure 
4-5) show a fasting insulin of 66.05 + 24.19 pM, which increases to a peak insulin of 
303.51 + 178.12 pM by 15 minutes. Plasma insulin levels then fall to 208.46 + 
137.87 pM at 60 minutes where they approximately remain, finishing the test at a 
mean plasma level of 180.66 + 88.51 pM insulin.
A more consistent pattern is seen in the individual NEFA results (Figure 4-4) that 
decrease at a constant rate from fasting reaching a plateau at approximately 45 
minutes. This pattern is further emphasised by the mean NEFA levels (Figure 4-3) 
that have a fasting level of 0.89 + 0.32 mM that decreases to 0.16 + 0.10 mM by 45 
minutes. The mean NEFA levels then remain at approximately this level for the 
remainder of the test finishing at 0.12 + 0.08 mM.
The results and calculations outlined in section 4.2.3 are presented in Table 4-3.
According to the WHO criteria all the dogs are glucose tolerant, despite the fasting 
and 2 hour plasma glucose levels being significantly different (P = 0.003). 
Comparing fasting and 3 hour plasma glucose levels shows no significant difference 
(P = 0.071), with plasma glucose levels having returned to baseline in two of the dogs.
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Table 4-3 Results and Calculations From Testing Five Dogs With an OGTT
Result L1427 L124 L215 L142 L150
Fasting glucose (mM)^ 4.71 4.61 4.70 5 j# 4.67
Fasting insulin (pM)** 53.8 84J 93^ 65.4 33.0
Fasting NEFA (mM) 1.01 0.87 0.51 0.70 1.35
2 hour glucose (mM) 6.35 6.37 5 j# 5.99 6.51
2 hour insulin (pM)®’** 288.9 263.7 291.4 149.3 840
3 hour glucose (mM) 6.20 5.52 4.72 6.16 4.76
3 hour insulin (pM)’’ 175.8 228.6 284a 167.6 46.5
TAUC glucose (mM.180 min) 1083 1058 1039 1093 1062
TAUC insulin (pM.180 min)*^ 56239 46107 52458 30765 13587
lAUC glucose (mM.180 min)“ 236 228 193 141 223
lAUC insulin (pM.180 min)* 46563 30905 35612 18988 7647
Parameters with similar suffixes are significantly correlated ’^V < 0 .0 5
’^"P<0.01
Correlation analysis of the data showed a significant negative relationship between 
fasting glucose and the incremental glucose response. There were no other significant 
relationships involving the glucose data. Analysing the insulin data showed a 
significant positive relationship between the incremental insulin response and insulin 
levels at 2 hours. There were also very significant positive relationships between 
fasting insulin levels and those at the end of the test, and between the incremental 
insulin response and insulin levels at 2 hours.
138
Chapter 4 -  Assessment of Three Methods to Determine Insulin Sensitivity in the Dog
Figure 4-1 Plasma glucose levels following an oral glucose (4g/kg body weight) in
healthy dogs. (Mean + SD, N=5)
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Figure 4-2 Plasma glucose levels following oral glucose (4g/kg body weight) in 
healthy dogs. (Individual values, N=5)
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Figure 4-3 Plasma NEFA levels following oral glucose (4g/kg body weight) in
healthy dogs. (Mean + SD, N=5)
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Figure 4-4 Plasma NEFA levels following oral glucose (4g/kg body weight) in 
healthy dogs. (Individual values, N=5)
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Figure 4-5 Plasma insulin levels following oral glucose (4g/kg body weight) in
healthy dogs. (Mean + SD, N=5)
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Figure 4-6 Plasma insulin levels following oral glucose (4g/kg body weight) in 
healthy dogs. (Individual values, N=5)
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4.3.2 Insulin Tolerance Test
The mean and individual plasma glucose results from the five dogs studied are shown 
in Figure 4-7 and Figure 4-8 respectively.
The mean plasma glucose results (Figure 4-7) show a fasting level of 4.94 + 0.51 that 
is maintained until 4 minutes. The glucose levels then decrease progressively 
reaching a minimum of 1.99 + 0.64 at 17 minutes. Glucose levels then begin to 
increase finishing the test at 2.27 + 0.07. The individual results (Figure 4-8) show a 
similar pattern with glucose levels remaining constant until 3-4 minutes before 
decreasing at a constant rate, which is different in each animal.
It should be noted that only 2 dogs (LI42 and LI 50) completed the test. The others 
had the test terminated at 14 minutes (L1427) and 18 minutes (LI24 and L215) as they 
showed clinical symptoms of hypoglycaemia. The calculated K m  for each dog are 
presented in Table 4-4. As some dogs did not show a decrease in glucose levels until 
4 minutes, K m ’s were calculated using later time frames (4-15 and 5-15 minutes) in 
such animals.
Table 4-4 Kitt (%/min) Results from Five Dogs Tested W ith an ITT Calculated 
From  Three Different Time Ranges
Time Range L1427 L124 L215 L142 L150
3 - 1 5 &82 7.71 6.40 8.15 7.97
4 - 1 5 &85 7.34 6.51 7.61 8.15
5 - 1 5 6.81 & 86 6.66 7.84 8.44
There were no significant differences between the ranges used to calculate the K m  for 
each dog studied.
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Figure 4-7 Plasma glucose levels following intravenous insulin (0.1 U/kg body 
weight) in healthy dogs. (Mean + SD, N=5)
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Figure 4-8 Plasma glucose levels following intravenous insulin (0.1 U/kg body 
weight) in healthy dogs. (Individual values, N=5)
a
ou
%
a
6.00 1
5.00
4.00  -
3.00
2.00  -
1.00
0.00
*-----L1427
-■ --L 1 2 4
-  - L142
— • ")K • • - L150
4 6 8 10 12 14 16 18 20
Time (minutes)
143
Chapter 4 -  Assessment o f Three Methods to Determine Insulin Sensitivity in the Dog
4.3.3 Intravenous Glucose Tolerance Test
The mean plasma glucose, NEFA and insulin results from the five dogs studied are 
shown in Figure 4-9 , Figure 4-11 and Figure 4-13, with the individual results shown 
in Figure 4-10 , Figure 4-12 and Figure 4-14.
The mean plasma glucose results (Figure 4-9) show a fasting level of 4.69 + 0.43 
increasing to a peak of 17,10 + 1.97 at 3 minutes. The mean glucose levels then 
decrease back to baseline, 4.94 + 1.42, by 30 minutes where they remain until the end 
of the test. The individual results (Figure 4-10) follow the same pattern as the mean 
results peaking at 3 minutes and then decreasing back to baseline by 30-45 minutes, 
where they remain until the end of the test.
The mean plasma insulin levels (Figure 4-13) start at a fasting level of 60.2 + 37.4 pM 
increasing quickly to 352.5 + 95.4 pM by 3 minutes. Insulin levels then increase at a 
slower rate peaking at 566.9 ± 558.5 pM by 15 minutes before dropping sharply to a 
baseline of 42.2 + 19.9 pM by 45 minutes where they remain until the end of the test. 
The individual results (Figure 4-14) show a similar pattern where insulin levels 
increase quickly from fasting reaching a peak between 3-15 minutes where they 
remain until 15 minutes. Plasma insulin levels then drop sharply returning to baseline 
by 30-45 minutes where they remain until the end of the test. The large variability 
seen in the mean plasma insulin levels between 3 and 15 minutes is due in part to one 
dog, L I42, as it has an excessively high insulin response resulting in insulin levels 
five times higher than the other animals. However, fasting and end of test insulin 
levels are unaffected as these are similar in all animals, including L142.
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From the individual NEFA results (Figure 4-12) it can be seen that one dog, L1427, 
has a fasting level of 1.65 mM, which is far greater than in the other dogs. Despite the 
elevated NEFA levels, this dog and all others respond to the test with a decrease in 
NEFA levels reaching a minimum by 15-30 minutes. After 30 minutes the NEFA 
levels then increase, returning to fasting levels by the end of the test. The mean 
NEFA results show a fasting level of 0.73 + 0.52 mM that decreases to 0.19 + 0.11 
mM by 15 minutes. From 30 minutes NEFA levels then increase finishing the test at a 
level of 0.79 + 0.56 mM.
The results and calculations outlined in section 4.2.3 are presented in Table 4-5.
Table 4-5 Results and Calculations From Testing Five Dogs With an IvGTT
Result L1427 L124 L215 LI42 L150
Fasting glucose (mM) 4.90 4.41 4.69 4.17 539
Fasting insulin (pM) 29.1 50.6 120.5 693 31.5
AI/AG (x 1 0 ’) 28.0 2&6 22.5 123.4 19.1
Rivgtt (%/min) 4.35 6.55 3.41 5.67 4.64
T % (minutes) 26.4 30.7 21.1 229 293
S i  ( x  10'  ^min \p M ’^ ) ^ 1.85 Z25 0.97 0.47 2.65
Sg ( x  10’^  min'^) 6.47 6.36 3.64 4.55 5.09
TAUCo-60 glucose (mM.60 min) 425.0 421.8 498.2 407.4 473.1
IAUCo-60 glucose (mM.60 min) 175.4 219.6 248.6 176.4 155.7
TAUCo-60 insulin (pM.60 min) '^^ 6153 9158 12904 30742 5979
IAUCo-60 insulin (pM.60 min)®’^ 4898 7663 9021 27111 4090
Parameters with similar suffixes are significantly correlated P <  0.05
< 0.01
< 0.001
Correlation analysis of the data showed a significant negative relationship between the 
glucose clearance rate, K ivgtt, and model derived insulin sensitivity index, Sj. There 
was also a very significant negative relationship between Kivgtt and the glucose half
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time, T VS. O f the positive relationships found there was a significant correlation 
between T V2 and Si. Finally the insulinogenic index (AI/AG), total insulin secretion 
(TAUC) and incremental insulin secretion (lAUC) were found to have very significant 
positive relationships.
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Figure 4-9 Plasma glucose levels following intravenous glucose (500mg/kg body 
weight) in healthy dogs. (Mean + SD, N=5)
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Figure 4-10 Plasma glucose levels following intravenous glucose (SOOmg/kg body 
weight) in healthy dogs. (Individual values, N=5)
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Figure 4-11 Plasma NEFA levels following intravenous glucose (500mg/kg body 
weight) in healthy dogs. (Mean + SD, N=5)
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Figure 4-12 Plasma NEFA levels following intravenous glucose (500mg/kg body 
weight) in healthy dogs. (Individual values, N=5)
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Figure 4-13 Plasma insulin levels following intravenous glucose (500mg/kg body 
weight) in healthy dogs. (Mean + SD, N=5)
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Figure 4-14 Plasma insulin levels following intravenous glucose (500mg/kg body 
weight) in healthy dogs. (Individual values, N=5)
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4.3.4 Correlation Analysis
Correlation analysis was used to investigate the relationships between each of the 
three tests used. Only significant relationships are presented below in Table 4-6.
Table 4-6 Significant Correlations Found Between an OGTT, IvGTT and ITT
Relationship r: P
Si V OGTT 2 hour glucose 0.936 0.019
IvGTT V OGTT 2 hour glucose 0.946 0.015
Analysing the data graphically showed that dog L I42 may have been an outlier as it’s 
results did not follow the general trends seen with the other dogs. Removing L I42 
and re-analysing the data set revealed the significant correlations seen in Table 4-7.
Table 4-7 Significant Correlations Found Between an OGTT, IvGTT and ITT,
Excluding Dog L142
Relationship r2 P
K nr 3-15 Y Si 0.9527 0.047
Si V OGTT 2 hour glucose 0.9693 0.031
AI/AG V OGTT lAUC glucose 0.9929 0.007
4.4 Discussion
4.4.1 Oral Glucose Tolerance Test
All the dogs in the study completed the OGTT without any problems. However, the 
plasma glucose profiles obtained do not compare to those reported in the literature 
(Kanekol989). According to Kaneko a normal plasma glucose profile should consist 
o f an increase from baseline reaching a peak between 30 and 60 minutes from the start
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of the test. After this point the plasma glucose levels should decrease at a steady rate 
returning to baseline by 2 hours and exhibiting very mild hypoglycaemia by 3 hours.
The mean results obtained in this study show the initial increase in plasma glucose 
reaching a peak 30-45 minutes from the start of the test. However, the expected 
decrease in plasma glucose levels following the initial peak was not seen. The mean 
plasma glucose results show a slight decrease between 45 and 60 minutes after which 
they remain relatively constant until 120 minutes. At this point the mean plasma 
glucose level is still significantly above baseline (P = 0.003). From 120 minutes there 
is a progressive fall in the mean plasma glucose level. This suggests that the dogs in 
this study have a degree of glucose intolerance and insulin resistance despite the 
WHO criteria which classes these dogs as normal with a mean 2 hour plasma glucose 
level below 7.8 mM.
The individual plasma glucose results differ from the mean results and suggest there is 
a problem with the test protocol. In all of the dogs there are two discernable glucose 
peaks during the course of the experiment. This is most clearly seen in the results 
from dogs L124 and L150. In both cases there is an initial peak at 30-40 minutes after 
which there is a return to baseline by 60 minutes. A second plasma glucose peak is 
then seen between 90-120 minutes followed by a return to baseline levels by the end 
of the test. The plasma glucose results for dog L1427 show an initial peak at 15-30 
minutes with a return to baseline by 45 minutes and a dramatic increase in plasma 
glucose levels by 60 minutes. However, unlike dogs L I24 and LI 50, there is no 
return to a baseline level and the plasma glucose remains elevated until the end of the
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test. The second plasma glucose peak in dog L I42 is less clear. After the initial 
plasma glucose peak at 15 minutes there is a slow decrease in plasma glucose, which 
comes close to baseline at 90 minutes. From 90 minutes there is an increase in the 
plasma glucose that appears to peak sometime after the end of the test. Finally L215 
differs from the other dogs in that following the initial plasma glucose peak at 30 
minutes there is a general return to baseline by the end of the test with two relatively 
small peaks at 60 and 120 minutes.
The appearance of a second peak in the plasma glucose profiles suggests that glucose 
is still being absorbed after 1 hour. The observation that this second peak tends to be 
clearly differentiable from the first suggests that the oral glucose bolus is being 
absorbed in a biphasic manner.
Further evidence supporting the idea that glucose is still being absorbed beyond the 
start of the test is given by the plasma NEFA profiles. In all o f the dogs the plasma 
NEFA levels become suppressed by 45 minutes, which is expected from the known 
actions of insulin on NEFA. However, plasma NEFA levels remain suppressed for 
the remainder of the test (P=0.004 at 2 hrs and P=0.006 at 3 hrs) when it would be 
expected that they would increase returning to baseline levels by at least 3 hours.
The plasma insulin responses show patterns almost identical to the corresponding 
plasma glucose profiles. The mean plasma insulin level peaked at 15 minutes 
followed by a slight decrease to 60 minutes where they remained until the end of the 
test, which is very similar to the mean plasma glucose profile. Unlike the mean
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plasma glucose profile the plasma insulin levels at 2 hours and 3 hours are 
significantly raised above baseline measurements (P = 0.013 and P = 0.017 
respectively).
Assuming the unexpected results obtained are due to continuing absorption of glucose 
beyond 60 minutes, the most likely cause is delayed gastric emptying. There are two 
possible reasons for this effect, the first of which is the hyperosmolar nature of the 
bolus. Because the bolus was given, as a non-physiological 50% solution, the high 
osmolality of the solution may have affected gut motility. Alternatively, the dose 
given, 4 g/kg body weight, may have been too large. Comparisons with the human 
OGTT show the dose given to be 4 times larger.
In evaluating the OGTT as a test for measuring insulin sensitivity, the overall 
conclusion is that this test would be unsuitable in the form used above. The most 
important problem is that the test is influenced by the rate of gastric emptying and of 
absorption by the gut, both of which may be affected by alterations in gut physiology 
or gut pathology.
4.4.2 Intravenous Insulin Tolerance Test
The ITT tests were the quickest and easiest of the three tests to carryout. However, as 
mentioned above, only 2 of the dogs completed the tests as the others were stopped 
early due to the dogs becoming hypoglycaemic. This fact gives an initial indication 
that at least 3 of the dogs are insulin sensitive, especially L I427, which showed signs
153
Chapter 4 -  Assessment of Three Methods to Determine Insulin Sensitivity in the Dog 
of hypoglycaemiaby 14-15 minutes.
Despite terminating three of the tests early, the plasma glucose profiles obtained 
compare well to those reported in the literature ((Akinmokun, Selby, Ramaiya, & 
Alberti1992; Gelding, Robinson, Lowe, Niththyananthan, & Johnstonl994; Hirst, 
Phillips, Vines, Clark, & Hales 1993; Young et al. 1996)). In all cases there was a 
delay of 3-4 minutes followed by an exponential fall in the plasma glucose. Looking 
at the mean plasma glucose results further highlights a possible problem in the data 
analysis. All o f the papers reviewed calculated the glucose disappearance constant, 
km , from 3-15 minutes. However, the results obtained from this study show that the 
point from which the plasma glucose declines is variable and in the majority of the 
dogs studied starts from about 4 minutes. It is not clear if  this has occurred in the 
studies reported as they either do not have a 4 minute time point (Hirst, Phillips, 
Vines, Clark, & Hales 1993), or the sample profiles given show a decline from 3 
minutes (Akinmokun, Selby, Ramaiya, & Alberti1992; Young, Critchley, Anderson, 
Lau, Lee, & Chanl996).
Table 4-4 shows the k m ’s calculated from the ranges 3-15, 4-15 and 5-15 minutes. 
Comparing the results for each time range shows that they are very close in value and 
are not significantly different. While the time range used may not overly affect the 
calculated values for km , it may have implications in discriminating between similar 
individuals or different dietary regimes. Looking closely at the results it can be seen 
that dogs L I42 and LI 50 swap order of insulin sensitivity if  4-15 minutes is used 
instead of 3-15 minutes for the data analysis. How significant these findings are is
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unclear and it would require further studies to investigate them. Further studies would 
also have to employ an alternative method of data analysis that would take the 
variable initial delay into account, which may or may not be related to the degree of 
insulin sensitivity.
The mean indices of insulin sensitivity for the three time ranges used were 7.41 
%/min, 7.29 %/min, and 7.32 %/min respectively. Compared to normal humans 
which have reported means of 5.65 %/min (Bonora, Moghetti, Zancanaro, Cigolini, 
Querena, M, Cacciatori, Corgnati, & Muggeol989) and 4.4 %/min (Hirst, Phillips, 
Vines, Clark, & Hales 1993), these dogs appear to be very insulin sensitive. This is in 
agreement with the hypoglycaemia experienced by some of the dogs, and the fact that 
they were very fit and healthy.
In summary the ITT was a very quick and easy test to undertake and in our hands 
produced results comparable to those reported in the literature. All of the dogs tested 
had high levels of insulin sensitivity, which unfortunately increased the risk of 
hypoglycaemia. A development of this test, should it be used routinely, would be to 
stop the test at 15 minutes and hopefully prevent the dogs becoming hypoglycaemic. 
Additional studies would also need to address the issue of the variable delay preceding 
the decrease in plasma glucose, and to develop an alternative form of data analysis.
4.4.3 Intravenous Glucose Tolerance Test
All of the dogs in this study completed the IvGTT’s without any problems obtaining
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plasma glucose and insulin profiles that were comparable to those reported in the 
literature. From the results were calculated measures for insulin sensitivity (k, T!4 
and Si) and pancreatic function (lo, AI, AI/AG and TIS).
As described above k measures the rate at which glucose is cleared from the plasma 
and is used as an index of insulin sensitivity and as an indicator for the presence of 
diabetes. Previous studies reported in the literature (Kaneko, Mattheeuws, Rottiers, & 
Vermeulenl978; Kaneko 1989; Rottiers, Mattheeuws, Kaneko, & Vermeulenl981) 
have calculated k using the plasma glucose levels from 15-45 minutes, however in this 
study the plasma glucose levels had returned to baseline by 30 minutes for three of the 
dogs. If this early return to baseline was not taken into account then it could result in 
artificially low k values. This problem could be resolved by calculating k from 15-30 
minutes. However this was considered unsuitable for this study as there were only 
two data points, which did not necessarily represent the glucose clearance rate. The 
plasma glucose data up to 15 minutes is not used to calculate k as the decline in 
plasma glucose during this phase has been attributed to extracellular mixing of the 
glucose infusion (Rottiers, Mattheeuws, Kaneko, & Vermeulenl981). However, the 
minimal model assumes complete mixing by 8 minutes (Bergman, Beard, & 
Chenl986; Pacini & Bergmanl986), and there are reports in the literature that 
calculate k from 10-42 minutes (Vega-Catalanl 990) and from 10-19 minutes (Steil, 
Murray, Bergman, & Buchananl994). To investigate the influence of using data prior 
to 15 minutes the values for k were calculated from 7 , 1 0  and 15 minutes to 30 
minutes and from 15-45 minutes (Table 4-8). From the results obtained and the 
comparisons made it can be seen that the values for k calculated from 15-45 minutes
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are significantly different firom the other three time ranges used. This indicates that 
for these dogs studied it is inadvisable to include the 45-minute data. It can also be 
seen that there were no significant differences {P > 0.800) in the k values obtained 
from the time ranges that do not include the 45-minute data. This gives an indication 
that plasma glucose levels are decreasing at a constant rate from 7-minutes onwards. 
Taking these findings into consideration the values for k were calculated from 10-30 
minutes as this time range ensures complete extracellular mixing of the glucose 
infusion and takes into account the return of plasma glucose levels to baseline by 30 
minutes.
Table 4-8 Influence of time range used on calculated k  values (%/min)
Time Range | L1427 L124 L215 L142 L150
7 - 3 0  mins ^ 4.27 6.46 3.31 5.50 4.38
10 -  30 mins 4.35 6.55 3.41 5.67 4.64
15 -  30 mins 3.77 6.70 3.37 6.42 4.75
15-45 mins^*’*^ 2.62 :226 128 3.03 238
Parameters with similar suffixes are significantly different :  ^P  = 0.012
= 0.005 
" P  = 0.007
From the literature values of k for healthy, non-diabetic dogs have been reported in 
the region of 2.76 ± 0.91 %/min (Kaneko, Mattheeuws, Rottiers, & Vermeulenl978) 
and 2.63 + 0.44 %/min (Mattheeuws, Rottiers, Kaneko, & Vermeulenl984). By 
comparison the dogs in this study are very insulin sensitive with a mean k of 4.92 ± 
1.21 %/min. In addition as a reduced k is an indicator for the presence of diabetes it is 
possible to say with a high degree of certainty that none of the dogs in this study were 
diabetic.
The parameters that describe pancreatic function are used to classify the type of
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diabetes dogs have when the k value is low. As none of the dogs in this study were 
considered diabetic we would expect the pancreatic function measurements to be 
within normal ranges. In all cases the fasting insulin levels (lo) were normal when 
compared to the reported values of 90 + 37 pM (Mattheeuws, Rottiers, Kaneko, & 
Vermeulenl984) and 43 + 12 pM (Kaneko, Mattheeuws, Rottiers, &
Vermeulenl978). With regards the other measurements, four o f the dogs studied were 
within normal measurement ranges. The exception, L I42, had an insulin response 
that was far greater than the other dogs. Despite having a normal fasting plasma 
insulin the incremental peak insulin (AI) of 1472 pM was over 4% times larger than 
the reported normal ranges (Kaneko, Mattheeuws, Rottiers, & Vermeulenl978; 
Mattheeuws, Rottiers, Kaneko, & Vermeulenl984; Rottiers, Mattheeuws, Kaneko, & 
Vermeulenl981). Also considering this dog had a normal plasma glucose profile it is 
no surprise that the insulinogenic index was 6 times larger than the reported normal 
ranges of 15 + 4 (Mattheeuws, Rottiers, Kaneko, & Vermeulenl984), 27 + 19 
(Rottiers, Mattheeuws, Kaneko, & Vermeulenl981) and 18 + 8 (Kaneko, Mattheeuws, 
Rottiers, & Vermeulenl978). Finally, as can be seen in Figure 4-14, the total insulin 
secretion (TIS) was greatly in excess of the expected values of 10312 + 2497 pM.min 
(Mattheeuws, Rottiers, Kaneko, & Vermeulenl984) and 6300 + 3540 pM.min 
(Rottiers, Mattheeuws, Kaneko, & Vermeulenl981).
While four of the dogs in this study are considered to have normal pancreatic function, 
L142 clearly does not. Despite the excessive insulin response this dog had a glucose 
profile that was very similar to the other dogs and a glucose clearance rate that was 
above the reported normal ranges and the group average. This suggests that this dog
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is not glucose intolerant or diabetic. The insulin response, though high, had a similar 
pattern to the responses of the other dogs. From a normal fasting level the insulin 
levels quickly increased, peaking between 7-15 minutes. Plasma insulin levels then 
quickly returned to a normal baseline level between 30-45 minutes. This response 
suggests that this dog requires an elevated insulin response to maintain a normal 
glucose clearance, but not in order to maintain a normal fasting glucose level. Based 
on this evidence it is considered that dog L I42 is in the first stages of insulin 
resistance for which it is able to maintain a normal glucose tolerance with an elevated 
insulin response.
While the measurements made can be used to identify glucose intolerance and 
describe the type of diabetes none of them give a clear measure of insulin sensitivity. 
As can be seen from the case of dog L I42 the glucose clearance rate does not take into 
account the underlying insulin response that may or may not be considered normal. 
Likewise the incremental plasma insulin, total insulin secretion and fasting insulin are 
not linked to the glucose response, which again may or may not be normal. Only the 
insulinogenic index takes into account both plasma insulin and glucose. However, the 
insulinogenic index only considers the first five minutes of the test, ignoring the rest 
of the data. These problems are highlighted when looking at the correlations between 
each of these measurements. When comparing the glucose clearance rate to the other 
measurements it was found only to correlate with the half time for glucose clearance 
(P = 0.004), which is not surprising as the T!4 for glucose is calculated from k. hr a 
similar manner the peak incremental insulin, total insulin secretion and insulinogenic 
index were found to have significant correlations between them (P >0.010), but not
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with any of the other measurements.
The glucose-insulin minimal model ((Bergman, Ider, Bowden, & Cobellil979), 
Chapter 3) resolves these problems as the measure for insulin sensitivity. Si, is derived 
from both the insulin and glucose responses. Though this study was performed prior 
to the establishment o f the minimal model and not designed for analysis by this 
method it was still possible to derive measures for Si from the available data. 
Presented in Table 4-5, the results of the minimal model analysis show that dog L I42 
was insulin resistant with an Si of 0.47 x IC^ min'VpM and the other dogs insulin 
sensitive with an average Si of 1 .93 ± 0.72 min'VpM.
Table 4-9 Model derived parameters, Si and Sq, from minimal model analysis of 
the IvGTT data generated for five dogs
Parameter L1427 L124 L215 L142 L150 Mean SD
Si (xlO^ min’\pM ’V
Sg (xlO^ min’V
1.85
6.47
2.25
6.36
0.97
3.64
0.47
4.55
2.65
5.09
1.64
5.22
0.90
1.21
Values reported in the literature for Si range from 0.27 + 0.05 min’VpM in obese 
glucose intolerant adults (Bergman, Beard, & Chenl986), to 1.43 ± 0.14 min’VpM in 
healthy young men (Ferrari, Alleman, Shaw, Riesen, & Weidmannl991).
To summarise, the IvGTT tests were completed successfully and without 
complications. From the measures for the rate of glucose clearance and pancreatic 
function it was found that four of the dogs were insulin sensitive and one, L142, was 
insulin resistant. It was also found that these measurements did not provide a single 
measure for insulin sensitivity that may be used for future intervention or population
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studies. However, this could be resolved with application of the glucose-insulin 
minimal model that provided a measure for insulin sensitivity, Sj.
4.4.4 Test result comparisons
Due to the unexpected and inconsistent results obtained from the OGTT’s it was 
considered unwise to compare these results to those obtained from the ITT’s and 
IvGTT’s. Initial Pearson product-moment correlation analysis between the ITT 
glucose clearance rates and the various measurements from the IvGTT’s found no 
significant correlations between any of the data. This was unexpected, as we would at 
least anticipate a significant relationship between k m  and Si as these represent direct 
measures o f insulin sensitivity. Analysing the different correlations graphically 
showed that, at least for the relationship between km(3-i5) and Si, one of the dogs, 
L142, may have been an outlier and skewing any significant relationships. Figure
4-15 presents graphically the relationship between km(3-i5) and Si, and shows how the 
values for L I42 deviate from the expected trend. For the group as a whole there was 
no significant correlation (r  ^ = 0.026, P = 0.796), however excluding dog L142 and 
performing correlation analysis found a positive significant correlation between km (3- 
15) and Si (P=0.047), and a possible trend between the km (4-i5) results and Si 
(P=0.076). There were no other significant correlations to report between the test 
results.
According to the results from the ITT, dog L142 is the most insulin sensitive dog in 
the group with a km(3-i5) of 8.15 %/min. However, as found from the IvGTT this dog
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is in the first stages of insulin resistance requiring an elevated insulin response to 
produce a normal glucose tolerance. This unexpected difference is most probably due 
to the supraphysiological insulin levels that follow insulin infusion in the ITT. 
Measurements for plasma insulin during an ITT for human subjects found that insulin 
levels reached a peak of 6500 pM, 1 minute after the infusion of insulin (Hirst, 
Phillips, Vines, Clark, & Hales 1993). This was 4 times larger than the insulin peak 
response for dog L142. It is no surprise then that dog L142 had a normal insulin 
sensitivity measured by the ITT as the insulin levels induced were greatly in excess of 
that required for normal glucose tolerance. This finding highlights a major problem 
with the ITT as subjects that are in the first stages of insulin resistance, or have mild 
insulin resistance, have the potential of being classified as insulin sensitive due to 
supraphysiological insulin levels stimulating a normal rate of glucose clearance.
Figure 4-15 Pearson product-moment correlation analysis between kiTX(3-i5) and 
Si derived from healthy dogs. (N=5)
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4.4.5 Summary
In conclusion all tests were completed successfully, despite the problems found during 
data analysis. Of the three test studied, the IvGTT was considered to be the most 
suitable to determine insulin sensitivity as it was not influenced by the gut and was the 
only test to detect that Dog L142 was insulin resistant.
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CHAPTER 5 - n-3 PUFA Dietary 
Supplementation in Dogs.
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5.1 Introduction
5.1.1 Aims
From human based epidemiological studies, it has emerged that a diet high in fish oil 
is associated with a lower risk of developing coronary heart disease. It is thought that 
fish oil improves insulin sensitivity, thereby reducing the derangements in metabolism 
associated with an insulin resistant state. It was therefore the aim of this study to 
determine the effect dietary supplementation with fish oil would have on insulin 
sensitivity within the dog, as assessed by the IvGTT with minimal model analysis.
5.2 Study Design
This study was an extension to a six month marine fish oil (MFO) safety trial which 
formed part of product development at the Waltham Centre for Pet Care and Nutrition 
(WCPN). At the end of the safety trial the six dogs used were tested with an IvGTT 
and had a blood sample taken to determine red blood cell fatty acid profiles. All dogs 
were then placed on a control diet, minus MFO, and after seven months were re-tested 
with an IvGTT and blood sample for red blood cell fatty acid profiling. The extension 
was approved by the veterinary surgeons and carried out by the animal handlers 
employed at the WCPN, and conducted in accordance with WCPN policy. Sample 
and data analysis was carried out in the Centre of Nutrition, University o f Surrey.
5.2.1 Animals
The six dogs on the MFO safety trial had a mean age of 5 years (SD 2.5) and were fed
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test product containing 0.08 g eicosapentaenoic acid (EPA) and 0.06 g 
docosahexaenoic acid (DHA) per 100 g food. During the control period the dogs were 
fed standard product without MFO. All dogs were kept on an adult weight 
maintenance regime with consistent levels of exercise during the study. The 
characteristics of the animals used in the study are presented in Table 5-1.
Table 5-1 Characteristics of the animals used in the study
Dog Sex Age (yrs) Breed
L124 Female 6 Labrador
L34 Female 8 Labrador
L198 Female 4.5 Labrador
L142 Male 7.5 Labrador
L1403 Female 2.5 Labrador
L1478 Female 2 Labrador
5.2.2 Methods
The IvGTT started at 9.00 am, with the animals fasted overnight and their water 
removed at 8.00  am.
Prior to commencement of the test two venous cannula were inserted into the 
Cephalic veins of the front left and right legs. Before starting the test 3 mis of blood 
were taken at -10  and 0 minutes for basal glucose and insulin measurements. The 
blood was aliquoted into fluoride/oxalate (1 ml) and Lithium heparin (2 mis) blood 
tubes respectively.
Glucose for intravenous injection was administered at 300 mg/kg body weight as a 
50% w/v solution over 30 seconds. The non-blood taking cannula was used for the 
infusion, and was removed afterwards. Timing started as soon as the glucose inftision 
began with venous blood samples being collected at 2, 4, 6 , 8 , 10, 12, 14, 16, 18, 20,
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24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 90 and 120 minutes. At each time point 3 mis of 
blood was collected and aliquoted in the same manner as the basal blood.
The blood was placed on ice and centrifuged at 1500 g  for 10 minutes at 4 °C, within 
20 minutes of collection. After centrifligation the plasma was removed from the 
samples and frozen at -20  °C for ftiture analysis.
One to two weeks after the IvGTT, 10 mis of blood was collected, from the jugular 
vein, for red blood cell fatty acid analysis. The blood sample was handled and 
analysed as described in Section 2.10.
After the sample for red blood cell fatty acid analysis was taken the dogs were placed 
on the control diet, which was not enriched with MFO. Seven months after the first 
IvGTT it was possible to re-test these dogs with a second IvGTT and to determine the 
red blood cell fatty acid profiles.
5.2.3 Statistics/Calculations
The data is expressed as the mean + standard deviation (mean + S.D.) in both tables 
and graphs, unless otherwise stated. Statistical significance was taken at P  < 0.05.
The indices of insulin sensitivity and glucose effectiveness. Si and So, were calculated 
using the glucose-insulin minimal model analysis of the IvGTT data. In addition 
fasting glucose and insulin plasma concentrations were noted together with the insulin 
peak response (IPR or AI) and the glucose peak response (AG). Both the AI and AG 
were taken as the maximum increment above fasting levels, for AG this was always at
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2 minutes post-infusion. The AI and AG were used to calculate the insulinogenic 
index (AI/AG).
The incremental insulin and glucose responses were calculated from 0 to 60 minutes 
using the trapezoidal rule on the IvGTT data, LAUCo-eo.
Finally the glucose fractional turnover rate (kivGir) was calculated as minus the 
gradient of the best-fit straight line from 15 to 45 minutes of natural log glucose 
against time, multiplied by 100. The kivoxT has units of percentage change glucose per 
minute (%/min).
The results were tested for approximation to normality using Shapiro-Wilks’ W test. 
If the data approximated to a normal distribution then the appropriate parametric tests 
were used (see below). Conversely, if  the data did not approximate to a normal 
distribution then non-parametiic tests were used.
Prior to comparisons between the diets the data was tested for homogeneity of 
variances using Bartlett’s test. This test examines whether the data, originating from 
different populations, have equal variations and standard deviations. If  the results had 
equal variances then the appropriate parametric tests were performed, otherwise the 
relevant non-parametric tests were used.
Differences in test results between the MFO and control diets were analysed using the 
two-tailed paired Student’s r-test (parametric) or the Wilcoxon matched pairs test 
(non-parametric).
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5.3 Results
All tests were completed successfully with the exception of the control diet IvGTT for 
dog L142 during which the cannula became blocked and the test was stopped. 
However, dog L I42 had been tested twelve months previously with an IvGTT (see 
chapter 4) while on the same diet and, as the initial plasma glucose and insulin 
responses to the intravenous bolus glucose in both control diet tests were similar, it is 
the complete data set from the earlier test which is presented here. The individual 
plasma glucose and insulin responses for the MFO enriched diet are presented in 
Figure 5-1 and the individual results from the control diet are presented in Figure 5-2. 
The mean plasma glucose and insulin data for each diet are presented in Figure 5-3. 
Finally, the mean red blood cell fatty acid profiles for each diet are presented in Figure
5-4.
In all dogs the fasting plasma glucose levels ranged between 3 .93 -5 .19  mM which, 
following the glucose bolus infusion, increased to a concentration of 12 -  17.5 mM by 
2 minutes. Plasma glucose levels then decreased progressively, returning to baseline 
levels between 3 6 - 9 0  minutes from the start of the test. This pattern is reflected in 
the mean glucose data where the control and MFO data have a mean fasting glucose 
of 4.67 + 0.47 mM and 4.39 + 0.13 mM that peaks at 14.21 + 0.64 mM and 13.35 + 
2.16 mM respectively by 2 minutes. Plasma glucose levels then decrease 
progressively in both instances with the control data returning to baseline by 60 
minutes and the MFO data by 44 minutes, where they remain until the end o f the test. 
There was no apparent difference between the mean control and MFO glucose 
profiles.
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Compared to the glucose data, individual insulin profiles were more variable with 
fasting insulin levels ranging from 31 -  106 pM. Following intravenous glucose 
plasma insulin levels peaked at levels between 200 -  1600 pM insulin by about 20 
minutes. Plasma insulin levels then progressively decreased returning to baseline by 
32 -  60 minutes. This variability is further reflected by the large standard deviations 
associated with the mean insulin data. The control and MFO data have mean fasting 
insulins of 53 + 36 pM and 57 + 21 pM respectively, that increase rapidly peaking at 
309 + 202 pM and 282 + 132 pM by 2 minutes. Following a slight dip in levels at 4 
minutes the mean plasma insulin levels for the control and MFO data peak by 12 
minutes at 434 + 299 pM and 367 + 196 pM respectively before progressively 
decreasing to baseline levels by 44 minutes.
Comparing the red blood cell fatty acid profiles for each diet revealed a significant 
increase in stearic acid (C l8) (P = 0.029), EPA (C20:5) (P > 0.001), and DHA 
(C22:6) (P = 0.007) with MFO dietary supplementation. Conversely there was a 
significant decrease in palmitic acid (C l6) (P = 0.039) with MFO dietary 
supplementation. However, there was no overall difference in the total saturated fatty 
acids (stearic acid + palmitic acid) between the control (36.2 + 7.6 mol%) and MFO 
(34.0 + 4.4 mol%) diets (P = 0.549). Total n3-PUFA, as EPA + DHA, was 
significantly between the control (1.7 + 0.4 mol%) and MFO (6.2 +1 .2  mol%) diets 
(P > 0.001). There were no significant differences in any of the other fatty acids.
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Figure 5-1 Plasma glucose and insulin responses in six dogs being fed a fish oil 
enriched diet (Individual results, N = 6)
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Figure 5-2 Plasma glucose and insulin responses in six dogs being fed a control
diet (Individual results, N = 6)
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Results from minimal model analysis of the IvGTT profiles and the calculations 
described in section 5.2.3 are presented in Table 5-2. Statistical analysis of the 
various measurements for glucose tolerance and insulin sensitivity found no 
significant differences between the control and MFO enriched diets.
5.4 Discussion
As mentioned above there were no significant changes detected with regards insulin 
sensitivity following dietary intervention with MFO. However, red blood cell fatty 
acid analysis did show a significant incorporation of EPA and DHA into cell 
membranes with levels over 3.5 times that seen with the control diet. There was also 
an increase in stearic acid incorporation though this was countered by a decrease in 
palmitic acid, resulting in no overall change in total saturated fatty acid content. The 
MFO intervention was therefore regarded successful in altering membrane fatty acid 
composition.
The lack of any significant change in insulin sensitivity may be due in part to the fact 
that healthy dogs were used in the study. From the literature normal human values for 
Si have been reported to range from 0.51 + 0.29 xlO*  ^min'\pM'^ (Avogaro, Bristow, 
et al. 1989) to 1.42 + 0.13 xlO'^ min'\pM'^ (Ferrari, Alleman, et al. 1991). Compared 
to the control values in this study all of the dogs can be classed as being insulin 
sensitive, despite dogs L I24, L I42 and L I403 having relatively low values for Si. In 
addition, MFO supplementation cannot be expected to improve insulin sensitivity if 
the subjects being tested are not insulin resistant. This is a major flaw in the design of 
the study and should therefore be repeated in dogs that are known, or are expected to 
have a degree of insulin resistance.
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Examining the values of Si between the diets shows that for all dogs, except LI403, 
insulin sensitivity increases, though not significantly. To what extent this change is 
real however is unclear due to its magnitude and the fact that only five dogs improve. 
Though encouraging further work would be needed with more dogs to improve the 
power of the study.
One point to note however is the insulin profile for dog L I42 which had an 
abnormally high insulin response. This finding had been found in earlier studies 
(Chapter 4). For this dog there appears to be a positive effect o f dietary 
supplementation with MFO. With the control diet this dog had on average an insulin 
response (IAUC0-120) of 34228 pM/120 minutes, which was approximately 5 times 
that of the other dogs. However, this was reduced following MFO dietary 
intervention to a level of 8478 pM/120 minutes, a quarter of what it had been 
previous. Similarly, insulin sensitivity, as assessed by the minimal model, was 
doubled following MFO supplementation (Control Si = 0.53 xlO"^ min'\pM"^). 
However, fasting glucose and insulin remained unchanged together with the glucose 
response (lAUCo-iio). This suggests that for dog L142 MFO supplementation has 
improved insulin sensitivity and consequently resulted in a lower insulin response. 
However, there has not been any apparent affect with regards the glucose response or 
fasting glucose and insulin levels.
In conclusion, the positive effect of MFO for all dogs, except L1403, is encouraging 
and suggests a positive effect of MFO supplementation on insulin sensitivity. 
However, this was only found in two of the six dogs tested and therefore warrants 
further investigation in dogs that are known to be insulin resistant.
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This thesis has focused on insulin responsiveness in dogs with a particular emphasis 
on methodological approaches.
Mathematical modelling formed the framework for approaching these studies. The 
model used was the “minimal model” as described by Bergman (1979). This is based 
on first principles but assumes that glucose and insulin behave as homogenous well- 
mixed pools, which may not be true. Reproducibility was tested using a number of 
software applications and a number of datasets and I was thus able to validate the use 
of this model within the Modelmaker programme.
Biological reproducibility of this type of model analysis was tested by model analysis 
of repeated IvGTT’s in three dogs. The insulin sensitivity parameter. Si, had a CV of 
about 16%, which is comparable to that found by other groups. Small changes in Si, 
less than 16% or one standard deviation, may therefore be difficult to detect by this 
approach. Such reproducibility is comparable to other methods, for determining 
insulin sensitivity, such as the ITT which has a CV of about 14% in our hands (data 
not shown). The “gold standard” is the euglycaemic clamp, which has a CV of about 
14% in repeat studies in the literature. A minimal model IvGTT is much easier 
technically than a euglycaemic clamp despite the complex data analysis. Both the 
modelled IvGTT and the euglycaemic clamp use the relationship between glucose and 
insulin to determine tissue insulin sensitivity whereas the ITT and non-modelled 
IvGTT just use plasma glucose data. Theoretically the modelled IvGTT and 
euglycaemic clamp should therefore yield a more biologically relevant description of 
the kinetic behaviour of insulin action on glucose disposal.
Investigations were also undertaken into the labelled IvGTT with ‘hot’ minimal model
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analysis. One problem with the standard model is that the parameter estimates 
measure glucose utilisation/disposal and the influence of glucose and insulin on the 
inhibition of hepatic glucose production. The ‘hot’ model removes the hepatic 
influence by using stable-isotope labelled glucose that measure glucose 
utilisation/disposal directly and as a result provide better precision for parameter 
estimates.
Conducted in six healthy dog and human subjects each individual underwent a single 
labelled IvGTT from which labelled and unlabelled data was obtained. From the 
results for the dog there was no overall improvement in the parameter precision 
though this was due to the low parameter errors in these experiments. In the human 
subjects there was an improvement in errors for So but not Si, though these data may 
have been skewed by a single outlier. In addition the calculated errors for the ‘hot’ 
model in the human subjects were still higher than the dog errors and those reported in 
the literature.
Overall these data suggest that in our hands the standard minimal model is as effective 
as the ‘hot’ model. However further work would need to be conducted in glucose 
intolerant dogs and those with NIDDM to check that the standard model performs as 
found here. Based purely on these findings the standard model appears to be the best 
for insulin sensitivity measurements in the dog, and possibly humans. While the ‘hot’ 
model provides a ‘cleaner’ profile that is easier to fit, the method is expensive, time 
consuming and requires more complex analysis, for no real improvements in 
parameter precision.
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In order to make a direct comparison of methods to be used in dog studies, five dogs 
were studied once each with the OGTT, ITT, and the IvGTT, unmodelled and 
modelled.
The OGTT appeared to be susceptible to variations in gastric emptying and glucose 
absorption with unexpected late rises in plasma glucose. Such problems may have 
been related to the magnitude of the glucose dose given, 4g/kg body weight, which 
was equivalent to four times the dose given to human subjects on a weight for weight 
basis. As a consequence, OGTT as used in this instance, although simple to perform, 
was considered unsuitable for assessing glucose tolerance. Any measures of glucose 
clearance from the OGTT will include a component from glucose absorption and it is 
therefore difficult to distinguish the component due to true insulin-mediated glucose 
clearance.
The ITT was rapid to perform and relatively easy, although it does carry a risk of 
hypoglycaemia. It yields a measure of fractional rate of glucose clearance per unit 
time, which is comprised of both insulin-dependent and insulin-independent 
components. In human studies the reproducibility has a CV of about 14% (data not 
shown). In our dog studies, we found values that were consistently in the high range of 
normal human values showing that these dogs have greater insulin sensitivity. Such a 
difference may arise from species differences or differences in body composition and 
pool sizes. Alternatively, it might arise because these were very fit healthy dogs taking 
regular exercise, analogous to the relatively high values for insulin sensitivity seen in 
very fit human subjects.
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The IvGTT was the most complex to perform of the three tests requiring frequent 
blood samples and intricate data analysis, when modelled. This test had the advantage 
of being most discriminating between dogs and is the only test that takes into account 
both the insulin and glucose responses to derive a measure of insulin sensitivity. 
Using the unmodelled approach, some of the measurements indicated a degree of 
insulin resistance in one of the dogs which was not supported by the other 
measurements. Specifically, this dog had an exaggerated incremental insulin response 
with a peak insulin far in excess of the other dogs in the study. This dog also showed 
marked disparity between the IvGTT and the ITT. The difference may arise from the 
fact that in the ITT a supraphysiological insulin dose is given which may be sufficient 
to induce a normal rate of glucose clearance. The ITT may not therefore be able to 
detect subtle changes within the physiological range or changes in early insulin 
resistance where a compensatory rise in insulin levels maintains normal glucose 
tolerance.
On the basis of the results presented, it appeared that, o f the three tests, the IvGTT 
with mathematical modelling was the most discriminating for the assessment of 
insulin sensitivity. This test was therefore chosen for the investigation of the effect of 
marine fish oil (MFC) dietary supplementation on insulin sensitivity in the dog.
Supplementation was shown to be successful in terms of incorporation of EPA and 
DHA into cell membranes by analysis of erythrocyte membrane composition. In terms 
of insulin sensitivity, no effect was seen between control and MFO enriched diets. 
This lack of effect may be related to the fact that only healthy dogs were entered in the 
study. If dogs with borderline or severe insulin resistance had been investigated, more
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significant effects may have been seen. The one dog, discussed above, with an 
abnormal IvGTT did show a decrease in the insulin response which was mirrored by a 
doubling of the insulin sensitivity, Sj. Further studies therefore, might be focussed on 
dogs with evidence of insulin resistance or other breeds particularly susceptible to 
diabetes and obesity.
Other studies in our laboratory have investigated the effects of MFO on insulin 
sensitivity in man. Much lower levels of EPA and DHA incorporation were found in 
human erythrocytes when compared with values firom the dogs studied here, even 
though the dietary intake in humans was two or three times higher on a per 
kilogramme body weight basis; 2-3g per 70kg in humans versus the eqivalent of Ig 
per 70kg in dogs. In the human studies, no effects of MFO on insulin sensitivity or 
insulin action were found despite a fall in triglyceride levels, as would be expected 
from previous studies (Prof J. Millward, personal communication). Triglyceride levels 
were not measured in these dogs due to limitations on blood sampling volume. In 
humans the lack of effect may be related to the lack of incorporation but the dog 
studies have demonstrated that even with high levels of incorporation, no effect may 
be seen with a normally functioning insulin-glucose axis.
Insulin resistance in dogs has not previously been extensively studied. These data 
therefore contribute to our understanding of dog glucose homeostasis. Quantitative 
differences from human studies have been demonstrated and methodological 
approaches validated and applied to the investigation of clinical effects of dietary 
manipulation.
182
Bibliography
Bibliography
183
Bibliography
Abu-Lebdeh, H. S. & Nair, K. S. 1996, "Protein metabolism in diabetes mellitus.", 
Baillieres Clinical Endocrinology & Metabolism, vol. 10, no. 4, pp. 589-601.
Akinmokun, A., Selby, P. L., Ramaiya, K., & Alberti, K. G. 1992, "The short insulin 
tolerance test for determination of insulin sensitivity: a comparison with the 
euglycaemic clamp". Diabetic Medicine, vol. 9, no. 5, pp. 432-437.
Annuzzi, G., Rivellese, A., Capaldo, B., Di Marino, L., lovine, C, Marotta, G., & 
Riccardi, G. 1991, "A controlled study on the effects of n-3 fatty acids on lipid and 
glucose metabolism in non-insulin-dependent diabetic patients". Atherosclerosis, vol. 
87, no. 1, pp. 65-73.
Apostolakou, F. 1995, Investigation o f  diurnal variation in insulin sensitivity in 
normal man, MSc, University of Surrey, Guildford.
Avogaro, A., Bristow, J. D., Bier, D. M., Cobelli, C., & Toffolo, G. 1989, "Stable- 
label intravenous glucose tolerance test minimal model". Diabetes, vol. 38, no. 8, pp. 
1048-1055.
Avogaro, A., Vicini, P., Valerio, A., Caumo, A., & Cobelli, C. 1996, "The hot but not 
the cold minimal model allows precise assessment o f insulin sensitivity in NIDDM 
subjects", Am J.Physiol, vol. 270, no. 3Pt 1, pp. E532-40.
Bennet, P. 2000, "Classification and diagnosis of diabetes mellitus and impaired 
glucose tolerance," pp. 37-44.
184
Bibliography
Bergman, R. N., Beard, J. C., & Chen, M. 1986, "The Minimal Modelling Method: 
Assessment of insulin sensitivity and B-cell function in vivo," in Methods in Diabetic 
Research: Clinical Methods, vol. 1 W. L. Clarke, J. Lamer, & Pohl S.L., eds., John 
Wiley & Sons, Inc., pp. 15-34.
Bergman, R. N., Ider, Y. Z., Bowden, C. R., & Cobelli, C. 1979, "Quantitative 
estimation of insulin sensitivity", American Journal o f  Physiology, vol. 236, no. 6, pp. 
E667-77.
Bergman, R. N., Yang, Y. J., Hope, 1. D., & Ader, M. 1990, "The role of the 
transcapillary insulin transport in the efficiency of insulin action: studies with glucose 
clamps and the minimal model. [Review] [34 refs]". Hormone & Metabolic Research 
- Supplement, vol. 24, pp. 49-56.
Boden, G., Chen, X., Desantis, R. A., & Kendrick, Z. 1993, "Effects of age and body 
fat on insulin resistance in healthy men". Diabetes Care, vol. 16, no. 5, pp. 728-733.
Boden, G., Jadali, F., White, J., Liang, Y., Mozzoli, M., Chen, X., Coleman, E., & 
Smith, C. 1991, "Effects of fat on insulin-stimulated carbohydrate metabolism in 
normal men". Journal o f  Clinical Investigation, vol. 88, no. 3, pp. 960-966.
Bonora, E., Moghetti, P., Zancanaro, C., Cigolini, M., Querena, M, Cacciatori, V., 
Corgnati, A., & Muggeo, M. 1989, "Estimates of in vivo insulin action in man: 
comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose 
clamp studies". Journal o f  Clinical Endocrinology & Metabolism, vol. 68, no. 2, pp. 
374-378.
185
Bibliography
Burkholder, W. J. & Toll, P. W. 2000, "Obesity," in Small Animal Clinical Nutrition, 
4th edn, Mark Morris Institute, ed., Walsworth Publishing Company, Marceline, 
Missouri, pp. 401-430.
Cherwell Scientific Ltd, 199, ModelMaker, vr 3.04, The Magdalen Centre, Oxford 
Science Park, Oxford 0X 4 4GA. modelmaker@cherwell.com. 
http://www.cherwell.com.
Civilized Software Inc, 1996, Mlab, 12109 Heritage Park Circle, Silverspring, MD 
20906, csi@civilized.com. http://www.civilised.com
Coates, P. A., Luzio, S. D., Brunei, P., & Owens, D. R. 1995, "Comparison of 
estimates of insulin sensitivity from minimal model analysis of the insulin-modified 
frequently sampled intravenous glucose tolerance test and the isoglycemic 
hyperinsulinémie clamp in subjects with NIDDM", Diabetes, vol. 44, no. 6, pp. 631- 
635.
Coates, P. A., Ollerton, R. L., Luzio, S. D., Ismail, 1. S., & Owens, D. 1993, "Reduced 
sampling protocols in estimation of insulin sensitivity and glucose effectiveness using 
the minimal model in NIDDM", Diabetes, vol. 42, no. 11, p. -41.
Cobelli, C., Pacini, G., Toffolo, G., & Sacca, L. 1986, "Estimation of insulin 
sensitivity and glucose clearance from minimal model: new insights from labeled 
IVGTT", American Journal o f  Physiology, vol. 250, no. 5 Pt 1, pp. E591-8.
186
Bibliography
Collier, G. R. & Sinclair, A. J. 1993, "Role of N-6 and N-3 fatty acids in the dietary 
treatment of metabolic disorders.". Annals o f  the New York Academy o f  Sciences, vol. 
683, pp. 322-330.
Cummings, M. H., Watts, G. F., Umpleby, A. M., Hennessy, T. R., Naoumova, R., 
Slavin, B. M., Thompson, G. R., & Sonksen, P. H. 1995, "Increased hepatic secretion 
of very-low-density lipoprotein apolipoprotein B-lOO in NIDDM", Diabetologia, vol. 
38, no. 8, pp. 959-967.
Davis, S. N., Monti, L., Piatti, P. M., Moller, N., Ng, L., Coppack, S., May, M., 
Brown, M. D., Orskov, H., & Alberti, K. G. 1993, "Estimates of insulin action in 
normal, obese and NIDDM man: comparison of insulin and glucose infusion test, 
CIGMA, minimal model and glucose clamp techniques". Diabetes Res., vol. 23, no. 1,
pp. 1-18.
Davis, S. N., Piatti, P. M., Monti, L., Moller, N., Ng, L. L., Coppack, S., Antsiferov, 
M., Brown, M. D., & Alberti, K. G. 1992, "A comparison of four methods for 
assessing in vivo beta-cell function in normal, obese and non-insulin-dependent 
diabetic man". Diabetes Res., vol. 19, no. 3, pp. 107-117.
DeFronzo, R. A. 1979, "Glucose intolerance and aging - evidence for tissue 
insensitivity to insulin". Diabetes, vol. 28, pp. 1095-1101.
Devynck, M. A. 1995, "Do cell membrane dynamics participate in insulin 
resistance?". Lancet, vol. 345, no. 8946, pp. 336-337.
187
Bibliography
Feldman, E. C. & Nelson, R. W. 1996, "Diabetes Mellitus," in Canine and feline 
endocrinology and reproduction, 2nd edn, E. C. Feldman & R. W. Nelson, eds., W.B. 
Saunders Company, pp. 339-391.
Ferrari, P., Alleman, Y., Shaw, S., Riesen, W., & Weidmann, P. 1991, 
"Reproducibility of insulin sensitivity measured by the minimal model method", 
Diabetologia, vol. 34, no. 7, pp. 527-530.
Finegood, D. T., Hramiak, I. M., & Dupre, J. 1990, "A modified protocol for 
estimation of insulin sensitivity with the minimal model of glucose kinetics in patients 
with insulin- dependent diabetes", J.Clin.EndocrinolMetab., vol. 70, no. 6, pp. 1538- 
1549.
Frayn, K. N. 1993, "Insulin resistance and lipid metabolism". Current Opinion In 
Lipidology, vol. 4, pp. 197-204.
Frayn, K. N., Coppack, S. W., Fielding, B. A., & Humphreys, S. M. 1995, 
"Coordinated regulation of hormone-sensitive lipase and lipoprotein lipase in human 
adipose tissue in vivo: implications for the control of fat storage and fat mobilization", 
Adv.Enzyme Regul, vol. 35, pp. 163-178.
Frayn, K. N. & Kingman, S. M. 1995, "Dietary sugars and lipid metabolism in 
humans", AmJ.Clin.Nutr., vol. 62, no. 1 Suppl, pp. 250S-261S.
188
Bibliography
Frayn, K. N., Shadid, S., Hamlani, R., Humphreys, S. M., Clark, M. L., Fielding, B. 
A., Boland, O., & Coppack, S. W. 1994, "Regulation of fatty acid movement in 
human adipose tissue in the postabsorptive-to-postprandial transition", American 
Journal o f  Physiology, vol. 266, no. 3 Pt 1, pp. E308-17.
Gelding, S. V., Coldham, N., Anyaoku, V., Heslop, K., Halliday, D., & Johnston, D. 
G. 1993, "Differential metabolic actions of biosynthetic insulin analogues in normal 
man assessed by stable isotopic tracers". Diabetic Medicine, vol. 10, no. 5, pp. 470- 
476.
Gelding, S. V., Robinson, S., Lowe, S., Niththyananthan, R., & Johnston, D. G. 1994, 
"Validation of the low dose short insulin tolerance test for evaluation of insulin 
sensitivity". Clinical Endocrinology, vol. 40, no. 5, pp. 611-615.
Gershenfeld, N. 1999a, "Finite Differences: Ordinary Differential Equations," in The 
Nature o f  Mathematical Modelling, 1st edn, N. Gershenfeld, ed., Cambridge 
University Press, Cambridge, pp. 67-77.
Gershenfeld, N. 1999a, "Function Fitting," in The Nature o f  Mathematical Modeling, 
1st edn, N. Gershenfeld, ed., Cambridge University Press, Cambridge, pp. 115-127.
Gershenfeld, N. 1999b, "Optimization and Search," in The Nature o f  Mathematical 
Modeling, 1st edn, N. Gershenfeld, ed., Cambridge University Press, Cambridge, pp. 
156-168.
189
Bibliography
Godsland, I. 1994, "Modelling analysis of the intravenous glucose tolerance test: 
Derivation of measures of insulin resistance, secretion and metabolism". Clinical 
Science Appendix 92/1 Available from the Royal Society o f  Medicine, London, pp. 1- 
16.
Griffin, B. A. 1995, "Low-density lipoprotein heterogenity", Baillieres Clinical 
Endocrinology & Metabolism, vol. 9, no. 4, pp. 697-701.
Hampton, S. M. 1983, The C-peptide o f  proinsulin, its diagnostic use and a possible 
physiological role, Ph.D., University of Surrey, Guildford.
Hasegawa, S., Sako, T., Koyama, H., & Motoyoshi, S. 1992, "Glucose utilization in 
cats, dogs and cows measured by euglycemic insulin clamp technique". Journal o f  
Veterinary Medical Science, vol. 54, no. 3, pp. 583-584.
Heine, R. J. 1993, "Dietary fish oil and insulin action in humans.". Annals o f  the New 
York Academy o f  Sciences, vol. 683, pp. 110-121.
Hermans, M. P., Levy, J. C., Morris, R. J., & Turner, R. C. 1999, "Comparison of 
insulin sensitivity tests across a range of glucose tolerance from normal to diabetes", 
Diabetologia, vol. 42, pp. 678-687.
Hirst, S., Phillips, D. I., Vines, S. K., Clark, P. M., & Hales, C. N. 1993, 
"Reproducibility of the short insulin tolerance test". Diabetic Medicine, vol. 10, no. 9, 
pp. 839-842.
190
Bibliography
Howard, B. V. 1993, "Insulin, insulin resistance, and dyslipidemia", Annals o f the 
New York Academy o f  Sciences, vol. 683, pp. 1-8.
Kahn, C. R. 1995, "Diabetes. Causes of insulin resistance". Nature, vol. 373, no. 
6513, pp. 384-385.
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., 
Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., Palmer, J. P., & et a 1994, 
"The contribution of insulin-dependent and insulin-independent glucose uptake to 
intravenous glucose tolerance in healthy human subjects". Diabetes, vol. 43, no. 4, pp. 
587-592.
Kaluzny, M. A., Duncan, L. A., Merritt, M. V., & Epps, D. E. 1985, "Rapid separation 
of lipid classes in high yield and purity using bonded phase columns". Journal o f  
Lipid Research, vol. 26, pp. 135-140.
Kaneko, J. J. 1989, "Carbohydrate metabolism and its diseases," in Clinical 
biochemistry o f domestic animals, 4 edn. Academic Press Inc, pp. 44-85.
Kaneko, J. J., Mattheeuws, D., Rottiers, R. P., & Vermeulen, A. 1978, "Glucose 
tolerance and insulin response in diabetes mellitus of dogs". Journal o f  Small Animal 
Practice, vol. 19, no. 2, pp. 85-94.
Keene, B. W. 2000, "Editorial", Journal o f  Veterinary International Medicine, vol. 
14, pp. 118-119.
191
Bibliography
Klimes, L, Howard, B. V., Storlein, L., & Sebokova, E. 1993, "Dietary lipids and 
insulin action.". Annals o f the New York Academy o f  Sciences pp. 683-689.
Knapp, D. R. 1979, Handbook o f  analytical derivatization reactions, 1 edn, John 
Wiley & Sons, New York.
Koranyi, L. I., Bourey, R. E., Slentz, C. A., Holloszy, J. O., & Permutt, M. A. 1991, 
"Coordinate reduction of rat pancreatic islet glucokinase and proinsulin mRNA by 
exercise training". Diabetes, vol. 40, no. 3, pp. 401-404.
Krempf, M., Got, I., Ziegler, O., Blanchard, P., Ranganathan, S., Drouin, P., & 
Charbonnel, B. 1994, "Minimal model for determination of insulin sensitivity: 
repeatability in control and obese subjects". Diabetes Research & Clinical Practice, 
vol. 26, no. 2, pp. 145-148.
Lewis, G. F. & Steiner, G. 1996, "Acute effects of insulin in the control of VLDL 
production in humans. Implications for the insulin-resistant state.". Diabetes Care, 
vol. 19, no. 4, pp. 390-393.
Lienhard, G. E., Slot, J. W., James, D. E., & Mueckler, M. M. 1992, "How cells 
absorb glucose". Scientific American, vol. 266, no. 1, pp. 86-91.
Markwell, P. J. & Butterwick, R. F. 1994, "Obesity," in The Waltham Book o f  
Clinical Nutrition o f the Dog and Cat, 1st edn, J. M. Wills & K. W. Simpson, eds., 
Pergamon, Oxford, pp. 131-148.
192
Bibliography
Markwell, P. J., Butterwick, R. P., Wills, J. M., & Raiha, M. 1994, "Clinical studies in 
the management of obesity in dogs and cats". International Journal o f  Obesity, vol. 
18, no. Suppl. 1, p. S39-S43.
Marquardt, D. W. 1963, "An algorithm for least-squares estimation of nonlinear 
parameters". Journal o f  the Society fo r  Indusrtial and Applied Mathematics, vol. 11, 
pp. 431-441.
Masked, I. E. & Graham, P. A. 1994, "Endocrine Disorders," in The Waltham Book o f  
Clinical Nutrition o f  the Dog and Cat, 1st edn, J. M. Wills & K. W. Simpson, eds., 
Pergamon, Oxford, pp. 373-393.
Mattheeuws, D., Rottiers, R., Kaneko, J. J., & Vermeulen, A. 1984, "Diabetes 
mellitus in dogs: relationship of obesity to glucose tolerance and insulin response", 
American Journal o f  Veterinary Research, vol. 45, no. 1, pp. 98-103.
Maunder, K. 1991, Dietary modification o f  membrane phospholipids in breat disease, 
Ph.D., University of Surrey, Guildford, Surrey, UK.
Millward, D. J. 1995, "Insulin and the regulation of amino acid catabolism and protein 
turnover.," in Amino acid metabolism and therapy in health and nutritional disease, 1 
edn, CRC Press, inc., pp. 127-138.
Millward, D. J., Fereday, A., Gibson, N. R., & Pacy, P. J. 1996, "Post-prandial protein 
metabolism.", Baillieres Clinical Endocrinology & Metabolism, vol. 10, no. 4, pp. 
533-549.
193
Bibliography
Moller, D. E. & Flier, J. S. 1991, "Insulin resistance—mechanisms, syndromes, and 
implications". New England Journal o f  Medicine, vol. 325, no. 13, pp. 938-948.
Morgan, L. 1992, "Insulin secretion and the entero-insular axis.," in Nutrient 
regulation o f  insulin secretion., 1 edn. The Biochemical Society, London, pp. 1-22.
Nelson, R. W. 1995, "Diabetes Mellitus," in Textbook o f  Veterinary Internal 
medicine, 4th edn, S. J. Eltinger & E. C. Feldman, eds., W.B. Saunders Company, pp. 
1510-1537.
Pacini, G. & Bergman, R. N. 1986, "MINMOD: a computer program to calculate 
insulin sensitivity and pancreatic responsivity from the frequently sampled 
intravenous glucose tolerance test". Computer Methods & Programs in Biomedicine, 
vol. 23, no. 2, pp. 113-122.
Pacy, P. J., Cheng, K. N., Thompson, G. N., & Halliday, D. 1989, "Stable isotopes as 
tracers in clinical research. [Review] [104 refs]". Annals o f  Nutrition & Metabolism, 
vol. 33, no. 2, pp. 65-78.
Page, R., Boolell, M., Kalfas, A., Sawyer, S., Pestell, R., Ward, G., & Alford, F. 1991, 
"Insulin secretion, insulin sensitivity and glucose-mediated glucose disposal in 
Cushing's disease: a minimal model analysis", Clin.Endocrinol.(Oxf)., vol. 35, no. 6, 
pp. 509-517.
Panayotou, G. & Waterfield, M. D. 1989, "Cell surface receptors for polypeptide 
hormones, growth factors and neuropeptides. [Review] [35 refs]". Current Opinion in 
Cell Biology, vol. 1, no. 2, pp. 167-176.
194
Bibliography
Popp-Snijders, C., Schouten, J. A., Heine, R. J., van der Meer, J., & van der Veen, E. 
A. 1987, "Dietary supplementation of omega-3 polyunsaturated fatty acids improves 
insulin sensitivity in non-insulin-dependent diabetes". Diabetes Research, vol. 4, no. 
3, pp. 141-147.
Press, W. H., Teukolsky, S. A., Vetterling, W. T., & Flannery, B. P. 1999a, 
"Integration of Ordinary Differential Equations," in Numerical Recipes in C, 2nd edn, 
W. H. Press et al., eds., Cambridge University Press, Cambridge, pp. 707-752.
Press, W. H., Teukolsky, S. A., Vetterling, W. T., & Flannery, B. P. 1999b, 
"Modelling of Data," in Numerical Recipe in C, 2nd edn, W. H. Press et al., eds., 
Cambride University Press, Cambridge, pp. 656-706.
Quon, M. J., Cochran, C., Taylor, S. I., & Eastman, R. C. 1994, "Direct comparison of 
standard and insulin modified protocols for minimal model estimation of insulin 
sensitivity in normal subjects". Diabetes Res., vol. 25, no. 4, pp. 139-149.
Randle, P. J., Garland, P. B., Hales, C., & Newshohne, E. A. 1963, "The glucose 
fatty-acid cycle: Its role in insulin sensitivity and the metabolic disturbances of 
diabetes mellitus". Lancet pp. 785-789.
Reaven, G. M. 1988, "Banting lecture 1988. Role of insulin resistance in human 
ôisQdiSQ.", Diabetes, vol. 37, no. 12, pp. 1595-1607.
Reaven, G. M. 1993a, "Role of insulin resistance in human disease (syndrome X): an 
expanded definition.". Annual Review o f  Medicine, vol. 44, pp. 121-131.
195
Bibliography
Reaven, G. M. 1993b, "Role of insulin resistance in the pathophysiology of non­
insulin dependent diabetes mellitus.", Diabetes-Metabolism Reviews, vol. 9 Suppl 1, 
pp. 5S-12S.
Reaven, G. M. 1995, "Pathophysiology of insulin resistance in human disease", 
Physiol.Rev., vol. 75, no. 3, pp. 473-486.
Reaven, G. M., Chen, Y. D., Jeppesen, J., Maheux, P., & Krauss, R. M. 1993, "Insulin 
resistance and hyperinsulinemia in individuals with small, dense low density 
lipoprotein particles". Journal o f Clinical Investigation, vol. 92, no. 1, pp. 141-146.
Rottiers, R., Mattheeuws, D., Kaneko, J. J., & Vermeulen, A. 1981, "Glucose uptake 
and insulin secretory responses to intravenous glucose loads in the dog", American 
Journal o f  Veterinary Research, vol. 42, no. 1, pp. 155-158.
Saad, M. P., Anderson, R. L., Laws, A., Watanabe, R. M., Kades, W. W., Chen, Y. D., 
Sands, R. E., Pei, D., Savage, P. J., & Bergman, R. N. 1994, "A comparison between 
the minimal model and the glucose clamp in the assessment of insulin sensitivity 
across the spectrum of glucose tolerance. Insulin Resistance Atherosclerosis Study", 
Diabetes, vol. 43, no. 9, pp. 1114-1121.
Salhanick, A. L, Schwartz, S. I., & Amatruda, J. M. 1991, "Insulin inhibits 
apolipoprotein B secretion in isolated human hepatocytes". Metabolism: Clinical & 
Experimental, vol. 40, no. 3, pp. 275-279.
Saam Institute Inc. 1997, SAAM II, vr 1.1 Demo, 4530 Union Bay place NE, Suite 
212, Seattle WA 98105, info@saam.com. http://www.saam.com
196
Bibliography
Sanger, F., Brown, H., & Kitai, R. 1955, Biochemical Journal, vol. 60, p. 556.
Schmarr, H., Gross, H. B., & Shibamoto, T. 1996, "Analysis of polar cholesterol 
oxidation products: Evaluation of a new method involving transesterefication, solid 
phase extraction, and gas chromotography". Journal o f  Agriculture and Food 
Chemistry, vol. 44, pp. 512-517.
Sethi, S., Gibney, M., & Williams, C. M. 1993, "Postprandial lipoprotein 
metabolism". Nutrition research reviews, vol. 6, pp. 161-183.
Shippee, R. L., Johnson, A. A., Cioffi, W. G., Lasko, J., LeVoyer, T. E., & Jordan, B. 
S. 1992, "Simultaneous determination of lactulose and mannitol in urine of bum 
patients by gas-liquid chromatography". Clinical Chemistry, vol. 38, no. 3, pp. 343- 
345.
Steil, G. M., Murray, J., Bergman, R. N., & Buchanan, T. A. 1994, "Repeatability of 
insulin sensitivity and glucose effectiveness from the minimal model. Implications for 
study design", Diabetes, vol. 43, no. 11, pp. 1365-1371.
Steil, G. M., Volund, A., Kahn, S. E., & Bergman, R. N. 1993, "Reduced sample 
number for calculation of insulin sensitivity and glucose effectiveness from the 
minimal model. Suitability for use in population studies". Diabetes, vol. 42, no. 2, pp. 
250-256.
Stryer, L. 2000, in Biochemistry, 3rd edn, W.H. Freeman and company. New York, 
pp. 994-998.
197
Bibliography
Tessari, P., Barazzoni, R., Zanetti, M., Kiwanuka, E., & Tiengo, A. 1996, "The role of 
substrates in the regulation of protein metabolism.", Baillieres Clinical Endocrinology 
& Metabolism, vol. 10, no. 4, pp. 511-532.
Thompson, G. N., Pacy, P. J., Ford, G. C., & Halliday, D. 1989, "Practical 
considerations in the use of stable isotope labelled compounds as tracers in clinical 
studies". Biomedical & Environmental Mass Spectrometry, vol. 18, no. 5, pp. 321- 
327.
Toffolo, G., Bergman, R. N., Finegood, D. T., Bowden, C. R., & Cobelli, C. 1980, 
"Quantitative estimation of beta cell sensitivity to glucose in the intact organism: a 
minimal model of insulin kinetics in the dog". Diabetes, vol. 29, no. 12, pp. 979-990.
Tong, P., Thomas, T., Berrish, T., Humphriss, D., Barriocanal, L., Stewart, M., 
Walker, M., Wilkinson, R., & Alberti, K. G. 1995, "Cell membrane dynamics and 
insulin resistance in non-insulin- dependent diabetes mellitus [see comments]". 
Lancet, vol. 345, no. 8946, pp. 357-358.
Umpleby, A. M. & Russell-Jones, D. L. 1996, "The hormonal control of protein 
metabolism.", Baillieres Clinical Endocrinology & Metabolism, vol. 10, no. 4, pp. 
551-570.
Vega-Catalan, F. J. 1990, "A program to estimate insulin sensitivity and pancreatic 
responsivity from an IVGTT using the minimal modeling technique", 
Comput.Biomed.Res., vol. 23, no. 1, pp. 1-9.
WHO 1985, Diabetes mellitus : report o f  a WHO study group, WHO, Geneva, 727.
198
Bibliography
Widen, E. 1993, "Does glibenclamide influence the clearance of insulin and glucose 
uptake in patients with type 2 diabetes mellitus?", ScandJ.Clin.Lab.Invest., vol. 53, 
no. 4, pp. 395-403.
Wiecko, J. & Sherman, W. R. 1976, "Boroacetylation of carbohydrates. Correlations 
between structure and mass spectral behavior in monoacetylhexose cyclic boronic 
esters". Journal o f  American Chemical Society, vol. 98, no. 24, pp. 7631-7637.
Wills, J. M., Johnson, J. V., & Whyte, A. L. 1992, "Nutrition of the dog". Journal o f  
Veterinary Nutrition, vo\. 1, pp. 1-15.
Wolfe, R. 1992, Radioactive and stable isotope tracers in biomedicine, 2nd edn, 
Wiley-Liss.
Young, R. P., Critchley, J. A., Anderson, P. J., Lau, M. S., Lee, K. K., & Chan, J. C. 
1996, "The short insulin tolerance test: feasibility study using venous sampling". 
Diabetic Medicine, vol. 13, no. 5, pp. 429-433.
199
Appendix A
Appendix A - Chapter 3; Tables of Results
2 0 0
Appendix A
Table A-1 Plasma glucose concentrations in dog EM3 following an intravenous 
glucose bolus of 300 mg/kg body weight on multiple occasions (N = 6)
Time
(minutes)
Plasma Glucose Concentration (mM)
Sep-97 Oct-97 Nov-97 Dec-97 Jan-98 Feb-98
-10 5.21 5.23 5.16 4.87 5.01 4.86
0 5.39 5.15 4.88 4.93
2 14.32 16.45 23.51 13.09 13.96
4 13.20 14.44 12.18 12.12 12.00 12.87
6 12.50 13.16 11.92 11.41 11.73 12.82
8 11.69 12.25 11.06 10.31 10.65 11.29
10 10.90 11.49 9.92 9.01 9.84 10.11
12 10.15 10.53 9.46 9.06 8.72 10.17
14 9.44 9.72 8.66 8.24 7.99 9.30
16 9.00 8.90 8.19 7.76 7.63 8.74
18 8.31 8.66 7.75 6.62 7.03 8.57
20 7.58 8.22 7.14 6.21 6.60 7.67
24 6.76 7.37 5.98 6.11 5.59 6.79
28 6.20 7.02 5.55 4.91 6.25
32 5.96 6.33 5.57 5.25 4.90 5.89
36 5.48 6.17 5.22 5.40 5.02 5.52
40 5.64 5.70 5.22 5.23 4.90 5.65
44 5.26 5.79 5.27 5.32 4.94 5.23
48 5.45 6.04 5.36 5.06 4.98 5.03
52 5.28 5.65 5.13 5.03 4.88 5.20
56 5.19 5.61 5.03 5.09 4.98 5.02
60 5.29 5.30 5.32 5.16 4.98 5.06
90 5.28 5.10 5.09 5.30 4.82 5.14
120 5.08 5.74 5.01 4.90 4.76 4.87
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Table A-2 Plasma insulin concentrations in dog EM3 following an intravenous 
glucose bolus of 300 mg/kg body weight on multiple occasions (N = 6)
Time
(minutes)
Plasma Insulin Concentration (pM)
Sep-97 Oct-97 Nov-97 Dec-97 Jan-98 Feb-98
-10 48 195 35 96 55 30
0 54 203 41 49 43 28
2 551 630 303 312 334
4 551 718 412 313 293
6 610 687 374 302 285 311
8 618 719 362 327 326 309
10 686 752 316 279 354 306
12 681 713 314 284 342 351
14 679 689 344 201 363 364
16 515 610 235 116 219 374
18 384 659 199 97 157 288
20 279 537 125 71 139 330
24 166 429 47 63 66 146
28 111 331 37 50 97
32 66 333 39 34 46 58
36 57 231 29 29 44 61
40 69 232 27 36 30 61
44 49 168 27 29 31 47
48 71 224 35 41 34 43
52 48 192 28 30 28 32
56 43 214 28 20 36 45
60 45 145 33 27 28 42
90 35 119 24 24 63 42
120 37 165 32 23 32 26
2 0 2
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Table A-3 Plasma glucose concentrations in dog EM4 following an intravenous 
glucose bolus of 300 mg/kg body weight on multiple occasions (N = 6)
Time
(minutes)
Plasma Glucose Concentration (mM)
Sep-97 Oct-97 Nov-97 Dec-97 Jan-98 Feb-98
-10 4.97 4.87 4.58 4.91 4.46 4.60
0 5.30 4.98 6.49 4.88 4.59 4.20
2 15.45 24.02 15.48 16.14 16.13 13.08
4 14.51 15.43 13.98 14.64 13.67 12.97
6 13.66 14.16 15.95 13.51 12.91 11.50
8 13.09 13.23 13.63 13.65 11.56 10.82
10 13.01 12.12 12.49 12.96 10.74 9.80
12 12.15 11.89 11.91 12.63 10.57 9.78
14 12.15 10.97 12.00 12.17 9.93 9.31
16 11.60 10.72 10.91 11.55 9.25 8.91
18 11.28 10.30 10.54 10.75 8.68 8.60
20 11.00 9.84 9.77 10.16 8.02 8.03
24 10.01 9.01 9.58 9.54 7.49 7.47
28 9.22 7.92 9.59 8.88 7.08 6.68
32 8.77 7.10 9.12 7.50 6.35 6.29
36 8.44 6.69 8.36 7.22 5.74 6.08
40 8.00 6.31 7.14 6.41 5.33 6.17
44 7.60 5.93 7.84 5.65 5.10 5.91
48 7.15 5.66 6.72 5.99 5.44 5.75
52 7.15 5.66 5.82 5.64 5.28 5.49
56 6.89 5.56 5.90 5.89 4.91 5.08
60 6.59 5.55 5.70 5.45 4.88 5.09
90 5.76 5.13 4.82 5.46 4.59 4.89
120 5.15 4.87 4.85 5.13 4.62 4.59
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Table A-4 Plasma insulin concentrations in dog EM4 following an intravenous 
glucose bolus of 300 mg/kg body weight on multiple occasions (N = 6)
Time
(minutes)
Plasma Insulin Concentration (pM)
Sep-97 Oct-97 Nov-97 Dec-97 Jan-98 Feb-98
-10 81 57 43 44 37 42
0 70 76 61 62 26 60
2 321 218 254 283 175 267
4 317 316 273 268 174 302
6 329 275 241 273 196 247
8 358 296 254 351 174 288
10 415 300 286 304 190 290
12 442 339 206 297 212 283
14 360 374 304 333 184 262
16 335 343 256 328 203 309
18 399 378 296 301 192 251
20 281 339 301 307 153 239
24 282 237 314 345 136 149
28 238 136 194 370 98 103
32 241 103 181 248 76 83
36 195 87 104 132 65 81
40 147 74 76 93 52 67
44 112 70 92 66 31 80
48 131 54 65 66 40 70
52 110 47 86 64 32 72
56 115 40 65 67 28 67
60 104 41 67 68 35 55
90 81 37 51 52 32 54
120 47 36 60 52 62 52
204
Appendix A
Table A-5 Plasma glucose concentrations in dog W H l following an intravenous 
glucose bolus of 300 mg/kg body weight on multiple occasions (N = 6)
Time
(minutes)
Plasma Glucose Concentration (mM)
Sep-97 Oct-97 Nov-97 Dec-97 Jan-98 Feb-98
-10 4.63 4.41 4.35 4.28 338 333
0 4.81 4.40 4.30 4.53 4.25
2 12.43 13.00 12.40 14.55 13.89 12.55
4 11.04 12.72 13.19 13.06 12.51 11.95
6 11.30 12.03 12.90 11.09 12.30 12.18
8 9.72 11.61 11.59 11.27 10.42 11.34
10 10.70 10.65 11.55 9.37 10.11 10.77
12 9.35 10.19 10.23 9.27 10.56 10.23
14 7.17 9.84 11.53 839 9.61 9.65
16 9.34 11.09 7.69 928 828
18 9.04 10.11 632 839 837
20 8 J2 839 6.76 835 7.62
24 7.57 823 5.15 7.63 7.05
28 6.78 6.59 7.34 4.62 6.62 5.64
32 6.49 6.10 4.28 5.84 5.13
36 5.58 535 4.19 5.49 5.17
40 5.67 528 638 4.29 5.21 4.83
44 4.87 5.02 738 4.38 5.02 4.23
48 4.71 4.73 839 4.32 4.74 4.49
52 4.22 4.70 6.20 4.14 4.67 4.10
56 4.42 4.70 4.22 4.48 4.06
60 4.31 438 4.24 428 3.93
90 4.74 4.51 5.70 4.41 4.39 3.67
120 4.60 4.60 4.36 4.59 4.54 4.15
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Table A-6 Plasma insulin concentrations in dog W Hl following an intravenous 
glucose bolus of 300 mg/kg body weight on multiple occasions (N = 6)
Time
(minutes)
Plasma Insulin Concentration (pM)
Sep-97 Oct-97 Nov-97 Dec-97 Jan-98 Feb-98
-10 61 51 40 88 33 75
0 75 59 29 59 53
2 225 370 254 503 465 443
4 234 372 322 504 406 384
6 197 383 290 427 438 377
8 237 368 316 493 410 397
10 303 402 385 572 448 468
12 349 564 372 534 542 512
14 309 562 446 564 525 642
16 522 471 440 520 489
18 536 444 308 546 486
20 418 390 265 602 417
24 284 273 130 387 232
28 214 249 111 184 129
32 112 123 78 116 88
36 95 91 61 86 71
40 65 83 75 59 61 69
44 57 78 85 58 52 61
48 55 78 45 70 56 63
52 52 75 57 47 52 61
56 62 57 47 47 54
60 63 50 41 50 41
90 36 35 47 52 45 38
120 38 79 61 59 40 74
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Table A-7 Plasma glucose concentrations in six dogs following an intravenous 
bolus of 12 % w/w [6,6-^H2]-glucose at 300mg/kg body weight
Time
(minutes)
Plasma Glucose Concentration (mM)
D1 D2 D3 D4 D5 D6
-10 4.44 4.17 4.33 4.29 4.82 5.06
0 4.57 4.47 4.40 4.26 4.95 4.98
2 13.46 13.04 13.39 14.75 17.23 15.22
4 13.22 12.01 12.58 12.25 15.12 13.38
6 12.24 11.81 12.84 12.07 13.65 12.64
8 11.90 11.85 12.38 11.40 11.79 12.19
10 11.36 11.80 11.63 11.29 11.17 11.61
12 10.91 11.09 11.18 10.54 9 j# 10.54
14 10.16 10.52 11.25 10.29 820 9.42
16 9.60 10.47 11.09 9.12 8.10 825
18 9.36 10.14 10.41 823 7.34 8.49
20 9.03 9 j# 10.40 7.27 6.73 8.08
24 8.46 8^7 10.09 6.54 5.71 7.25
28 7.48 7.96 9.00 5.80 4.91 6.24
32 6j% 7.48 822 5.25 4.62 5.81
36 6.44 6.79 7.77 4.49 4.67 5.28
40 5.92 6^2 7.44 4.19 4.44 4.87
45 5 J8 5.90 &85 3.96 4.60 4.62
50 5.30 5.40 6.56 4.25 4.57 4.53
60 4.90 4.94 6.20 4.14 4.73 4.61
70 4.34 4.97 5.58 4.31 4.81 4.49
80 4.52 4.54 5.15 4.54 4.96 4.71
90 4.31 4.43 4.80 4.44 4.91 4.72
100 4.34 4.27 4.62 4.41 4.80 4.72
110 4.49 4.20 4.56 4.48 4.69 422
120 4.73 4.00 4.74 4.38 4.89 4.72
140 4.85 3.90 4.68 4.46 4.92 4.66
160 4.85 4.56 4.55 4.13 4.91 4.77
180 4.94 4.20 4.53 4.73 4.88 4.75
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Table A-8 Plasma insuUn concentrations in six dogs following an intravenous 
bolus of 12 % w/w [ 6 , -glucose at 300 mg/kg body weight
Time
(minutes)
Plasma Insulin Concentration (pM)
D1 D2 D3 D4 D5 D6
-10 16 21 30 24 27 25
0 14 31 26 16 59 18
2 175 209 358 274 786 344
4 163 152 256 159 455 213
6 207 157 252 193 442 162
8 255 153 295 217 548 166
10 259 152 326 186 590 176
12 297 197 334 268 624 183
14 331 209 337 225 570 186
16 249 164 371 172 496 190
18 209 137 327 218 397 181
20 179 112 327 113 190 169
24 150 108 300 61 105 143
28 110 109 206 36 69 84
32 83 90 202 25 49 62
36 82 94 120 35 60 77
40 76 44 97 22 36 47
45 37 83 64 22 50 46
50 34 37 67 17 42 34
60 42 25 33 15 49 31
70 27 34 39 21 66 27
80 17 33 34 21 26 26
90 27 21 38 24 25 24
100 16 31 21 23 15 30
110 18 21 17 32 31 28
120 10 28 19 30 20 28
140 38 18 22 16 35 30
160 20 18 22 33 66 28
180 14 21 17 23 64 36
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Table A-9 Labelled plasma glucose concentrations in six dogs following an 
intravenous bolus of 12 % w/w [6,6-^H2]-glucose at 300 mg/kg body weight
Time Labelled Plasma Glucose Concentration (mM)
ninutes) D1 D2 D3 D4 D5 D6
2 8.44 8.52 8.67 9.77 11.98 10.45
4 8.11 7.55 7.92 7.49 10.29 842
6 7.30 7.34 8JT 7.30 8.81 7 J8
8 7.40 7.31 7.87 6 j# 6.97 7.42
10 6jW 7.23 7.28 6.67 6.51 7.03
12 6.32 6.69 6.84 6.19 5.64 6.16
14 5.70 6.00 6 j# 6.14 4.83 5 j#
16 5.19 6.20 6.73 5.21 4.33 4.84
18 5.05 6.00 6.24 4.53 3 j# 4.67
20 5.01 5.62 6 j8 3.97 3 J8 4.53
24 4.52 4.94 6.03 3.47 2.95 3.98
28 4.09 4.46 5.26 3.00 2.45 3.34
32 3.65 4.30 4.98 2.74 2.19 2.91
36 3.47 3.81 4.64 2.23 2.10 Z68
40 2 j# 3.35 4.42 1.99 1.93 2.43
45 2.73 3.16 3.93 1.83 1.79 2.23
50 2.54 2jG 3.73 1.87 1.69 2.14
60 2.36 2.47 3.37 1.67 1.57 1.99
70 1.99 248 2.99 1.62 1.44 1.75
80 1.91 2.09 2.73 1.48 1.33 1.58
90 1.77 1.92 2.36 1.44 1.23 1.17
100 1.59 1.71 2.20 1.33 1.16 1.13
110 1.53 1.55 2.02 1.20 1.01 1.02
120 1.56 1.34 2.04 1.06 0.92 O j#
140 1.42 0.87 1.38 0.71 0.83 0.77
160 1.27 0.90 1.74 0.86 0.67 0.64
180 1.19 0.75 1.49 0.62 0.57 0.54
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Table A-10 The calculated fraction standard deviations of the labelled plasma 
glucose concentrations in six dogs following an intravenous bolus of 12 % w/w 
[6,6-^H2]-glucose at 300 mg/kg body weight
Time Labelled Plasma Glucose Fractional Standard Deviation
(minutes) D1 D2 D3 D4 D5 D6
2 0.0488 0.0480 0.0474 0.0476 0.0475 0.0481
4 0.0494 0.0490 0.0481 0.0496 0.0481 0.0504
6 0.0502 0.0493 0.0477 0.0499 0.0494 0.0510
8 0.0491 0.0495 0.0479 0.0500 0.0518 0.0513
10 0.0498 0.0497 0.0482 0.0505 0.0522 0.0514
12 0.0510 0.0501 0.0488 0.0507 0.0522 0.0524
14 0.0519 0.0516 0.0488 0.0503 0.0540 0.0537
16 0.0530 0.0506 0.0490 0.0514 0.0548 0.0537
18 0.0531 0.0506 0.0493 0.0525 0.0554 0.0542
20 0.0522 0.0512 0.0487 0.0528 0.0549 0.0536
24 0.0534 0.0513 0.0494 0.0536 0.0559 0.0543
28 0.0527 0.0521 0.0500 0.0544 0.0570 0.0551
32 0.0532 0.0515 0.0494 0.0541 0.0587 0.0572
36 0.0531 0.0521 0.0494 0.0556 0.0607 0.0567
40 0.0554 0.0534 0.0496 0.0570 0.0619 0.0574
45 0.0561 0.0534 0.0505 0.0580 0.0663 0.0584
50 0.0568 0.0539 0.0507 0.0598 0.0687 0.0592"
60 0.0567 0.0556 0.0520 0.0629 0.0737 0.0625
70 0.0583 0.0557 0.0525 0.0658 0.0791 0.0667
80 0.0613 0.0584 0.0527 0.0723 0.0853 0.0736
90 0.0622 0.0606 0.0551 0.0723 0.0896 0.0911
100 0.0670 0.0636 0.0560 0.0762 0.0918 0.0933
110 0.0703 0.0668 0.0584 0.0826 0.1004 0.1023
120 0.0717 0.0713 0.0594 0.0885 0.1108 0.1132
140 0.0779 0.0949 0.0758 0.1216 0.1213 0.1242
160 0.0839 0.1037 0.0639 0.0993 0.1434 0.1477
180 0.0895 0.1130 0.0704 0.1437 0.1628 0.1684
2 1 0
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Table A l l  Plasma glucose concentrations in six humans following an 
intravenous bolus of 12 % w/w [6 ,6-^H2]-glucose at 300mg/kg body weight
Time
(minutes)
Plasma Glucose Concentration (mM)
IVl IV2 IV3 IV4 IV5 IV6
-10 4.89 &28 4.80 5.06 4j% 4.53
0 4.90 6.16 4.81 5.05 5.00 4.61
2 16.80 13.44 9.23 15.23 13.37 15.84
4 16.32 14.46 11.32 17.69 14.26 14.05
6 15.03 14.05 11.91 15.44 15.06 12.78
8 13.82 14.12 11.98 14.49 13.96 13.64
10 13.29 13.90 12.48 14.06 13.46 13.11
12 12.40 13.40 11.86 13.51 13.21 12.92
14 11.38 13.44 11.81 13.09 12.27 12.50
16 10.94 12.61 11.29 12.70 11.85 12.10
18 10.08 12.24 11.06 11.89 11.02 11.42
20 9.57 12.22 10.70 11.89 10.77 11.02
24 7.98 11.36 10.05 10.95 10.06 10.54
28 7.34 11.10 9.22 10.37 938 933
32 7.06 10.71 8.75 9.74 837 9.20
36 5.87 10.16 7.80 9.17 8.14 8.70
40 5.05 9.94 7.38 8.81 7.59 8.10
45 4.78 9.65 6.07 8.08 7.18 7.57
50 4.33 9.17 7.21 6.79 7.13
60 4.49 8.51 5.05 6.13 5.75 6.07
70 4.43 7.75 4.80 5.25 5.15 5.21
80 4.66 7.18 4.70 4.52 4.66 4.79
90 4.61 6.49 4.64 4.08 4.38 4.50
100 4.63 6.31 4.73 4.14 4.45 4.19
110 4.60 5.79 4.81 4.19 4.56 333
120 4.65 5.65 4.73 4.33 4.46 3.91
140 4.81 5.56 4.86 4.61 4.60 3.74
160 4.80 5 J8 4.76 4.86 4.58 339
180 4.68 5.63 4.65 4.69 4.35 4.00
210 4jG 5.59 4.75 4.90 4.69 4.14
240 4.84 5.87 4.68 4.96 4.37 3.89
2 1 1
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Table A-12 Plasma insulin concentrations in six humans following an 
intravenous bolus of 12 % w/w [6,6-^H2]-glucose at 300 mg/kg body weight
Time
(minutes)
Plasma Insulin Concentration (pM)
IVl IV2 IV3 IV4 IV5 IV6
-10 25 19 37 36 28 46
0 21 22 40 31 27 53
2 667 22 164 43 160 308
4 639 127 277 733 549 901
6 474 106 347 448 349 599
8 327 88 353 414 289 585
10 332 58 287 282 215 437
12 272 61 281 281 195 401
14 283 53 239 258 161 376
16 253 46 128 269 141 364
18 236 40 187 246 146 318
20 184 42 201 265 127 255
24 145 34 165 256 130 267
28 122 41 116 228 129 245
32 101 46 104 200 120 268
36 90 44 77 198 115 217
40 69 37 73 197 108 206
45 55 40 76 177 95 167
50 43 44 172 78 151
60 44 32 61 130 56 107
70 32 30 43 76 44 90
80 44 37 39 63 43 60
90 33 24 29 39 39 61
100 35 22 31 47 27 39
110 31 27 46 35 26 46
120 30 31 20 29 19 64
140 32 16 31 46 22 64
160 34 11 25 30 26 50
180 34 15 29 34 19 39
210 30 15 27 33 20 45
240 27 15 34 26 24 45
2 1 2
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Table A-13 Labelled plasma glucose concentrations in six humans following an 
intravenous bolus of 12 % w/w [6,6-^H2]-glucose at 300 mg/kg body weight
Time Labelled Plasma Glucose Concentration (mM)
ninutes) IVl 1V2 1V3 1V4 1V5 1V6
2 10.63 6.45 3.75 9.21 7.84 10.45
4 10.44 6.79 5.55 11.80 8^8 8 j#
6 9.11 7.10 626 9.63 9.35 7.53
8 7.70 6.94 6.19 10.89 8^2 8.44
10 8.53 6.50 827 8.92 822 8.34
12 8.09 6.04 7.06 8.24 7.77 8.02
14 7.45 7.20 6^3 8.20 7.15 7.64
16 6.23 6.98 6.45 7.72 &69 7.59
18 5.72 6.65 6.34 7.53 5 j# 6.85
20 5.50 6.60 6.51 7.17 6.18 6.50
24 4.38 5.97 528 6.29 5.60 6.04
28 3 j# 5.73 5.06 5.90 5.05 5.77
32 3.90 5.35 5.21 5.78 4.68 4.97
36 3.18 4.94 4.45 5.37 4.47 4.80
40 2 j8 5.05 4.07 4.88 3^2 4.51
45 2.37 4.76 3.12 4.17 3.65 4.07
50 2.13 4.62 3.80 3.33 3 j#
60 1.97 4.12 1.82 3.02 222 3.12
70 1.66 3.70 1.61 2.57 2.36 2.60
80 1.59 3.25 2.07 2.05 2.00 2.33
90 1.36 2 j# 1.67 1.71 1.76 2.05
100 1.21 2.60 1.59 1.57 1.66 1.76
110 1.16 2.17 1.38 1.41 1.43 1.53
120 1.01 2.09 1.31 1.33 1.20 1.39
140 0.84 1.79 1.08 1.24 1.06 1.07
160 0.63 1.58 0.91 1.02 O j# 0.76
180 0.52 1.28 0.80 0.91 0.80 0.59
210 0.44 1.05 0.58 0.68 0.57 0.46
240 0.34 0.86 0.42 0.54 0.45 0.31
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Table A-14 The calculated fraction standard deviations of the labelled plasma 
glucose concentrations in six humans following an intravenous bolus of 12 % 
w/w [6,6-^H2]-glucose at 300 mg/kg body weight
Time Labelled Plasma Glucose Fractional Standard Deviation 
(minutes) IVl 1V2 1V3 1V4 1V5 1V6
2 0.0502 0.0603 0.0647 0.0510 0.0515 0.0481
4 0.0499 0.0611 0.0576 0.0483 0.0508 0.0493
6 0.0514 0.0584 0.0553 0.0501 0.0499 0.0511
8 0.0539 0.0594 0.0559 0.0454 0.0504 0.0498
10 0.0498 0.0612 0.0486 0.0496 0.0503 0.0491
12 0.0494 0.0626 0.0515 0.0507 0.0514 0.0497
14 0.0493 0.0565 0.0524 0.0500 0.0516 0.0501
16 0.0532 0.0554 0.0527 0.0508 0.0525 0.0495
18 0.0533 0.0560 0.0526 0.0497 0.0542 0.0506
20 0.0529 0.0562 0.0509 0.0510 0.0521 0.0511
24 0.0544 0.0571 0.0554 0.0525 0.0530 0.0519
28 0.0556 0.0577 0.0540 0.0527 0.0540 0.0513
32 0.0541 0.0589 0.0515 0.0515 0.0546 0.0536
36 0.0548 0.0598 0.0528 0.0519 0.0534 0.0530
40 0.0567 0.0582 0.0538 0.0535 0.0552 0.0528
45 0.0576 0.0593 0.0561 0.0557 0.0558 0.0538
50 0.0580 0.0586 0.0551 0.0569 0.0535
60 0.0622 0.0600 0.0699 0.0573 0.0581 0.0551
70 0.0687 0.0605 0.0733 0.0575 0.0593 0.0561
80 0.0733 0.0625 0.0615 0.0602 0.0616 0.0569
90 0.0808 0.0637 0.0699 0.0631 0.0642 0.0592
100 0.0883 0.0663 0.0733 0.0673 0.0674 0.0623
110 0.0904 0.0706 0.0816 0.0729 0.0754 0.0657
120 0.1010 0.0713 0.0838 0.0775 0.0838 0.0692
140 0.1198 0.0784 0.0988 0.0851 0.0936 0.0801
160 0.1507 0.0881 0.1108 0.1025 0.1080 0.1060
180 0.1743 0.1010 0.1207 0.1091 0.1118 0.1321
210 0.2093 0.1174 0.1600 0.1423 0.1569 0.1673
240 0.2597 0.1437 0.2085 0.1736 0.1811 0.2217
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Appendix B - Chapter 4: Tables of Results
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Table B-1 Plasma glucose concentrations in the dog following an oral glucose 
bolus of 4 g/kg body weight (Individual results, N = 5)
Time
(minutes)
Plasma Glucose Concentration (mM)
L1427 L124 L215 L142 L150
-10 4.49 4.54 4.54 5^8 4.65
0 4.92 4.68 4.85 4.99 4.68
5 A88 4.43 4.36 5.12 4.90
15 5.65 5.25 5.03 7.12 5.54
30 5.63 6.47 6.81 &63 6.44
45 4.77 6.49 6.53 6.84 7.11
60 6.59 5.17 6.81 5^3 4.94
90 6.26 6.15 5.71 5.48 &48
120 6.35 6.37 5 j# 5.99 6.51
180 6.20 5.52 4.72 6.16 4.76
Table B-2 Plasma NEFA concentrations in the dog following an oral glucose 
bolus Of 4 g/kg body weight (Individual results, N = 5)
Time  Plasma NEFA Concentration (mM)
(minutes) L1427 L124 L215 L142 L150
-10 1.03 0.79 0.46 0.77 1.20
0 0.99 0.94 0.56 0.62 1.50
5 0.68 0.87 0.47 0.58 1.19
15 0.22 0.76 0.32 0.53 0.86
30 0.12 0.47 0.13 0.23 0.63
45 0.07 0.23 0.05 0.18 OJ#
60 0.04 0.16 0.03 0.20 0.39
90 0.03 0.10 0.03 0.16 0.25
120 0.02 0.05 0.02 0.32 0.41
180 0.15 0.05 0.06 0.24 0.12
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Table B-3 Plasma insulin concentrations in the dog following an oral glucose 
bolus of 4 g/kg body weight (Individual results, N = 5)
Time
(minutes)
Plasma Insulin Concentration (pM)
L1427 L124 L215 L142 L150
-10 45 72 68 72 26
0 62 88 73 58 40
5 50 166 119 72 88
15 425 184 374 480 55
30 188 470 395 242 106
45 160 373 311 254 79
60 324 191 372 102 53
90 654 215 213 86 97
120 289 264 291 149 86
180 176 229 285 168 47
Table B-4 Plasma glucose concentrations in the dog following an intravenous 
glucose bolus of 500 mg/kg body weight (Individual results, N = 5)
Time  Plasma Glucose Concentration (mM)
(minutes) L1427 L124 L215 L142 L150
-10 4.85 4.09 4.69 4.00 5.35
0 4.94 4.73 A68 4.33 5.23
3 15.18 19.05 19.40 16.10 15.77
5 14.58 16.20 16.44 14.18 15.09
7 13.49 14.77 14.76 13.65 14.03
10 12.81 12.37 13.88 11.44 13.29
15 9.14 9.20 11.61 10.08 10.79
30 5.19 3.37 7.00 3 j3 5.29
45 4.16 4.67 4.34 4.06 5.29
60 4.52 4.82 4.16 4.43 5.43
90 4.95 5.41 4.55 4.68 5.14
120 4.91 4.90 5.20 5.43 5 J9
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Table B-5 Plasma NEFA concentrations in the dog following an intravenous 
glucose bolus of 500 mg/kg body weight (Individual results, N = 5)
Time
(minutes)
Plasma NEFA Concentration (mM)
L1427 L124 L215 L142 L150
-10 1.80 0.34 0.57 0.62 0.49
0 1.49 0.35 0.50 0.36 0.80
3 1.39 0.36 0.32 0.30 0.67
5 1.29 0.34 0.28 0.29 0.60
7 1.11 0.31 0.27 0.28 0.51
10 0.84 0.24 0.22 0.20 0.38
15 0.36 0.13 0.14 0.08 0.26
30 0.19 0.25 0.06 0.05 0.28
45 1.07 0.75 0.11 0.22 0.52
60 1.25 0.74 0.36 0.20 0.65
90 1.48 0.60 0.45 0.31 1.04
120 1.63 0.74 0.13 0.49 0.97
Table B-6 Plasma insulin concentrations in the dog following an intravenous 
glucose bolus of 500 mg/kg body weight (Individual results, N = 5)
Time  Plasma Insulin Concentration (pM)
(minutes) L1427 L124 L215 L142 L150
-10 29 30 71 38
0 29 71 50 67 25
3 245 282 377 706 152
5 295 299 359 793 137
7 286 283 429 1480 186
10 317 308 359 1091 232
15 184 440 452 1541 218
30 38 57 168 161 56
45 24 25 65 62 35
60 21 29 72 61 46
90 21 30 32 52 42
120 22 41 46 69 28
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Table B-7 Plasma glucose concentrations in the dog following an intravenous 
insulin bolus of 0.1 U/kg body weight (Individual results, N = 5)
Time Plasma Glucose Concentration (mM)
(minutes) L1427 L124 L215 L142 L150
-10 4.50 5.02 6.14 4.91 4.91
0 4.48 4.71 5.47 4.49 4.77
1 4.63 5.08 5.74 4.74 4.45
2 4.76 4.84 5.35 4.94 4.76
3 4.42 4.87 5.45 4.87 4.58
4 4.18 4.43 5.14 3.67 4.24
5 4.04 3 J8 5.01 3 j# 4.23
6 3.50 3.45 4.59 3.48 3.87
7 3.55 3.01 4.37 3.19 3.39
8 3.65 298 4.14 2.64 3.36
9 2.36 2 j# 3 j^ 2^8 2 j#
10 2.62 2.55 3.61 2 J 2 2^5
11 2.46 2.35 3.43 2.09 2.46
12 2.63 2.21 3.00 1.78 2.33
13 2.13 2.07 2.91 1.90 2.26
14 2.27 2.01 2.69 1.76 1.92
15 1.89 2.64 2.04 1.76
16 1.94 2.46 1.82 2.07
17 2.44 1.54
18 2.31 2.45 2.17 2.11
19 2.05
20 2.32 2.22
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Appendix C
Table C-1 Plasma glucose concentrations in dogs on a control diet following an 
intravenous glucose bolus of 300 mg/kg body weight (Individual results, N = 6)
Time
(minutes)
Plasma Glucose Concentration (mM)
L124 L34 L198 L142 L1403 L1478
-10 5.09 4.36 5.24 4.85 3 j# 4.96
0 4.75 4.15 5.13 4.70 3.98 4.90
2 15.00 15.04 13.51 13.93 13.85 13.95
4 13.51 14.64 13.43 12.90 12.29 13.77
6 12.38 14.42 12.83 11.95 11.60 12.93
8 12.30 13.50 12.11 12.02 11.09 11.91
10 12.31 13.19 11.64 11.07 11.24 10.88
12 11.68 13.05 11.40 10.66 10.29 9 J6
14 11.01 12.45 11.30 10.18 9.61 8 J9
16 11.15 12.16 10.49 9.23 &57 7.62
18 10.80 11.95 9.54 8.86 8.11 6.81
20 10.09 11.55 9 J^ 7.74 A68 6.18
24 9.35 10.49 8^3 5.23 6.94 5.73
28 8 J2 9.76 7.23 4.60 6.05 5.00
32 8.02 8.70 6.37 4.05 5.71 4.95
36 7.51 7.83 5.65 5.13 4.92
40 6.73 7.14 5.41 5.21 5.09
44 6.43 6.54 5.10 4.92 5.16
48 6.17 6.15 5.01 4.90 5.04
52 5.90 5.76 5.11 4.66 5.12
56 5.69 5.38 4.93 4.74 5.17
60 5.50 4.90 5.05 A83 5.00
90 5.14 4.17 4.76 4.53 538
120 4.96 3.97 4.87 3.97 5.22
2 2 1
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Table C-2 Plasma insulin concentrations in dogs on a control diet following an 
intravenous glucose bolus of 300 mg/kg body weight (Individual results, N = 6)
Time
(minutes)
Plasma Insulin Concentration (pM)
L124 L34 L198 L142 L1403 L1478
-10 93 28 58 106 24 29
0 89 27 27 105 15 33
2 266 143 237 710 275 220
4 251 134 203 512 236 212
6 260 154 249 750 189 217
8 352 176 328 928 405 259
10 383 234 292 998 366 271
12 363 228 312 1036 327 335
14 374 235 318 1180 281 233
16 419 224 336 1142 256 160
18 395 237 264 1071 202 110
20 365 237 287 829 143 71
24 390 248 231 415 110 57
28 309 279 115 257 72 35
32 273 270 49 161 48 30
36 212 139 33 43 33
40 147 116 26 35 32
44 112 69 30 29 32
48 140 47 26 40 32
52 89 60 20 32 27
56 103 59 20 61 45
60 66 61 26 35 29
90 42 32 16 33 27
120 56 34 36 31 15
2 2 2
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Table C-3 Plasma glucose concentrations in dogs on a MFO enriched diet 
following an intravenous glucose bolus of 300 mg/kg body weight (Individual
results, N = 6)
Time
(minutes)
Plasma Glucose Concentration (mM)
L124 L34 L198 L142 L1403 L1478
-10 4.07 4.43 4.19 4.44 4.50 4.71
0 4.53 4.27 4.25 4.39 4.65 4.24
2 11.96 12.19 11.68 13.71 17.47 13.11
4 11.41 11.46 10.53 12.72 13.46 11.84
6 11.34 11.52 10.69 11.71 14.22 11.55
8 11.24 10.54 10.20 10.39 13.10 10.90
10 10.81 11.49 10.00 10.47 11.47 10.32
12 10.74 10.87 9.45 9.95 11.38 9.97
14 10.55 10.31 9.11 9.18 10.92 9.33
16 10.21 10.55 8.76 8.11 10.49 828
18 10.00 10.11 830 7.81 9.85 8.50
20 9.84 10.05 9.14 6.65 9.16 7.99
24 842 926 6.47 539 8.47 639
28 7.47 9.02 5.74 4.49 T.68 5.44
32 6.85 8.14 5.14 4.08 7.39 4.52
36 6.57 7.94 4.59 3.79 &99 3.77
40 6.06 7.36 4.46 3.71 6.49 338
44 5.49 6.94 4.13 4.15 6.33 3.94
48 5.34 6 j# 4.37 4.29 6.11 4.09
52 5.47 6.43 4.30 4.31 6.04 333
56 5.57 6.22 4.38 4.59 539
60 5.42 5.80 4.42 4.65 5.55 4.56
90 5.44 5.3 4.38 4.7 5.45 4.53
120 5.4 5.36 4.46 4.64 5.53 4.34
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Table C-4 Plasma insulin concentrations in dogs on a MFO enriched diet 
following an intravenous glucose bolus of 300 mg/kg body weight (Individual
results, N = 6)
Time __________ Plasma Insulin Concentration (pM)__________
(minutes) L124 L34 L198 L142 L1403 L1478
-10 110.91 48.44 52.07 81.85 66.03 40.57
0 76.60 31.70 53.80 48.65 30.80
2 282.64 148.60 251.04 505.74 345.77 160.86
4 246.86 144.69 240.91 518.81 272.02 151.96
6 343.73 165.93 329.53 607.67 284.04 154.08
8 362.23 139.21 306.75 600.53 258.16 195.44
10 436.33 204.72 328.90 598.79 330.37 157.40
12 460.95 216.06 377.07 703.95 270.87 173.75
14 489.69 218.19 370.11 559.20 271.53 177.77
16 559.07 241.72 408.73 517.91 229.57 131.66
18 636.73 209.65 380.56 412.39 214.17 156.10
20 589.46 245.90 317.13 284.44 204.53 161.30
24 458.46 196.89 188.26 202.18 154.43 168.25
28 336.16 209.16 96.14 114.30 127.84 77.86
32 253.19 210.98 49.19 81.26 81.18 34.38
36 185.03 150.37 36.06 72.02 61.92 23.74
40 118.49 162.00 31.24 56.16 54.01 25.39
44 106.13 113.97 26.93 41.10 43.89 19.38
48 93.17 91.39 30.27 44.02 37.23 28.99
52 79.61 105.98 24.12 44.33 47.13 17.73
56 85.94 66.56 23.10 42.80 37.78 28.80
60 90.32 68.68 20.48 52.60 30.76 25.48
90 94.89 59.35 21.23 41.70 30.01 22.54
120 92.27 60.11 19.05 47.21 31.92 23.56
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Table C-5 Red blood cell fatty acid profiles from dogs on a control diet
(Individual results, N = 6)
Fatty
Acid
Membrane Fatty Acid Composition (Mol %)
L56 L55 L1405 L325 L200 L40
C16:0 22.3 13.3 12.1 8.0 12.1 14.2
C18:0 28.0 17.5 18.2 23^ 23.4 24.5
C18:l 14.7 9.1 8.9 10.0 11.4 10.3
C18:2 18.4 14.8 19.5 12.6 12.5 12.0
C20:l 1.4 0.7 4.5 0.8 0.7 0.5
C20:3 1.8 1.1 3.9 1.5 1.6 1.3
C20:4 2.9 34.0 252 35.7 292 30.2
C20:5 0.8 0.7 1.7 0.5 1.4 0.8
C22:4 2.2 1.8 2.1 2.7 2.6 1.8
C22:6 0.6 0.7 0.6 0.9 0.9 0.9
Table C-6 Red blood cell fatty acid profiles from dogs on a MFO enriched diet
(Individual results, N = 6)
Fatty Membrane Fatty Acid Composition (Mol %)
Acid L124 L34 L198 L142 L1403 L1478
C16:0 8.9 7.7 1.7 4.9 4.3 10.7
C18:0 28.7 27.7 29.3 26.6 24.0 292
C18:l 10.6 9.0 9.9 10.9 10.3 10.4
C182 11.5 10.9 12.3 11.0 10.7 10.9
C20:l 0.7 1.4 0.0 0.0 0.8 0.7
C20:3 0.0 1.9 2.1 1.6 1.8 1.7
C20:4 31.4 29.8 3Z8 33.5 27.6 27.4
C20:5 3.7 5.2 5.4 4.9 3.6 3.6
C22:4 1.8 0.7 0.0 1.1 10.4 0.7
C22:6 1.5 1.6 2.5 1.9 2.0 1.2
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The effect of marine fish oil supplementation on insulin sensitivity in the dog. By A J. IRVINE\ 
R. BUTTERWICK^ T. WATSON^ D J. MILLWARD^ and L.M. MORGAN^  ^ Centre for Nutrition and
Food Safety, School o f Biological Sciences, University o f Surrey, Guildford GU2 5XH and Waltham Centre for Pet Nutrition, Freehy 
Lane, Waltham-on-the-Wolds, Melton Mowbray, Leicestershire LE 14 4RT
Obesity is increasingly common in dogs, with observed incidence between 24 and 44% in the UK. As 
with human subjects, obesity in dogs is associated with fasting hyperinsulinaemia, impaired glucose 
tolerance and an increased insulin response to a glucose load, which worsens with the degree of obesity 
and age. Obesity confers an increased risk of cardiovascular disease and maturity onset diabetes 
mellitus. Recent human studies have shown that dietary supplementation with n-2> polyunsaturated 
fatty acids (PUFA) can improve insulin sensitivity and reduce the risk of cardiovascular disease. The 
present study was carried out to establish a suitable method for assessing insulin sensitivity in dogs and 
to investigate the effect o f dietary «-3 PUFA on insulin sensitivity in these animals.
Insulin sensitivity was assessed using an oral glucose tolerance test (OGTT, 4 g glucose/kg 
body weight), an intravenous glucose tolerance test (IVGTT, 500 mg glucose/kg body weight) and an 
insulin tolerance test (ITT, 0.1 U insulin/kg body weight). Five dogs were tested in random order, at 
least 1 week apart, following an overnight fast. The OGTT was found to be unsuitable due to delayed 
gastric emptying, which caused mean plasma glucose levels to be elevated 3 h following the glucose 
load (basal glucose 4.08 (SD 0.17) mmol/1, after 3 h 5.47 (SD 0.72) mmol/1, P=0.053). The ITT was 
quick and easy to perform, but there was the possible risk of the dogs becoming hypoglycaemic. The 
IVGTT was similarly easy to perform, without risks of hypoglycaemia. Glucose disappearance rates 
(K) for the ITT were 7.41 (SD 0.76) %/min (CV 10.3%) and for the IVGTT 4.89 (SD 1.2) %/min (CV 
24.4%). Repeatability studies (one animal, four repeated tests) showed intraindividual CV of 12.8% 
and 24.5% respectively. The IVGTT was used for further studies because of the potential to apply 
kinetic modelling to glucose and insulin data, and because of the risk of hypoglycaemia with the ITT.
To determine the effect of «-3 PUFA on insulin sensitivity six Labrador dogs, aged 6 (SD 2) 
years were placed on a standard weight-maintenance diet (Canned Diet; kJ metabolic energy/d = 460 x 
body weight (kg)®'^ )^ enriched with marine fish oil (MFO) containing 0.08g eicosapentaenoic acid and 
0.06g docosahexaenoic acid/100 g for 7 months. These animals were tested with an IVGTT following 
an overnight fast with six matched dogs that had been on the same standard diet without the MFO 
supplementation. One control dog failed to complete the IVGTT. Comparison of the K values 
between the MFO diet (mean 2.60 %/min, SD 1.24) and control diet (mean 2.19 %/min, SD 0.47) 
showed no significant difference (P=0.744). Similarly, no significant differences (P=0.482) were 
found when comparing the integrated area under the curve (lAUC) for the glucose response. A trend 
(P=0.053) towards higher plasma insulin on the MFO-supplemented diet was found when comparing 
the LAUC for the insulin response. However using minimal model analysis, no significant differences 
were found in insulin sensitivity (Si) and glucose utilisation (Sg) between diets.
A diet enriched with MFO at this level therefore had little effect on insulin sensitivity in dogs. 
The lack of effect could be because the animals used were non-obese, healthy and regularly exercised 
and had a high basal insulin sensitivity before dietary intervention.
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